P R O D U C T S , S E R V I C E S A N D S O L U T I O N S F O R
T H E C H A N G I N G N E E D S O F H E A LT H C A R E
ANN UA L RE POR T 2014
HENRY SCHEIN FINANCIAL HIGHLIGHTS
2010–2014
NET SALES
($ in Millions)
ADJUSTED OPERATING INCOME
($ in Millions)
$10,000
$10,371
CAGR 8%*
$9,561
$8,940
$8,000
$8,530
$7,527
$6,000
$4,000
$2,000
$0
2010
2011
2012
2013
2014
ADJUSTED EARNINGS PER DILUTED SHARE
$5.00
$4.00
$3.00
$2.00
$1.00
$0
$5.44
$4.95
CAGR 11%*
$4.44
$3.97
$3.58
2010
2011
2012
2013
2014
$700
$600
$715
CAGR 8%*
$677
$634
$582
$500
$533
$400
$300
$
0
$200
$
1
.
0
0
$
2
.
0
0
$
3
.
0
0
$
4
.
0
0
$
5
.
0
0
$
0
$
2
,
0
0
0
$
4
,
0
0
0
$
6
,
0
0
0
$
1
0
,
0
0
0
2
0
1
0
$100
$0
$700
$600
$500
$400
$
1
0
0
$300
$200
$
$
0
0
$
3
9
$
4
5
$100
$
5
1
$0
$0
$
6
0
$
8
2
2
0
1
1
2
0
1
2
2
0
1
3
2
0
1
4
2
0
1
0
2
0
1
1
2
0
1
2
2
0
1
3
2
0
1
4
$
3
.
5
8
$
3
.
9
7
2010
2011
2012
2013
2014
$
4
.
4
4
OPERATING CASH FLOW
AND CAPITAL EXPENDITURES
($ in Millions)
$
4
.
9
5
$
5
.
4
4
$664
$593
$555
$395
$
2
0
0
$408(1)
$
4
0
0
$
3
0
0
$
5
0
0
$
6
0
0
$
7
0
0
$
0
$
1
0
0
$
2
0
0
$
3
0
0
$
4
0
0
$
6
0
0
$
7
0
0
2
0
1
0
2
0
1
1
2
0
1
2
2
0
1
3
2
0
1
4
2
0
1
0
2
0
1
1
2
0
1
2
2
0
1
3
2
0
1
4
$
7
,
5
2
7
$
8
,
0
0
0
$
8
,
5
3
0
$
8
,
9
4
0
$
9
,
5
6
1
$
1
0
,
3
7
1
$
5
0
0
$
5
3
3
$
5
8
2
$
6
3
4
$
6
7
7
$
7
1
5
$
5
5
5
$82
2014
$
5
9
3
$60
2013
$
6
6
4
$
3
9
5
$
4
0
8
$39
$45
$51
1
)
(
2010
2011
2012
OPERATING CASH FLOW
CAPITAL EXPENDITURES
*Four-year Compound Annual Growth Rate
(1) Net of temporary forward inventory buy-ins of $150MM.
NOTE:
Operating Income and Earnings Per Diluted Share attributable to Henry Schein, Inc. for 2010, 2012, and 2013, have been adjusted to exclude certain one-time items. Refer to Non-GAAP
Disclosures on page 12. Additionally, refer to our annual consolidated financial statements for a complete presentation of our Consolidated Statements of Cash Flows.
ABOUT HENRY SCHEIN
Henry Schein, Inc. is the world's largest provider of health care products and services
to office-based dental, animal health and medical practitioners.
The Company also serves dental laboratories, government and institutional health care clinics, and other alternate care
sites. A Fortune 500® Company and a member of the S&P 500® and the NASDAQ 100® Indexes, Henry Schein employs
approximately 18,000 Team Schein Members and serves more than one million customers.
The Company offers a comprehensive selection of products and services, including value-added solutions for operating
efficient practices and delivering high-quality care. Henry Schein operates through a centralized and automated
distribution network, with a selection of more than 100,000 branded products and Henry Schein private-brand products
in stock, as well as more than 150,000 additional products available as special-order items. The Company also offers
its customers exclusive, innovative technology solutions, including practice management software and e-commerce
solutions, as well as a broad range of financial services.
Headquartered in Melville, New York, Henry Schein has operations or affiliates in 29 countries. The Company's
sales reached a record $10.4 billion in 2014, and have grown at a compound annual rate of approximately
16 percent since Henry Schein became a public company in 1995. For more information, visit the Henry Schein website
at www.henryschein.com.
(As of April 2015)
About the cover theme: Today’s health care market is rapidly evolving. Patients and clinicians are increasingly focused on
wellness and prevention, which means clinicians must embrace solutions that promote better outcomes and more efficient
health care delivery through technological advances. Henry Schein’s expert knowledge of the health care market allows us
to anticipate change and develop solutions that help our customers navigate this evolving landscape. As trusted advisors to
our customers, we are a valued resource for innovative solutions across the spectrum of products, services, technology and
support. Practitioners know they can “Rely on Us” as their long-term partner to understand their needs and to help them
grow their practices beyond their expectations, so they can focus on delivering the highest quality patient care.
HENRY SCHEIN 2014
HENRY SCHEIN AT A GLANCE
$10.4
BILLION
2014
GLOBAL
NET SALES
51.9% DENTAL
27.9% ANIMAL HEALTH
16.8% MEDICAL
3.4% TECHNOLOGY & VALUE-ADDED SERVICES
DENTAL
2014 net sales of
$5.4 billion
ANIMAL HEALTH
2014 net sales of
$2.9 billion
MEDICAL
2014 net sales of
$1.7 billion
Only global dental distributor to general practitioners, specialists, and laboratories
Growth Opportunities:
• Geographic expansion
• Advancing practice management solutions
• Acceleration of high-technology solutions
• Greater penetration of specialty markets
• Continued focus on large group practices
• Digitalization of prosthetic solutions
(Implants, Orthodontics, and Endodontics)
Only global distributor to veterinarians
Growth Opportunities:
• Geographic expansion
• Advancing technology solutions, including practice management
• Focus on practice-building products and services
• Increasing pet ownership
• Continued focus on large group practices
A leading U.S. distributor to primary care physicians and specialists,
group practices, physician-owned labs, and ambulatory surgery centers
Operations in certain European markets
Growth Opportunities:
• Greater penetration of U.S. market
• Continued focus on large group practices
• Select international opportunities
TECHNOLOGY & VALUE-ADDED SERVICES
2014 net sales of
$348.9 million
Only practice management software solutions provider serving dental,
animal health, and medical practitioners
Full-service provider of financial services
Growth Opportunities:
• Geographic expansion
• Ability to serve large practices
• Facilitating financial services for technology investments and office expansion
HENRY SCHEIN 2014
ABOUT
HENRY SCHEIN
HENRY SCHEIN HIGHLIGHTS
(As of April 2015)
(As of April 2015)
OPERATIONS OR AFFILIATES IN 29 COUNTRIES
3,650
FIELD SALES
CONSULTANTS
1,825
TELESALES
REPRESENTATIVES
83
YEARS IN
BUSINESS
18,000
APPROX.
TEAM SCHEIN MEMBERS
31.7MILLION
DIRECT MARKETING
PIECES DISTRIBUTED
199
EQUIPMENT SALES
& SERVICE CENTERS
65 DISTRIBUTION
CENTERS
MORE THAN
3,000
SUPPLIER
PARTNERS
SERVING MORE THAN
1MILLION
CUSTOMERS
AVERAGE OF
150,000
CARTONS
SHIPPED DAILY
99% OF ITEMS ORDERED ARE SHIPPED ON
THE SAME BUSINESS DAY THE ORDER IS RECEIVED
100,000
PRODUCTS IN STOCK
150,000
ADDITIONAL PRODUCTS
AS SPECIAL-ORDER ITEMS
HENRY SCHEIN 2014
HENRY SCHEIN 2014
A MESSAGE FROM THE CHAIRMAN OF THE BOARD
AND CHIEF EXECUTIVE OFFICER
During 2014, Henry Schein delivered solid financial performance across each of
our business groups and demonstrated that our strategic priorities are enabling
us to invest for profitable growth. Our position of acting as a trusted advisor to
our customers and supplier partners continues to drive our success. Our customers
“Rely on Us” because we provide a wide selection of products, value-added
services and solutions, along with expert advice and support for their evolving
needs. Our strategy is built upon the strength of our trusted relationships.
2014 marked the culmination of our three-year strategic plan aimed at expanding
our geographic operations, enhancing our commitment to global corporate
social responsibility, and refining our strategic focus for the future. The results
reflect the commitment of Team Schein Members across the globe embracing
and driving that strategy. Specifically, during that three-year period, we entered
five new countries, strengthening our position as a leading global provider of
value-added solutions for our customers. We successfully added more than 30 companies and more than 2,500
Team Schein Members. We reorganized to align our interests among three global vertical business groups and
strengthened our market position as the number one global dental distributor, the top global animal health
distributor, the second-largest physician and alternate-care distributor, and the number one global practice
management solutions provider.
From a financial perspective, 2014 net sales increased by 8.5% to $10.4 billion, exceeding the $10 billion threshold
for the first time. Operating cash flow and free cash flow of $592.5 million and $510.4 million, respectively, both
exceeded net income, which is one of our longstanding financial goals. Diluted earnings per share of $5.44 set a
record, and increased 9.9% when adjusted for non-GAAP items in 2013*. We also repurchased $300 million of our
common stock, in line with our annual share repurchase goal.
This strong financial performance was also evident by the progress among our four global business groups, each
of which gained market share during 2014 and posted record sales. Dental sales reached $5.4 billion, up 7.7% over
the previous year, and Animal Health sales increased 11.5% to $2.9 billion. Medical sales were up 6.1% to $1.7
billion, while Technology and Value-Added Services sales were $348.9 million, up 9.0%.
Henry Schein’s financial success fueled the Company’s climb up the ranks of the
FORTUNE 500® list of America’s largest companies by revenue. The Company
now ranks number 292 on the FORTUNE 500, having debuted on the list in 2004
at number 497. In recent months, we were pleased to be selected as a component
of the S&P 500® index, widely considered a leading indicator of U.S. equity trading.
#292 ON FORTUNE 500
LIST OF AMERICA’S
LARGEST
COMPANIES
Last year, we further expanded Henry Schein’s operations geographically and strategically. We entered Japan, the
world’s second-largest dental market, with an investment in Iwase Dental Supply, and we established operations
in South America with an investment in Dental Speed Graph in Brazil. We now have operations or affiliates in
29 countries on six continents.
* See reconciliation of GAAP and Non-GAAP measures on page 12.
HENRY SCHEIN 2014
We made important investments and significantly expanded
our dental distribution and dental laboratory presence in
France and the Benelux countries, expanded our animal
health business in Europe with the acquisition of Medivet
in Poland, and increased our dental laboratory business in
North America with the acquisition of Lincoln Dental Supply.
Henry Schein Medical entered into a strategic agreement
with athenahealth to provide physicians with electronic
health records, patient communications, and other services.
Henry Schein Animal Health acquired a majority interest in
SmartPak, which provides equine supplements and horse
supplies, and we formed
strategic relationships with
Abaxis, Heska and Antech to
bring diagnostic products to
U.S. veterinary practices. We
recently completed the
acquisition of scil animal care,
a distributor of animal health
laboratory and imaging diagnostic products and services to
veterinarians primarily in North America and Europe, which
was a significant step forward in expanding our diagnostics
product offering.
We opened new, state-of-the-art facilities with our Medcare
South building in the United Kingdom, our Henry Schein
Animal Health building in Lexington, Kentucky, and our
Henry Schein Practice Solutions headquarters in American
Fork, Utah, which features a “Center of Excellence” equipped
with advanced digital dental equipment and technology
that is also used to provide care to underserved members of
that community.
Among the more significant developments of the year, we
acquired Cardinal Health’s physician office business and
entered into a strategic supply agreement with the company.
This agreement is designed to provide one of the most
comprehensive service and product offerings to office-based
medical practices and Integrated Delivery Networks across
the United States, and underscores our longstanding
commitment to serving the needs of a quickly changing
medical market. We are in the process of consolidating
Cardinal Health’s 180-member physician office-focused
commercial organization into Henry Schein’s Medical
business, adding service to more than 25,000 physician
office locations nationwide and more than $300 million in
annual revenue.
In 2014, we also strengthened our corporate governance by
welcoming two new Directors. Dr. Dianne Rekow, Dean of
King’s College London Dental Institute, joined our Board in
June; and Dr. Lawrence Bacow, former Tufts University
President, MIT Professor and a long-time Harvard University
scholar, joined our Board in December.
We believe a critical component of our success is tied to
serving society and “doing well by doing good.”
Henry Schein continues to be recognized for its strong
commitment to corporate social responsibility and the work
we are doing around the world through Henry Schein Cares,
our corporate social responsibility program. In early 2015,
FORTUNE announced that
we ranked first in our industry
on the magazine’s list of the
World’s Most Admired
Companies, our 14th
consecutive year on this list.
We also ranked first in every
one of the nine sub-categories,
including social responsibility. In addition, the Ethisphere
Institute named Henry Schein to its list of the World’s Most
Ethical Companies for the fourth year in a row. Most recently,
Henry Schein was named to the Forbes list of one of
“America’s Best Employers.”
Throughout 2014, I traveled to Henry Schein facilities around
the world and met with thousands of Team Schein Members.
During those meetings, we discussed the importance of
enhancing engagement with our five constituencies, which
has been central to our sustained success: our supplier
partners, who view Henry Schein as a strong global
HENRY SCHEIN 2014
A MESSAGE FROM THE CHAIRMAN OF THE BOARDAND CHIEF EXECUTIVE OFFICER organization with proven
success in growing market
share; our customers, who
appreciate that we are a
valued source for innovative,
integrated solutions that
include products, services,
equipment, technology,
expert advice, and support; Team Schein, our Company’s
greatest asset; our investors, who trust Henry Schein to
continue to deliver reliable financial results year after year;
and society, which we serve through our many Henry Schein
Cares activities around the world.
It is important that we continually find new ways to strengthen
the relationships that are important to our business. To our
customers, Henry Schein strives to be a trusted advisor.
We want to be a long-term partner in building our customers’
practices — understanding and aligning with their needs,
and helping practitioners to grow beyond their expectations.
We firmly believe that our engagement with and dedication
to serving the full spectrum of our key constituents furthers
our long-term success. As part of this commitment,
Henry Schein is a “Higher Ambition” company that
focuses on earning the respect and trust of our team,
customers, supplier partners, society and investors as the
foundation for our success in the marketplace. Ultimately,
we believe that Higher Ambition companies simultaneously
create long-term economic value, generate wider benefits
for society, and build robust social capital within their
organization all at once.
In this time of rapid change in the markets we serve, we have
positioned Henry Schein to successfully navigate health care
reform, demographic shifts, continued customer consolidation,
and other market transitions. From Henry Schein’s long
history of effective reinvention, we know first-hand the
companies that anticipate and adapt to market change are
the ones that thrive. We will continue our reinvention by
investing in new product categories, new geographies,
Forward looking statements made in this report are subject to the reservations
specified in the Safe Harbor statement noted in the Company’s 10-K filing.
new markets, new customer sets, and new technology
solutions, as well as in the professional development of Team
Schein Members. In these ways, we will seek to position
Henry Schein for new heights of success.
Now we have embarked upon our next three-year strategic
plan, holding steadfast to our vision of helping practitioners
improve the efficiency of their practices so they can focus
on providing quality patient
care. We continue to build
trusted relationships with our
global supplier partners by
enhancing their brand value
and helping to drive their
share of the market. Our
customers rely upon our
world-class delivery capabilities, product expertise,
technological offerings, and value-added solutions that
improve their patients’ experience. We have healthy cash
flows to invest in our future and expand our position in the
market. And most importantly, we have the support of
Team Schein Members across the globe, all of whom are
dedicated first and foremost to providing the best service to
our customers.
With this vision, and with a team dedicated to delivering
on our commitments, I believe Henry Schein’s best years
are yet to come. On behalf of our Board of Directors
and my Team Schein colleagues, thank you for your
continued support of our Company and thank you for
continuing to “Rely on Us.”
Sincerely,
Stanley M. Bergman
Chairman of the Board and
Chief Executive Officer
April 2015
HENRY SCHEIN 2014
A MESSAGE FROM THE CHAIRMAN OF THE BOARDAND CHIEF EXECUTIVE OFFICER
HENRY SCHEIN CARES
HELPING HEALTH HAPPEN
More than 18,000 Team
Schein Members in 29
countries serve more than
one million customers
around the world. And, as
our sales have grown from
approximately $600 million in 1995 when Henry Schein first
became a publicly traded company, to more than $10 billion
in 2014, so has our ability to “help health happen” through
Henry Schein Cares, the Company’s global corporate social
responsibility program.
Henry Schein Cares was established on the philosophy of
enlightened self-interest — a belief that we can “do well by
doing good.” Enlightened self-interest is an opportunity to
create shared value for society and business.
We firmly believe that “doing well by doing good” is a
powerful engine that drives Henry Schein’s ability to create
long-term economic and social value. Henry Schein’s deep
commitment to balancing the needs of the full spectrum of
stakeholders — our team, our customers, our suppliers, our
investors, and society — has been central to our success.
Henry Schein carries out its commitment to corporate social
responsibility by creating programs and driving strategic
initiatives that fall within four key areas of focus: Access to
Health Care, Team Schein Engagement, Environmental
Sustainability, and Accountability.
INDUSTRY
RECOGNITION
Henry Schein has been a FORTUNE
World’s Most Admired Company
for 14 years, and in 2014 and
2015
ranked
first overall
in
the Wholesalers: Health Care industry, and first in all nine
sub-categories of the list’s ranking, which are Management
Quality; Quality of Products and Services; Innovativeness; Value
as a Long-Term Investment; Soundness of Financial Position;
Ability to Attract, Develop and Retain Talent; Community
Responsibility; Wise Use of Corporate Assets; and Effectiveness
in Conducting a Global Business. Henry Schein has been one
of Ethisphere Institute’s World’s Most Ethical Companies for
four years in a row, and most recently, was named by Forbes
magazine as one of “America’s Best Employers 2015.”
ACCESS TO HEALTH CARE
Because no single corporation can solve all of society’s
problems, a company must select issues that intersect with
its particular business. In Henry Schein’s case, we seek to
create shared value by expanding access to health care for
underserved and vulnerable populations around the world.
We promote wellness, prevention, treatment and education;
provide emergency preparedness and relief; and build health
care capacity by strengthening educational platforms to train
health professionals and enhancing health care infrastructure.
TEAM SCHEIN ENGAGEMENT
A key part of our Team Schein culture is a deep commitment
to serving the communities in which we operate and giving
back to society. Team Schein Members around the world
participate in community outreach through their active
engagement in a myriad of flagship corporate volunteer and
community service programs. Being a member of Team
Schein provides ongoing opportunities to contribute to the
Company’s larger effort to making the world a better place.
ENVIRONMENTAL SUSTAINABILITY
Henry Schein firmly believes that protecting the health of
our planet is an important part of our commitment to “helping
health happen.” We embrace the principles of environmental
stewardship at our corporate facilities by minimizing the
consumption of resources and reducing negative
environmental impacts. We also promote environmental
sustainability among our customers by encouraging the
“greening” of health professionals’ offices, supporting efforts
to reduce their total carbon footprint with the use of eco-
friendly products, and creating office spaces that meet
world-recognized sustainability and green design standards.
ACCOUNTABILITY
For 83 years, Henry Schein has built an environment of ethics
and compliance that is based on our Team Schein Values
and our commitment to our five constituencies. We ensure
accountability by upholding ethical standards in all areas
and levels of our business.
HENRY SCHEIN 2014
DOING WELL
BY DOING GOOD
Harvard Business School teaches
MBAs about Henry Schein’s model of
“Doing Well By Doing Good” and the
Company’s “Higher Ambition.”
Harvard Business School published a case
study entitled, “Henry Schein: Doing Well
By Doing Good?” and it served as the basis
for class discussions in two-year MBA and
executive programs at Harvard and other
business schools around the country. The
case study focuses on Henry Schein’s journey
to become a highly successful, values-driven
global health care company and explores
the Company’s culture of care and respect,
deep commitment to corporate social
responsibility, and unique acquisition
model. The
inaugural teaching of
Henry Schein’s case study took place at the
2014 Leading with Higher Ambition CEO
Conference and was the basis of discussion
for the participating CEOs and other thought
leaders from around the world, including
former Vice President Al Gore. The annual
conference, organized by the Center for
Higher Ambition Leadership, brings
together select leaders who possess a “higher
ambition”: the belief that organizations can
best realize their potential by creating
long-term economic value, generating wider
benefits for society, and building robust
social capital all at once. Henry Schein is a
founding member of The Center for Higher
Ambition Leadership. Recent studies by
Harvard Business School, Babson College,
and other academic institutions have
demonstrated that firms that prioritize
stakeholder engagement and have a long-
term orientation — two of the key elements
of “higher ambition” companies —
significantly outperform their counterparts
in the stock market over time.
HENRY SCHEIN 2014
EXECUTIVE OFFICERS
Front Row, from Left to Right
Leonard A. David
Walter Siegel
Senior Vice President and Chief Compliance Officer
Senior Vice President and General Counsel
James A. Harding
Senior Vice President and Chief Technology Officer
Stanley M. Bergman
Chairman of the Board and Chief Executive Officer
James P. Breslawski
Lorelei McGlynn
President, Henry Schein, Inc., and Chief Executive Officer, Global Dental Group, Member of the Board of Directors
Senior Vice President, Global Human Resources and Financial Operations
Stanley Komaroff
Senior Advisor
Back Row, from Left to Right
Bob Minowitz
Steven Paladino
President, International Dental Group
Executive Vice President, Chief Financial Officer, Member of the Board of Directors
Gerald A. Benjamin
Executive Vice President, Chief Administrative Officer, Member of the Board of Directors
Lonnie Shoff
Paul Rose
Chief Executive Officer, Global Animal Health and Strategic Partnership Group
Senior Vice President, Global Supply Chain
David C. McKinley
President, Medical Group
Mark E. Mlotek
Michael Racioppi
Executive Vice President, Chief Strategic Officer, Member of the Board of Directors
Senior Vice President, Chief Merchandising Officer
Michael S. Ettinger
Senior Vice President, Corporate & Legal Affairs, Chief of Staff and Secretary
HENRY SCHEIN 2014
BOARD OF DIRECTORS
Front Row, from Left to Right
Barry J. Alperin
Retired Vice Chairman, Hasbro, Inc.; Member of the Board of Directors of Fiesta Restaurant Group, Inc., Jefferies Group LLC, K’NEX Industries, Inc.
and Weeks Marine, Inc. (1) (2) (3)
E. Dianne Rekow, DDS, Ph.D.
Dean of the Dental Institute at King’s College London and Professor of Orthodontics; Former Professor of Orthodontics, Senior Vice Provost of Engineering Technology
and Provost of Polytechnic Institute at New York University
Stanley M. Bergman
James P. Breslawski
Paul Brons
Donald J. Kabat
Chairman of the Board and Chief Executive Officer
President, Henry Schein, Inc., and Chief Executive Officer, Global Dental Group
Former Member of the Board of Management of Akzo Nobel, N.V., Former President of Organon International BV (4)
Former Chief Financial Officer of Central Park Skaters, Inc.; Former President of D.J.K. Consulting Services, Inc.; Retired Partner, Accenture PLC Ireland;
and Member of the Board of Directors for several not-for-profit organizations (1) (2)
Back Row, from Left to Right
Steven Paladino
Gerald A. Benjamin
Louis W. Sullivan, M.D.
Carol Raphael
Lawrence S. Bacow, Ph.D.
Norman S. Matthews
Philip A. Laskawy
Mark E. Mlotek
Bradley T. Sheares, Ph.D.
Executive Vice President, Chief Financial Officer
Executive Vice President, Chief Administrative Officer
Former U.S. Secretary of Health and Human Services; Founding Dean, Director and President Emeritus of the Morehouse School of Medicine;
Member of the Board of Directors of United Therapeutics Corporation and Emergent BioSolutions Inc. (3) (4)
Senior Advisor for Manatt Health Solutions; Former President and CEO, Visiting Nurse Service of New York; Board Chair of AARP;
Member of the Board of Directors of the New York eHealth Collaborative
Leader-in-Residence, Center for Public Leadership at Harvard’s Kennedy School of Government; Member and Chair of the Joint Committee on Inspection,
Harvard Corporation; Member of the Board of Directors of Liquidnet Holdings, Inc. and Loews Corporation
Former President, Federated Department Stores, Inc.; Member of the Board of Directors of Duff & Phelps Corp., Spectrum Brands, Inc., Party City Holdings, Inc.;
and Chairman of the Board of The Children’s Place Retail Stores, Inc. (2) (4)
Retired Chairman, Ernst & Young, LLP (now known as EY LLP) and Member of the Board of Directors of Lazard Ltd. and Loews Corporation (1) (3) (4)
Executive Vice President, Chief Strategic Officer
Former CEO, Reliant Pharmaceuticals and Former President of U.S. Human Health for Merck & Co.,
Member of the Board of Directors of Honeywell International and The Progressive Corporation (4)
(1) Member of Audit Committee (2) Member of Compensation Committee
(3) Member of Nominating and Governance Committee (4) Member of Strategic Advisory Committee
HENRY SCHEIN 2014
COMMON STOCK
Henry Schein Common Stock trades on the NASDAQ® Stock Market under the symbol “HSIC.”
ANNUAL MEETING OF SHAREHOLDERS
Our Annual Meeting of Shareholders will be held on June 22, 2015 at 10:00 a.m. EDT at The Melville Marriott Long Island,
located at 1350 Walt Whitman Road, Melville, New York 11747.
SHAREHOLDER REPORTS AND INVESTOR INQUIRIES
For shareholder inquiries, including requests for quarterly and annual reports, contact our Investor Relations department at (631) 843-5611,
or e-mail your request to investor@henryschein.com. Printed materials can also be requested through the Company’s website.
FORM 10-K
Our Annual Report on Form 10-K for the fiscal year ended December 27, 2014 has been filed with the SEC and is available free of charge through
our Internet website, www.henryschein.com. Stockholders may also obtain a copy of the Form 10-K upon written request to Henry Schein, Inc.,
135 Duryea Road, Melville, New York 11747, Attn: Investor Relations, via e-mail at investor@henryschein.com or facsimile at (631) 843-5541. In response
to such request, the Company will furnish without charge the Form 10-K including financial statements, financial schedules and a list of exhibits.
INDEPENDENT AUDITORS
BDO USA, LLP
100 Park Avenue, New York, New York 10017
LEGAL COUNSEL
Proskauer Rose, LLP
Eleven Times Square, New York, New York 10036
STOCK TRANSFER AGENT
For address changes, account cancellation, registration changes and lost stock certificates, please contact:
Continental Stock Transfer & Trust Company
17 Battery Place, 8th Floor, New York, New York 10004
(212) 509-4000
NoN-GAAP Disclosures
NON-GAAP DISCLOSURES
The following table sets forth, for the applicable periods, a reconciliation of operating income attributable to Henry Schein, Inc.
adjusted to reflect the effects of restructuring costs.
The following table sets forth, for the applicable periods, a reconciliation of operating income, net income attributable to Henry Schein, Inc., and diluted earnings per share adjusted to reflect the effects
of restructuring costs and other adjustments.
Years Ended
December 28,
December 29,
December 25,
2013
2012
2010
(in thousands, except per share data)
Operating income, as reported
$ 677,054
$ 618,961
$ 521,131
Operating margin, as reported
7.1%
6.9%
6.9%
Adjustments:
Restructuring costs (1)
Adjusted operating income
Adjusted operating margin
Net income attributable to Henry Schein, Inc.:
As reported
Adjustments, net of tax:
Restructuring costs (1)
Foreign tax benefit (2)
Loss on sale of equity investment (3)
–
$
15,192
$ 12,285
$ 677,054
$ 634,153
7.1%
7.1%
$ 533,416
7.1%
$ 431,554
$ 388,076
$ 325,789
USE OF NON-GAAP MEASURES:
The information (left) includes financial measures that are not calculated and presented in
accordance with accounting principles generally accepted in the United States (“GAAP”).
The table (left) reconciles operating income, income attributable to Henry Schein, Inc., and
diluted earnings per share attributable to Henry Schein, Inc., our most directly comparable
measure calculated and presented in accordance with GAAP, to comparable amounts as
adjusted to eliminate the effect of restructuring costs.
We eliminated the effect of restructuring costs to assist in evaluating the underlying operational
performance of our business, excluding such costs, over the periods presented. We believe that
this presentation is appropriate and facilitates such an evaluation by us, investors and analysts.
These measures should be considered supplemental to, and not a substitute for or superior to,
financial measures calculated in accordance with GAAP.
–
$ 10,537
$ 8,260
(1) During 2012, we recorded restructuring costs of $15.2 million pre-tax ($10.5 million
NOTES:
$ (13,398)
$ 12,535
–
–
–
–
–
–
Accelerated amortization of deferred financing costs (4)
$
2,679
Adjusted income attributable to Henry Schein, Inc.:
$ 433,370
$ 398,613
$ 334,049
Diluted earnings per share attributable to Henry Schein, Inc.:
As reported
Adjusted
$
4.93
$
4.95
$
$
4.32
4.44
$ 3.49
$ 3.58
Diluted weighted-average common shares outstanding:
87,622
89,823
93,268
post-tax). During 2010, we recorded restructuring costs of $12.3 million pre-tax ($8.3 million
post-tax). The effect that these charges had on earnings per diluted share attributable
to Henry Schein, Inc. was ($0.12) and ($0.09), respectively.
(2) During 2013, we reduced the remaining valuation allowance of $13.4 million on the deferred
tax asset associated with a net operating loss carryforward outside of the United States. The
effect that this transaction had on earnings per diluted share attributed to Henry Schein, Inc.
was $0.15.
(3) Represents a loss on divestiture in 2013 of a noncontrolling interest in a dental wholesale
distributor in the Middle East. The effect that this transaction had on earnings per diluted
share attributable to Henry Schein, Inc. was ($0.14).
USE OF NON-GAAP MEASURES:
The above information includes financial measures that are not calculated and presented in accordance with accounting principles generally accepted in the United States (“GAAP”).
The above table reconciles operating income, income attributable to Henry Schein, Inc., and diluted earnings per share attributable to Henry Schein, Inc., our most directly comparable
measure calculated and presented in accordance with GAAP, to comparable amounts as adjusted to eliminate the effect of restructuring costs.
We eliminated the effect of restructuring costs to assist in evaluating the underlying operational performance of our business, excluding such costs, over the periods
presented. We believe that this presentation is appropriate and facilitates such an evaluation by us, investors and analysts. These measures should be considered supplemental to,
and not a substitute for or superior to, financial measures calculated in accordance with GAAP.
(4) In February 2013, we repaid the then outstanding debt related to the Henry Schein Animal
Health, formerly Butler Schein Animal Health, transaction. As part of this transaction, we
recorded a one-time interest charge of $6.2 million pre-tax ($2.7 million post-tax) related to
the accelerated amortization of deferred financing costs. The effect that this transaction had
on earnings per diluted share attributed to Henry Schein, Inc. was ($0.03).
(1) During 2012, we recorded restructuring costs of $15.2 million pre-tax ($10.5 million post-tax). The effect that these charges had on earnings per diluted share
attributable to Henry Schein, Inc. was ($0.12).
(2) During 2013, we reduced the remaining valuation allowance of $13.4 million on the deferred tax asset associated with a net operating loss carryforward outside of the
United States. The effect that this transaction had on earnings per diluted share attributed to Henry Schein, Inc. was $0.15.
(3) Represents a loss on divestiture in 2013 of a noncontrolling interest in a dental wholesale distributor in the Middle East. The effect that this transaction had on earnings per diluted
share attributable to Henry Schein, Inc. was ($0.14).
(4) In February 2013, we repaid the then outstanding debt related to the Henry Schein Animal Health, formerly Butler Schein Animal Health, transaction. As part of this transaction, we
recorded a one-time interest charge of $6.2 million pre-tax ($2.7 million post-tax) related to the accelerated amortization of deferred financing costs. The effect that this transaction
had on earnings per diluted share attributed to Henry Schein, Inc. was ($0.03).
NOTES:
12
HENRY SCHEIN 2014
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
X ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 27, 2014
__ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number 0-27078
HENRY SCHEIN, INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of
incorporation or organization)
11-3136595
(I.R.S. Employer Identification No.)
135 Duryea Road
Melville, New York
(Address of principal executive offices)
11747
(Zip Code)
(631) 843-5500
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Common Stock, par value $.01 per share
Name of each exchange on which registered
The NASDAQ Global Select Market
Securities registered pursuant to Section 12(g) of the Act:
None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
YES: X NO: __
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
YES: __ NO: X
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
YES: X NO: __
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every
Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or
for such shorter period that the registrant was required to submit and post such files).
YES: X NO: __
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be
contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this
Form 10-K or any amendment to this Form 10-K. X
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the
Exchange Act.
Large accelerated filer: X Accelerated filer: __ Non-accelerated filer: __ Smaller reporting company: __
(Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES: __ NO: X
The aggregate market value of the registrant’s voting stock held by non-affiliates of the registrant, computed by reference to the closing
sales price as quoted on the NASDAQ Global Select Market on June 28, 2014, was approximately $10,105,730,000.
As of February 2, 2015, there were 83,801,860 shares of registrant’s Common Stock, par value $.01 per share, outstanding.
Portions of the Registrant’s definitive proxy statement to be filed pursuant to Regulation 14A not later than 120 days after the end of the
fiscal year (December 27, 2014) are incorporated by reference in Part III hereof.
Documents Incorporated by Reference:
TABLE OF CONTENTS
PART I.
ITEM 1.
ITEM 1A.
ITEM 1B.
ITEM 2.
ITEM 3.
ITEM 4.
PART II
ITEM 5.
ITEM 6.
ITEM 7.
ITEM 7A.
ITEM 8.
ITEM 9.
ITEM 9A.
ITEM 9B.
PART III
ITEM 10.
ITEM 11.
ITEM 12.
ITEM 13.
ITEM 14.
PART IV
ITEM 15.
Business ............................................................................................................................................
Risk Factors ......................................................................................................................................
Unresolved Staff Comments .............................................................................................................
Properties ..........................................................................................................................................
Legal Proceedings .............................................................................................................................
Mine Safety Disclosures ...................................................................................................................
Market for Registrant's Common Equity, Related Stockholder Matters
and Issuer Purchases of Equity Securities ....................................................................................
Selected Financial Data ....................................................................................................................
Management's Discussion and Analysis of Financial Condition
and Results of Operations ............................................................................................................
Quantitative and Qualitative Disclosures About Market Risk ..........................................................
Financial Statements and Supplementary Data .................................................................................
Changes in and Disagreements With Accountants on Accounting
and Financial Disclosure ..............................................................................................................
Controls and Procedures ...................................................................................................................
Other Information .............................................................................................................................
Directors, Executive Officers and Corporate Governance ................................................................
Executive Compensation ..................................................................................................................
Security Ownership of Certain Beneficial Owners and Management
and Related Stockholder Matters .................................................................................................
Certain Relationships and Related Transactions, and Director Independence ..................................
Principal Accountant Fees and Services ...........................................................................................
Exhibits, Financial Statement Schedules ..........................................................................................
Signatures .........................................................................................................................................
Exhibit Index ....................................................................................................................................
Page
Number
3
19
30
30
31
31
31
34
36
59
60
101
101
104
104
104
105
105
105
106
107
110
2
ITEM 1. Business
General
PART I
We believe we are the world’s largest provider of health care products and services primarily to office-based
dental, animal health and medical practitioners. We serve more than 1 million customers worldwide including
dental practitioners and laboratories, animal health clinics and physician practices, as well as government,
institutional health care clinics and other alternate care clinics. We believe that we have a strong brand identity due
to our more than 82 years of experience distributing health care products.
We are headquartered in Melville, New York, employ more than 17,500 people (of which approximately 8,000
are based outside the United States) and have operations or affiliates in 28 countries, including the United States,
Australia, Austria, Belgium, Brazil, Canada, Chile, China, the Czech Republic, France, Germany, Hong Kong SAR,
Iceland, Ireland, Israel, Italy, Japan, Luxembourg, the Netherlands, New Zealand, Poland, Portugal, Slovakia, South
Africa, Spain, Switzerland, Thailand and the United Kingdom.
We offer a comprehensive selection of products and services and value-added solutions for operating efficient
practices and delivering high quality care. We operate through a centralized and automated distribution network
with a selection of more than 100,000 branded products and Henry Schein private brand products in stock, as well
as more than 150,000 additional products available as special order items. We also offer our customers exclusive,
innovative technology solutions, including practice management software and e-commerce solutions, as well as a
broad range of financial services.
We have established over four million square feet of space in 65 strategically located distribution centers
around the world to enable us to better serve our customers and increase our operating efficiency. This
infrastructure, together with broad product and service offerings at competitive prices, and a strong commitment to
customer service, enables us to be a single source of supply for our customers’ needs. Our infrastructure also
allows us to provide convenient ordering and rapid, accurate and complete order fulfillment.
We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and
value-added services. These segments offer different products and services to the same customer base.
The health care distribution reportable segment aggregates our global dental, animal health and medical
operating segments. This segment distributes consumable products, small equipment, laboratory products, large
equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic
tests, infection-control products and vitamins. Our global dental group serves office-based dental practitioners,
dental laboratories, schools and other institutions. Our global animal health group serves animal health practices
and clinics. Our global medical group serves office-based medical practitioners, ambulatory surgery centers, other
alternate-care settings and other institutions.
Our global technology and value-added services group provides software, technology and other value-added
services to health care practitioners. Our technology group offerings include practice management software
systems for dental and medical practitioners and animal health clinics. Our value-added practice solutions include
financial services on a non-recourse basis, e-services, practice technology, network and hardware services, as well
as continuing education services for practitioners.
Industry
The health care products distribution industry, as it relates to office-based health care practitioners, is highly
fragmented and diverse. This industry, which encompasses the dental, animal health and medical markets, was
estimated to produce revenues of approximately $45 billion in 2014 in the global markets. The industry ranges
from sole practitioners working out of relatively small offices to group practices or service organizations ranging in
size from a few practitioners to a large number of practitioners who have combined or otherwise associated their
practices.
3
Due in part to the inability of office-based health care practitioners to store and manage large quantities of
supplies in their offices, the distribution of health care supplies and small equipment to office-based health care
practitioners has been characterized by frequent, small quantity orders, and a need for rapid, reliable and
substantially complete order fulfillment. The purchasing decisions within an office-based health care practice are
typically made by the practitioner or an administrative assistant. Supplies and small equipment are generally
purchased from more than one distributor, with one generally serving as the primary supplier.
The health care products distribution industry continues to experience growth due to the aging population,
increased health care awareness, the proliferation of medical technology and testing, new pharmacology treatments
and expanded third-party insurance coverage, partially offset by the effects of unemployment on insurance
coverage. In addition, the physician market continues to benefit from the shift of procedures and diagnostic testing
from acute care settings to alternate-care sites, particularly physicians’ offices.
We believe that consolidation within the industry will continue to result in a number of distributors, particularly
those with limited financial, operating and marketing resources, seeking to combine with larger companies that can
provide growth opportunities. This consolidation also may continue to result in distributors seeking to acquire
companies that can enhance their current product and service offerings or provide opportunities to serve a broader
customer base.
In recent years, the health care industry has increasingly focused on cost containment. This trend has benefited
distributors capable of providing a broad array of products and services at low prices. It also has accelerated the
growth of HMOs, group practices, other managed care accounts and collective buying groups, which, in addition to
their emphasis on obtaining products at competitive prices, tend to favor distributors capable of providing
specialized management information support. We believe that the trend towards cost containment has the potential
to favorably affect demand for technology solutions, including software, which can enhance the efficiency and
facilitation of practice management.
Competition
The distribution and manufacture of health care supplies and equipment is highly competitive. Many of the
health care distribution products we sell are available to our customers from a number of suppliers. In addition, our
competitors could obtain exclusive rights from manufacturers to market particular products. Manufacturers also
could seek to sell directly to end-users, and thereby eliminate or reduce our role and that of other distributors.
In North America, we compete with other distributors, as well as several manufacturers, of dental, animal
health and medical products, primarily on the basis of price, breadth of product line, customer service and value-
added products and services. In the dental market, our primary competitors are the Patterson Dental division of
Patterson Companies, Inc. and Benco Dental Supply Company. In addition, we compete against a number of other
distributors that operate on a national, regional and local level. In the animal health market, our primary
competitors are MWI Veterinary Supply, Inc. and the Patterson Veterinary division of Patterson Companies, Inc.
Our primary competitor in the medical market is McKesson Corporation, which is a national distributor. We also
compete against a number of regional and local animal health and medical distributors, as well as a number of
manufacturers that sell directly to veterinarians and physicians. With regard to our dental practice management
software, we compete against numerous companies, including Carestream Health, Inc. and the Patterson Dental
division of Patterson Companies, Inc. In the animal health practice management market, our primary competitors
are IDEXX Laboratories, Inc. and the Patterson Veterinary division of Patterson Companies, Inc. The medical
practice management and electronic medical records market is very fragmented and we compete with numerous
companies such as the NextGen division of Quality Systems, Inc., eClinicalWorks and Allscripts Healthcare
Solutions, Inc.
We also face significant competition internationally, where we compete on the basis of price and customer
service against several large competitors, including the GACD Group, Pluradent AG & Co., Lifco AB, Planmeca
Oy, Billericay Dental Supply Co. Ltd., National Veterinary Services, Centaur Services Limited and Alcyon SA, as
well as a large number of dental, animal health and medical product distributors and manufacturers in Australia,
Austria, Belgium, Brazil, Canada, Chile, China, the Czech Republic, France, Germany, Hong Kong SAR, Iceland,
Ireland, Israel, Italy, Japan, Luxembourg, the Netherlands, New Zealand, Poland, Portugal, Slovakia, South Africa,
Spain, Switzerland, Thailand and the United Kingdom.
4
Significant price reductions by our competitors could result in a similar reduction in our prices. Any of these
competitive pressures may materially adversely affect our operating results.
Competitive Strengths
We have more than 82 years of experience in distributing products to health care practitioners resulting in
strong awareness of the Henry Schein® brand. Our competitive strengths include:
A focus on meeting our customers’ unique needs. We are committed to providing customized solutions to our
customers that are driven by our understanding of the market and reflect the technology-driven products and
services best suited for their practice needs.
Direct sales and marketing expertise. Our sales and marketing efforts are designed to establish and solidify
customer relationships through personal visits by field sales representatives, frequent direct marketing and
telesales contact, emphasizing our broad product lines, including exclusive distribution agreements,
competitive prices and ease of order placement. The key elements of our direct sales and marketing efforts
are:
• Field sales consultants. We have approximately 3,650 field sales consultants, including equipment
sales specialists, covering major North American, European and other international markets. These
consultants complement our direct marketing and telesales efforts and enable us to better market,
service and support the sale of more sophisticated products and equipment.
• Direct marketing. During 2014, we distributed approximately 31.7 million pieces of direct marketing
material, including catalogs, flyers, order stuffers and other promotional materials to existing and
potential office-based health care customers.
• Telesales. We support our direct marketing effort with approximately 1,825 inbound and outbound
telesales representatives, who facilitate order processing and generate new sales through direct and
frequent contact with customers.
• Electronic commerce solutions. We provide our customers and sales teams with innovative and
competitive Internet, PC and mobile e-commerce solutions.
• Social media. Our operating entities and employees engage our customers and supplier partners
through various social media platforms.
Broad product and service offerings at competitive prices. We offer a broad range of products and services
to our customers, at competitive prices, in the following categories:
• Consumable supplies and equipment. We offer over 100,000 Stock Keeping Units, or SKUs, to our
customers. Of the SKUs offered, approximately 50,000 are offered to our dental customers,
approximately 13,000 to our animal health customers and approximately 41,000 to our medical
customers. We offer over 150,000 additional SKUs to our customers in the form of special order items.
• Technology and other value-added products and services. We sell practice management software
systems to our dental, animal health and medical customers. Our practice management solutions
provide practitioners with electronic medical records, patient treatment history, billing, accounts
receivable analyses and management, appointment calendars, electronic claims processing and word
processing programs. As of December 27, 2014, we have an active user base of more than 90,000
practices, including users of Dentrix® Dental Systems, Dentrix® Enterprise, Dentrix® Dental Vision®,
Dentrix Ascend®, Easy Dental®, OasisTM, Evolution® and EXACT®, Gesden®, Julie®Software,
Power Practice® Px, AxiUmTM, EndoVision®, PerioVision®, OMSVision® and Viive® for dental
practices, Advantage+TM, AVImark®, DVM Manager®, InfinityTM, SunpointTM, Triple CrownTM,
Vetech AdvantageTM, VisionVPMTM and Robovet® for animal health practices and MicroMD® for
physician practices.
• Repair services. We have 199 equipment sales and service centers worldwide that provide a variety of
repair, installation and technical services for our health care customers. Our technicians provide
installation and repair services for: dental handpieces; dental, animal health and medical small
equipment; table top sterilizers; and large dental equipment.
5
• Financial services. We offer our customers solutions in operating their practices more efficiently by
providing access to a number of financial services and products (including non-recourse financing for
equipment, technology and software products; non-recourse patient financing; collection services and
credit card processing) at rates that we believe are generally lower than what our customers would be
able to secure independently. We also provide consulting services, dental practice valuation and
brokerage services.
Commitment to superior customer service. We maintain a strong commitment to providing superior
customer service. We frequently monitor our customer service through customer surveys, focus groups and
statistical reports. Our customer service policy primarily focuses on:
• Exceptional order fulfillment. We ship an average of approximately 150,000 cartons daily.
Approximately 99% of items ordered are shipped without back ordering and are shipped on the same
business day the order is received.
• Streamlined ordering process. Customers may place orders 24 hours a day, 7 days a week by mail, fax,
telephone, e-mail, Internet and by using our computerized order entry systems.
Integrated management information systems. Our information systems generally allow for centralized
management of key functions, including accounts receivable, inventory, accounts payable, payroll,
purchasing, sales and order fulfillment. These systems allow us to manage our growth, deliver superior
customer service, properly target customers, manage financial performance and monitor daily operational
statistics.
Cost-effective purchasing. We believe that cost-effective purchasing is a key element to maintaining and
enhancing our position as a competitive-pricing provider of health care products. We continuously evaluate
our purchase requirements and suppliers’ offerings and prices in order to obtain products at the lowest
possible cost. In 2014, our top 10 health care distribution suppliers and our single largest supplier accounted
for approximately 36% and 7%, respectively, of our aggregate purchases.
Efficient distribution. We distribute our products from our strategically located distribution centers. We
strive to maintain optimal inventory levels in order to satisfy customer demand for prompt delivery and
complete order fulfillment. These inventory levels are managed on a daily basis with the aid of our
management information systems. Once an order is entered, it is electronically transmitted to the
distribution center nearest the customer’s location and a packing slip for the entire order is printed for order
fulfillment.
6
Products
The following table sets forth the percentage of consolidated net sales by principal categories of products
offered through our health care distribution and technology reportable segments:
Health care distribution:
Dental products (1) ..........................................................................
Animal health products (2) .............................................................
Medical products (3) .......................................................................
51.9 %
27.9
16.8
52.3 %
27.2
17.2
Total health care distribution .....................................................
96.6
96.7
53.4 %
26.0
17.4
96.8
2014
2013
2012
Technology:
Software and related products and
other value-added products (4) ...........................................
3.4
3.3
3.2
Total .......................................................................................................
100.0 %
100.0 %
100.0 %
(1)
Includes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants,
gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, equipment
repair and high-tech and digital restoration equipment.
(2)
Includes branded and generic pharmaceuticals, surgical and consumable products and services and equipment.
(3)
Includes branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products,
equipment and vitamins.
(4) Consists of practice management software and other value-added products, which are distributed primarily to health care providers,
and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services.
Business Strategy
Our objective is to continue to expand as a global value-added provider of health care products and services to
office-based dental, animal health and medical practitioners. To accomplish this, we will apply our competitive
strengths in executing the following strategies:
• Increase penetration of our existing customer base. We have over 1 million customers worldwide and we
intend to increase sales to our existing customer base and enhance our position as their primary supplier.
• Increase the number of customers we serve. This strategy includes increasing the number and productivity of
field sales consultants, as well as using our customer database to focus our marketing efforts in all of our
operating segments. In the dental business, we provide products and services to traditional dental practices as
well as new emerging segments, such as dental service organizations and community health
centers. Leveraging our unique assets and capabilities, we offer solutions to address these new markets. In
the medical business, we have expanded to serve customers located in settings outside of the traditional
office, such as urgent care clinics, retail and occupational health settings. As settings of health care shift, we
remain committed to serving these practitioners and providing them with the products and services they need.
7
• Leverage our value-added products and services. We continue to increase cross-selling efforts for key
product lines utilizing a consultative selling process. In the dental business, we have significant cross-selling
opportunities between our dental practice management software users and our dental distribution customers.
In the animal health business, we have opportunities to cross-sell practice management software and other
products. In the medical business, we have opportunities to expand our vaccine, injectables and other
pharmaceuticals sales to health care practitioners, as well as cross-selling core products and electronic health
record and practice management software. Our strategy extends to providing health systems, integrated
delivery networks and other large group and multi-site health care organizations, that include physician
clinics, these same value added products and services. As physicians and health systems closely align, we
have increased access to opportunities for cross-marketing and selling our product and service portfolios.
• Pursue strategic acquisitions and joint ventures. Our acquisition strategy includes acquiring businesses and
entering into joint ventures complementary to ours that will provide, among other things, additional sales to
be channeled through our existing distribution infrastructure, access to additional product lines and field sales
consultants and an opportunity to further expand into new geographic markets.
Markets Served
Demographic trends indicate that our markets are growing, as an aging U.S. population is increasingly using
health care services. Between 2014 and 2024, the 45 and older population is expected to grow by approximately
12%. Between 2014 and 2034, this age group is expected to grow by approximately 23%. This compares with
expected total U.S. population growth rates of approximately 8% between 2014 and 2024 and approximately 15%
between 2014 and 2034.
In the dental industry, there is predicted to be a rise in oral health care expenditures as the 45 and older segment
of the population increases. There is increasing demand for new technologies that allow dentists to increase
productivity, and this is being driven in the U.S. by lower insurance reimbursement rates. At the same time, there is
an expected increase in dental insurance coverage.
We support our dental professionals through the many SKUs that we offer, as well as through important value-
added services, including practice management software, electronic claims processing, financial services and
continuing education, all designed to help maximize a practitioner’s efficiency.
The animal health market, impacted by growing companion pet ownership and care, as well as increased focus
on safety and efficiency in livestock production, continues to provide additional growth opportunities for us. We
support the animal health practitioners we serve through the distribution of biologicals, pharmaceuticals, supplies
and equipment and by actively engaging in the development, sale and distribution of veterinary practice
management software.
There continues to be a migration of procedures from acute-care settings to physicians’ offices, a trend that we
believe provides additional opportunities for us. There also is the continuing use of vaccines, injectables and other
pharmaceuticals in alternate-care settings. We believe we have established a leading position as a vaccine supplier
to the office-based physician practitioner.
Additionally, we are expanding our dental full-service model, our animal health presence and our medical
offerings in countries where opportunities exist. Through our “Schein Direct” program, we also have the capability
to provide door-to-door air package delivery to practitioners in over 190 countries around the world.
For information on revenues and long-lived assets by geographic area, see Note 15 of “Notes to Consolidated
Financial Statements,” which is incorporated herein by reference.
8
Seasonality and Other Factors Affecting Our Business and Quarterly Results
We experience fluctuations in quarterly earnings. As a result, we may fail to meet or exceed the expectations
of securities analysts and investors, which could cause our stock price to decline.
Our business is subject to seasonal and other quarterly fluctuations. Net sales and operating profits generally
have been higher in the third and fourth quarters due to the timing of sales of seasonal products (including influenza
vaccine, equipment and software products), purchasing patterns of office-based health care practitioners and year-
end promotions. Net sales and operating profits generally have been lower in the first quarter, primarily due to
increased sales in the prior two quarters. We expect our historical seasonality of sales to continue in the foreseeable
future. Quarterly results may also be adversely affected by a variety of other factors, including:
• timing and amount of sales and marketing expenditures;
• timing of pricing changes offered by our vendors;
• timing of the introduction of new products and services by our vendors;
• timing of the release of upgrades and enhancements to our technology-related products and services;
• changes in or availability of vendor contracts or rebate programs;
• vendor rebates based upon attaining certain growth goals;
• changes in the way vendors introduce or deliver products to market;
• costs of developing new applications and services;
• our ability to correctly identify customer needs and preferences and predict future needs and
preferences;
• exclusivity requirements with certain vendors may prohibit us from distributing competitive products
manufactured by other vendors;
• loss of sales representatives;
• costs related to acquisitions and/or integrations of technologies or businesses;
• costs associated with our self-insured medical and dental insurance programs;
• general market and economic conditions, as well as those specific to the health care industry and
related industries;
• our success in establishing or maintaining business relationships;
• unexpected difficulties in developing and manufacturing products;
• product demand and availability or recalls by manufacturers;
• exposure to product liability and other claims in the event that the use of the products we sell results in
injury;
• increases in the cost of shipping or service issues with our third-party shippers;
• fluctuations in the value of foreign currencies;
• restructuring costs; and
• changes in accounting principles.
Any change in one or more of these or other factors could cause our annual or quarterly operating results to
fluctuate. If our operating results do not meet market expectations, our stock price may decline.
9
Governmental Regulations
Operating, Security and Licensure Standards
Certain of our businesses involve the distribution of pharmaceuticals and medical devices, and in this regard we
are subject to various local, state, federal and foreign governmental laws and regulations applicable to the
distribution of pharmaceuticals and medical devices. Among the United States federal laws applicable to us are the
Controlled Substances Act, the Federal Food, Drug, and Cosmetic Act, as amended, and Section 361 of the Public
Health Service Act. We are also subject to comparable foreign regulations.
The Federal Food, Drug, and Cosmetic Act (“FDC Act”) generally regulates the introduction, manufacture,
advertising, labeling, packaging, storage, handling, reporting, marketing and distribution of, and record keeping for,
pharmaceuticals and medical devices shipped in interstate commerce, and states may similarly regulate such
activities within the state. Section 361 of the Public Health Service Act, which provides authority to prevent the
spread of communicable diseases, serves as the legal basis for the United States Food and Drug Administration’s
(“FDA”) regulation of human cells, tissues and cellular and tissue-based products, also known as HCT/P products.
The FDC Act, as amended by the Drug Quality and Security Act of 2013, establishes certain requirements with
respect to the pharmaceutical supply chain, including with respect to product tracing, the licensure and operations
of prescription drug wholesale distributors and third party logistics providers (“3PLs”), and the pre-emption of state
law. At the federal level, pursuant to the FDC Act, the FDA has generally required wholesalers to provide a drug
pedigree for each wholesale distribution of a prescription drug, which is the record that tracks the chain of
ownership of a prescription drug as it is distributed through the United States pharmaceutical supply chain. Over
the last several years, many states have also implemented or proposed their own prescription drug pedigree laws
and regulations which were intended to protect the integrity of the pharmaceutical supply chain. This created a
patchwork of state licensing and drug pedigree (i.e., track and trace) requirements.
The Drug Quality and Security Act of 2013 brings about significant changes with respect to pharmaceutical
supply chain requirements and pre-empts state law. Title II of this measure, known as the Drug Supply Chain
Security Act (“DSCSA”), will be phased in over 10 years, and is intended to build a national electronic,
interoperable system to identify and trace certain prescription drugs as they are distributed in the United States.
The law began to take effect in January 2015, and on that date specific product tracing requirements for
manufacturers, wholesalers, repackagers and dispensers (e.g., pharmacies) of prescription drugs took effect,
although the FDA, in a Final Guidance issued on December 23, 2014, stated that in order to minimize possible
disruptions in the distribution of prescription drugs in the United States, it would not take action for noncompliance
with these track and trace requirements prior to May 1, 2015. These new product tracing requirements replace the
former FDA drug pedigree requirements and pre-empt state requirements that are inconsistent with, more stringent
than, or in addition to, the DSCSA requirements. Also in January 2015, the DSCSA required manufacturers and
wholesale distributors to have systems in place by which they can identify whether a product in their possession or
control is a “suspect” or “illegitimate” product, and handle it accordingly.
The DSCSA also establishes certain requirements for the licensing and operation of prescription drug
wholesalers and 3PLs, and includes the creation of national wholesaler and 3PL licenses in cases where states do
not license such entities. The DSCSA requires that wholesalers and 3PLs distribute drugs in accordance with
certain standards regarding the recordkeeping, storage and handling of prescription drugs. Wholesalers and 3PLs
are also required to submit annual reports to the FDA beginning on January 1, 2015, which include information
regarding each state where the wholesaler or 3PL is licensed, the name and address of each facility and contact
information. According to FDA guidance, states are pre-empted from imposing any licensing requirements that are
inconsistent with, less stringent than, directly related to, or covered by the standards established by federal law in
this area. Current state licensing requirements will likely remain in effect until the FDA issues new regulations as
directed by the DSCSA. In addition, the FDA is required to issue guidance and hold public meetings regarding the
implementation of the DSCSA’s track and trace requirements over the course of the next few years. The FDA has
begun this process, including by holding a public workshop in May 2014 and issuing various guidance documents,
including regarding suspect products, product tracing requirements, annual reporting to the FDA and the effect of
the law’s pre-emption provisions. We are in the process of analyzing the impact of the DSCSA on our business.
10
The FDC Act also requires the FDA to establish standards and identify and validate effective technologies for
the purpose of securing the pharmaceutical supply chain against counterfeit drugs. These standards include any
track and trace or authentication technologies, such as radio frequency identification, or RFID, and other
technologies. The FDA has also continued to develop its policies with respect to the integrity of the supply chain
by issuing a Final Guidance in 2010 regarding standardized numerical identification for prescription drug packages,
and a final rule in 2013 for a unique medical device identification system to be phased in over seven years that will
require most medical devices distributed in the United States to carry a unique device identifier. The DSCSA also
addresses product tracing using unique product identifiers on packaging, and may affect previously issued FDA
guidance regarding standardized numerical identifiers. The DSCSA and its forthcoming implementing regulations
may affect previously issued FDA guidance regarding standardized numerical identifiers.
Under the Controlled Substances Act, as a distributor of controlled substances, we are required to obtain and
renew annually registrations for our facilities from the United States Drug Enforcement Administration (“DEA”)
permitting us to handle controlled substances. We are also subject to other statutory and regulatory requirements
relating to the storage, sale, marketing, handling and distribution of such drugs, in accordance with the Controlled
Substances Act and its implementing regulations, and these requirements have been subject to heightened
enforcement activity in recent times. We are subject to inspection by the DEA.
Certain of our businesses are also required to register for permits and/or licenses with, and comply with
operating and security standards of, the DEA, the FDA, the United States Department of Health and Human
Services, and various state boards of pharmacy, state health departments and/or comparable state agencies as well
as comparable foreign agencies, and certain accrediting bodies depending on the type of operations and location of
product distribution, manufacturing or sale. These businesses include those that distribute, manufacture and/or
repackage prescription pharmaceuticals and/or medical devices and/or HCT/P products, or own pharmacy
operations, or install, maintain or repair equipment. In addition, Section 301 of the National Organ Transplant Act,
and a number of comparable state laws, impose civil and/or criminal penalties for the transfer of certain human
tissue (for example human bone products) for valuable consideration, while generally permitting payments for the
reasonable costs incurred in procuring, processing, storing and distributing that tissue. We are also subject to
foreign government regulation of such products. The DEA, the FDA and state regulatory authorities have broad
inspection and enforcement powers, including the ability to suspend or limit the distribution of products by our
distribution centers, seize or order the recall of products and impose significant criminal, civil and administrative
sanctions for violations of these laws and regulations. Foreign regulations subject us to similar foreign powers.
Furthermore, compliance with legal requirements has required and may in the future require us to institute
voluntary recalls of products we sell, which could result in financial losses and potential reputational harm. Our
customers are also subject to significant federal, state, local and foreign governmental regulation.
Certain of our businesses are subject to various additional federal, state, local and foreign laws and regulations,
including with respect to the sale, transportation, storage, handling and disposal of hazardous or potentially
hazardous substances, and safe working conditions. There have also been increasing efforts by various levels of
government globally to regulate the pharmaceutical distribution system in order to prevent the introduction of
counterfeit, adulterated or misbranded pharmaceuticals into the distribution system.
Certain of our businesses also maintain contracts with governmental agencies and are subject to certain
regulatory requirements specific to government contractors.
Health Care Fraud
Certain of our businesses are subject to federal and state (and similar foreign) health care fraud and abuse,
referral and reimbursement laws and regulations with respect to their operations. Some of these laws, referred to as
“false claims laws,” prohibit the submission or causing the submission of false or fraudulent claims for
reimbursement to federal, state and other health care payers and programs. Other laws, referred to as “anti-
kickback laws,” prohibit soliciting, offering, receiving or paying remuneration in order to induce the referral of a
patient or ordering, purchasing, leasing or arranging for or recommending ordering, purchasing or leasing, of items
or services that are paid for by federal, state and other health care payers and programs.
11
The fraud and abuse laws and regulations have been subject to varying interpretations, as well as heightened
enforcement activity over the past few years, and significant enforcement activity has been the result of “relators,”
who serve as whistleblowers by filing complaints in the name of the United States (and if applicable, particular
states) under federal and state false claims laws. Under the federal False Claims Act relators can be entitled to
receive up to 30% of total recoveries. Also, violations of the federal False Claims Act can result in treble damages,
and each false claim submitted can be subject to a penalty of up to $11,000 per claim. The Health Care Reform
Law significantly strengthened the federal False Claims Act and the anti-kickback law provisions, which could lead
to the possibility of increased whistleblower or relator suits, and among other things made clear that a federal anti-
kickback law violation can be a basis for federal False Claims Act liability.
The United States government has expressed concerns about financial relationships between suppliers on the
one hand and physicians and dentists on the other. As a result, we regularly review and revise our marketing
practices as necessary to facilitate compliance. We had discussions with the government regarding certain of our
marketing practices and have concluded such discussions in a manner that is not material to the Company. In
addition, under the reporting and disclosure obligations of the Physician Payment Sunshine Act provisions of the
Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, each
enacted in March 2010, generally known as the “Health Care Reform Law” (discussed in more detail in Health
Care Reform, below), on September 30, 2014 the general public and government officials were provided with
access to detailed information with regard to payments or other transfers of value to certain practitioners (including
physicians, dentists and teaching hospitals) by applicable drug and device manufacturers subject to such reporting
and disclosure obligations, which includes us. This information may lead to greater scrutiny, which may result in
modifications to established practices and additional costs. We also are subject to foreign regulations pertaining to
financial relationships between suppliers and physicians, dentist and other customers.
We also are subject to certain United States and foreign laws and regulations concerning the conduct of our
foreign operations, including the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act and other anti-bribery
laws and laws pertaining to the accuracy of our internal books and records, which have been the focus of increasing
enforcement activity globally in recent years.
Failure to comply with fraud and abuse laws and regulations could result in significant civil and criminal
penalties and costs, including the loss of licenses and the ability to participate in federal and state health care
programs, and could have a material adverse effect on our business. Also, these measures may be interpreted or
applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our
operations or incur substantial defense and settlement expenses. Even unsuccessful challenges by regulatory
authorities or private relators could result in reputational harm and the incurring of substantial costs. In addition,
many of these laws are vague or indefinite and have not been interpreted by the courts, and have been subject to
frequent modification and varied interpretation by prosecutorial and regulatory authorities, increasing the risk of
noncompliance.
While we believe that we are substantially compliant with fraud and abuse laws and regulations, and have
adequate compliance programs and controls in place to ensure substantial compliance, we cannot predict whether
changes in applicable law, or interpretation of laws, or changes in our services or marketing practices in response to
changes in applicable law or interpretation of laws, could adversely affect our business.
Health Care Reform
The United States Health Care Reform Law also included other provisions to reduce fraud and abuse and
Medicare expenditures and the cost of health care generally, to increase federal oversight of private health
insurance plans and to increase access to health coverage, some of which impact and further regulate some of our
businesses. In particular, a Health Care Reform Law provision, generally referred to as the Physician Payment
Sunshine Act or Open Payments Program, has imposed new reporting and disclosure requirements for drug and
device manufacturers with regard to payments or other transfers of value made to certain practitioners (including
physicians, dentists and teaching hospitals), and for such manufacturers and for group purchasing organizations,
with regard to certain ownership interests held by physicians in the reporting entity. On February 1, 2013, the
Centers for Medicare and Medicaid Services (“CMS”) released the final rule to implement the Physician Payment
Sunshine Act. Under this rule, data collection activities began on August 1, 2013, and first disclosure reports were
due by March 31, 2014 for the period August 1, 2013 through December 31, 2013. As required under the Physician
Payment Sunshine Act, CMS published information from these reports, on a publicly available website, including
amounts transferred and physician, dentist and teaching hospital identities, on September 30, 2014.
12
The final rule implementing the Physician Payment Sunshine Act is complex, ambiguous and broad in
scope. CMS commentary on the final rule and more recent CMS communications indicate that wholesale drug and
device distributors that take title to such products are to be treated as “applicable manufacturers” subject to full
reporting requirements. In addition, certain of our subsidiaries manufacture drugs and devices. Accordingly, we
are required to collect and report detailed information regarding certain financial relationships we have with
physicians, dentists and teaching hospitals. It is difficult to predict how the new requirements may impact existing
relationships among manufacturers, distributors, physicians, dentists and teaching hospitals. The Physician Payment
Sunshine Act pre-empts similar state reporting laws, although we or our subsidiaries may be required to report
under certain of such state laws in addition to Physician Payment Sunshine Act reporting, and some of these state
laws are also ambiguous. We completed the initial Physician Payment Sunshine Act submission to CMS due
March 31, 2014, covering the period August 1 to December 31, 2013. Beginning in 2014 and each year thereafter,
data collection for each calendar year must be submitted by March 31 of the subsequent year. We are also subject
to foreign regulations requiring transparency of certain interactions between suppliers and their customers. While
we believe we have substantially compliant programs and controls in place to comply with the Physician Payment
Sunshine Act requirements (and similar foreign requirements), our compliance with the new final rule (and similar
foreign requirements) imposes additional costs on us.
On June 28, 2012, the United States Supreme Court upheld as constitutional a key provision in the Health Care
Reform Law often referred to as the “individual mandate,” which will require most individuals to have health
insurance in 2014, or to pay a penalty. However, the decision also invalidated a provision in the Health Care
Reform Law requiring states in 2014 to expand their Medicaid programs or risk the complete loss of all federal
Medicaid funding. The Court held that the federal government may offer states the option of accepting the
expansion requirement, but that it may not take away pre-existing Medicaid funds in order to coerce states into
complying with the expansion. Almost half the states have not yet accepted the Medicaid expansion, so the full
extent of increased health care coverage under the Health Care Reform Law is uncertain. Subsequent litigation has
focused on whether the Health Care Reform Law permits the use of health insurance subsidies for low and
moderate income individuals who purchase coverage through the health insurance exchanges established by the
federal government. In most states, the health insurance exchanges are established by the federal government, not
the state itself, and federal courts have issued contradictory rulings on this matter. The United States Supreme
Court has agreed to hear a case in which a federal appeals court upheld the subsidies for federal health insurance
exchanges. The Supreme Court is expected to issue a ruling by the end of June 2015, and if the subsidies are held
to be unavailable through federal health insurance exchanges, this might significantly limit the application of the
Health Care Reform Law. Adding to this uncertainty, in responding to difficulties encountered in implementing
Health Care Reform, the White House and federal agencies have instituted various temporary implementation
delays, such as regarding the “employer mandate.” With respect to the employer mandate, starting in 2015
employers with 100 or more full-time employees must generally provide certain health insurance to their workforce
or pay specified fines, while starting in 2016 the requirement will apply to employers with 50 or more full-time
employees.
Regulated Software; Electronic Health Records
The FDA has become increasingly active in addressing the regulation of computer software intended for use in
health care settings, and has been developing policies on regulating clinical decision support tools as medical
devices. Certain of our businesses involve the development and sale of software and related products to support
physician and dental practice management, and it is possible that the FDA or comparable foreign government
authorities could determine that one or more of our products is a medical device, which could subject us or one or
more of our businesses to substantial additional requirements with respect to these products.
Certain of our businesses involve access to personal health, medical, financial and other information of
individuals, and are accordingly directly or indirectly subject to numerous federal, state, local and foreign laws and
regulations that protect the privacy and security of such information, and require, among other things, the
implementation of various recordkeeping, operational, notice and other practices intended to safeguard that
information, limit its use to allowed purposes and notify individuals in the event of privacy and security breaches.
13
Failure to comply with these laws can result in substantial penalties and other liabilities. As a result of the
federal Health Information Technology for Economic and Clinical Health Act (“HITECH Act”), which was passed
in 2009, some of our businesses that were previously only indirectly subject to federal Health Insurance Portability
and Accountability Act of 1996 (“HIPAA”) privacy and security rules became directly subject to such rules
because such businesses serve as “business associates” of HIPAA covered entities, such as health care providers.
On January 17, 2013 the Office for Civil Rights of the Department of Health and Human Services released a final
rule implementing the HITECH Act and making certain other changes to HIPAA privacy and security
requirements. Compliance with the rule was required by September 23, 2013, and increases the requirements
applicable to some of our businesses.
In addition, federal initiatives, including in particular the HITECH Act, are providing a program of incentive
payments available to certain health care providers involving the adoption and use of certain electronic health care
records systems and processes. The HITECH initiative includes providing, among others, physicians and dentists,
with financial incentives, if they meaningfully use certified electronic health record technology (“EHR”) in
accordance with applicable requirements. With respect to recognizing “certified” EHR technology, CMS
regulations reference an older “2011 edition certified technology,” which is to be replaced by a newer “2014 edition
certified technology.” In addition, Medicare-eligible providers that fail to timely adopt certified EHR systems and
meet “meaningful use” requirements for those systems in accordance with regulatory requirements are to be subject
to cumulative Medicare reimbursement reductions, which reductions for eligible health professionals (including
physicians and dentists) began on January 1, 2015. This reduction is subject to a grant of a “hardship” exemption
by CMS, which generally permits providers to avoid Medicare reimbursement reductions where they can show that
demonstrating meaningful use of EHR would result in a significant hardship. Qualification for the incentive
payments requires the use of EHRs that have certain capabilities for meaningful use pursuant to standards adopted
by the Department of Health and Human Services. Initial (“Stage 1”) standards addressed criteria for periods
beginning in 2011. CMS has also issued a final rule with more demanding “Stage 2” criteria for periods beginning
in 2014 for eligible health professionals (including physicians and dentists).
Recognizing difficulties encountered by some providers in acquiring and implementing 2014 edition-certified
EHR technology, CMS published a final rule on September 4, 2014 that adds flexibility to the manner in which
physicians, dentists and others may demonstrate meaningful use of EHR by extending through the 2014 reporting
period the ability, in certain circumstances, to use 2011 edition-certified technology to attest to meaningful use,
rather than requiring the use of 2014 edition-certified technology. The rule also delays for one year implementation
of more rigorous “Stage 3” measures, and under this rule eligible health professionals (including physicians and
dentists) would begin Stage 3 in calendar year 2017. In addition, also in recognition of difficulties encountered by
some providers in acquiring and implementing 2014 edition-certified EHR technology, CMS has specifically
recognized that a hardship exemption may be granted, among other reasons, where the provider’s failure to
demonstrate meaningful use was caused by its EHR vendor’s failure to timely obtain 2014 certification for its EHR
technology, and extended the deadline for health care professionals to file hardship exemption applications from
July 1, 2014 to November 30, 2014. On January 29, 2015, CMS announced an intent to engage in further
rulemaking under the EHR incentive program to redress the Stage 2 reporting burden on providers. Among other
things, the new rule, expected in the Spring of 2015, will tie EHR reporting to a calendar year, modify other aspects
of the program and shorten the EHR reporting period in 2015 to 90 days. Certain of our businesses involve the
manufacture and sale of certified EHR systems and other products linked to incentive programs, and so must
maintain compliance with, and are affected by, these evolving governmental criteria.
14
Also, HIPAA requires certain health care providers, such as physicians, to use certain transaction and code set
rules for specified electronic transactions, such as transactions involving claims submissions. Commencing July 1,
2012, CMS required that electronic claim submissions and related electronic transactions be conducted under a new
HIPAA transaction standard called Version 5010. CMS has required this upgrade in connection with another new
requirement applicable to the industry, the implementation of new diagnostic code sets to be used in claims
submission. The new diagnostic code sets are called the ICD-10-CM. They were originally to be implemented on
October 1, 2013 (and CMS delayed the implementation date until October 1, 2014), but as part of the Protecting
Access to Medicare Act of 2014, enacted on April 1, 2014, Congress prohibited the Secretary of Health and Human
Services from implementing ICD-10-CM any earlier than October 1, 2015. CMS published a final rule on
August 4, 2014 adopting the October 1, 2015 compliance date and requiring the use of ICD-9-CM code sets
through September 30, 2015, and there is no suggestion that implementation will be further delayed. Certain of our
businesses provide electronic practice management products that must meet those requirements, and while we
believe that we are prepared to timely adopt the new standards, it is possible that the transition to these new
standards, particularly the transition to ICD-10-CM, may result in a degree of disruption and confusion, thus
potentially increasing the costs associated with supporting this product.
International Transactions
In addition, United States and foreign import and export laws and regulations require us to abide by certain
standards relating to the importation and exportation of products. We also are subject to certain laws and
regulations concerning the conduct of our foreign operations, including the U.S. Foreign Corrupt Practices Act, the
U.K. Bribery Act and other anti-bribery laws and laws pertaining to the accuracy of our internal books and records,
as well as other types of foreign requirements similar to those imposed in the United States.
While we believe that we are substantially compliant with the foregoing laws and regulations promulgated
thereunder and possess all material permits and licenses required for the conduct of our business, there can be no
assurance that regulations that impact our business or customers’ practices will not have a material adverse effect
on our business. As a result of political, economic and regulatory influences, the health care distribution industry in
the United States is under intense scrutiny and subject to fundamental changes. We cannot predict what further
reform proposals, if any, will be adopted, when they may be adopted, or what impact they may have on us.
See “ITEM 1A. Risk Factors” for a discussion of additional burdens, risks and regulatory developments that
may affect our results of operations and financial condition.
Proprietary Rights
We hold trademarks relating to the “Henry Schein®” name and logo, as well as certain other trademarks. We
intend to protect our trademarks to the fullest extent practicable.
15
Employees
As of December 27, 2014, we employed more than 17,500 full-time employees, including approximately 1,825
telesales representatives, 3,650 field sales consultants, including equipment sales specialists, 3,400 warehouse
employees, 550 computer programmers and technicians, 900 management employees and 7,475 office, clerical and
administrative employees. Over 310, or 1.8%, of our employees were subject to collective bargaining agreements.
We believe that our relations with our employees are excellent.
Available Information
We make available free of charge through our Internet website, www.henryschein.com, our annual report on
Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, statements of beneficial ownership of
securities on Forms 3, 4 and 5 and amendments to these reports and statements filed or furnished pursuant to
Section 13(a) and Section 16 of the Securities Exchange Act of 1934 as soon as reasonably practicable after such
materials are electronically filed with, or furnished to, the United States Securities and Exchange Commission, or
SEC.
The above information is also available at the SEC’s Office of Investor Education and Advocacy at United
States Securities and Exchange Commission, 100 F Street, N.E., Washington, D.C. 20549-0213 or obtainable by
calling the SEC at (800) 732-0330. In addition, the SEC maintains an Internet website at www.sec.gov, where the
above information can be viewed.
Our principal executive offices are located at 135 Duryea Road, Melville, New York 11747, and our telephone
number is (631) 843-5500. Unless the context specifically requires otherwise, the terms the “Company,” “Henry
Schein,” “we,” “us” and “our” mean Henry Schein, Inc., a Delaware corporation, and its consolidated subsidiaries.
16
Executive Officers of the Registrant
The following table sets forth certain information regarding our executive officers:
Name
Age
Position
Stanley M. Bergman ..................... 65
Gerald A. Benjamin ...................... 62
James P. Breslawski ...................... 60
Leonard A. David .......................... 66
Michael S. Ettinger ....................... 53
James A. Harding .......................... 59
Stanley Komaroff .......................... 79
Lorelei McGlynn ........................... 51
David C. McKinley ....................... 62
Bob Minowitz ............................... 56
Mark E. Mlotek ............................. 59
Steven Paladino ............................. 57
Michael Racioppi .......................... 60
Paul Rose ...................................... 57
Lonnie Shoff ................................. 56
Walter Siegel ................................. 55
Chairman, Chief Executive Officer, Director
Executive Vice President, Chief Administrative Officer, Director
President, Henry Schein and CEO, Global Dental Group, Director
Senior Vice President, Chief Compliance Officer
Senior Vice President, Corporate and Legal Affairs & Secretary
Senior Vice President, Chief Technology Officer
Senior Advisor
Senior Vice President, Global Human Resources and Financial Operations
President, Medical Group
President, International Dental Group
Executive Vice President, Chief Strategic Officer, Director
Executive Vice President, Chief Financial Officer, Director
Senior Vice President, Chief Merchandising Officer
Senior Vice President, Global Supply Chain
CEO, Global Animal Health and Strategic Partnership Group
Senior Vice President and General Counsel
Stanley M. Bergman has been our Chairman and Chief Executive Officer since 1989 and a director since
1982. Mr. Bergman held the position of President from 1989 to 2005. Mr. Bergman held the position of Executive
Vice President from 1985 to 1989 and Vice President of Finance and Administration from 1980 to 1985.
Gerald A. Benjamin has been our Executive Vice President and Chief Administrative Officer since 2000 and a
director since 1994. Prior to holding his current position, Mr. Benjamin was Senior Vice President of
Administration and Customer Satisfaction since 1993. Mr. Benjamin was Vice President of Distribution
Operations from 1990 to 1992 and Director of Materials Management from 1988 to 1990. Before joining us in
1988, Mr. Benjamin was employed for 12 years in various management positions at Estée Lauder, Inc., where his
last position was Director of Materials Planning and Control.
James P. Breslawski has been our President since 2005 and a director since 1992. Mr. Breslawski is also the
Chief Executive Officer of our Henry Schein Global Dental Group. Mr. Breslawski held the position of Executive
Vice President and President of U.S. Dental from 1990 to 2005, with primary responsibility for the North American
Dental Group. Between 1980 and 1990, Mr. Breslawski held various positions with us, including Chief Financial
Officer, Vice President of Finance and Administration and Controller.
Leonard A. David has been our Senior Vice President and Chief Compliance Officer since 2006. Mr. David
held the position of Vice President and Chief Compliance Officer from 2005 to 2006. Mr. David held the position
of Vice President of Human Resources and Special Counsel from 1995 to 2005. Mr. David held the position of
Vice President, General Counsel and Secretary from 1990 through 1994 and practiced corporate and business law
for eight years prior to joining us.
Michael S. Ettinger has been Senior Vice President, Corporate and Legal Affairs & Secretary since 2013.
Prior to holding his current position, Mr. Ettinger served as Corporate Senior Vice President, General Counsel &
Secretary from 2006 to 2013, Vice President, General Counsel and Secretary from 2000 to 2006, Vice President
and Associate General Counsel from 1998 to 2000 and Associate General Counsel from 1994 to 1998. Before
joining us, Mr. Ettinger served as a senior associate with Bower & Gardner and as a member of the Tax Department
at Arthur Andersen.
James A. Harding has been our Chief Technology Officer since 2005 and Senior Vice President since 2001.
Prior to holding his current position, Mr. Harding was Chief Information Officer since 2001, with primary
responsibility for worldwide information technology.
17
Stanley Komaroff has been our Senior Advisor since 2003. Prior to joining us, Mr. Komaroff was a partner
for 35 years in the law firm of Proskauer Rose LLP, counsel to us. He served as Chairman of that firm from 1991
to 1999.
Lorelei McGlynn has served as Senior Vice President, Global Human Resources and Financial Operations
since 2013. Since joining us in 1999, Ms. McGlynn has served as Vice President, Global Human Resources and
Financial Operations from 2008 to 2013, Chief Financial Officer, International Group and Vice President of Global
Financial Operations from 2002 to 2008 and Vice President, Finance, North America from 1999 to 2002. Prior to
joining us, Ms. McGlynn served as Assistant Vice President of Finance at Adecco Corporation.
David C. McKinley has been President of Henry Schein’s Medical Group since 2008. Before assuming his
current position, Mr. McKinley was President of Henry Schein Practice Solutions from 2006 to 2008 and President
of Dental Prosthetic Solutions from 2005 to 2006. Prior to joining us, Mr. McKinley served as the Group
Executive for Olympus Medical North America and as General Manager for the Bard Urology and Bard Germany
businesses. Mr. McKinley currently serves on the Health Industry Distributors Association (HIDA) Education
Foundation.
Bob Minowitz has been President of Henry Schein’s International Dental Group since 2012. Up until 2012,
Mr. Minowitz held various roles throughout the Company, including President, Henry Schein European Dental
Group from 2009 to 2012, President, Henry Schein Western Europe, Middle East and Pacific Regions from 2006 to
2009, Managing Director, Henry Schein U.K. Holdings from 2003 to 2006, President Henry Schein Western
Europe from 2004 to 2006 and President Henry Schein Europe from 2001 to 2004. Prior to joining us, Mr.
Minowitz was employed by Bristol-Myers Company as a Senior Internal Auditor.
Mark E. Mlotek has been Executive Vice President and Chief Strategic Officer since 2012. Mr. Mlotek was
Senior Vice President and subsequently Executive Vice President of the Corporate Business Development Group
between 2000 and 2012. Prior to that, Mr. Mlotek was Vice President, General Counsel and Secretary from 1994 to
1999 and became a director in 1995. Prior to joining us, Mr. Mlotek was a partner in the law firm of Proskauer
Rose LLP, counsel to us, specializing in mergers and acquisitions, corporate reorganizations and tax law from 1989
to 1994.
Steven Paladino has been our Executive Vice President and Chief Financial Officer since 2000. Prior to
holding his current position, Mr. Paladino was Senior Vice President and Chief Financial Officer from 1993 to
2000 and has been a director since 1992. From 1990 to 1992, Mr. Paladino served as Vice President and Treasurer
and from 1987 to 1990 served as Corporate Controller. Before joining us, Mr. Paladino was employed in public
accounting for seven years, most recently with the international accounting firm of BDO USA, LLP. Mr. Paladino
is a certified public accountant.
Michael Racioppi has been our Senior Vice President, Chief Merchandising Officer since 2008. Prior to
holding his current position, Mr. Racioppi was President of the Medical Division from 2000 to 2008 and Interim
President from 1999 to 2000, and Corporate Vice President from 1994 to 2008. Mr. Racioppi served as Senior
Director, Corporate Merchandising from 1992 to 1994. Before joining us in 1992, Mr. Racioppi was employed by
Ketchum Distributors, Inc. as the Vice President of Purchasing and Marketing.
Paul Rose has served as Senior Vice President, Global Supply Chain since 2013. Prior to assuming his current
position, Mr. Rose served as Vice President, Global Supply Chain from 2008 to 2013, Vice President, Global
Inventory Management from 2004 to 2008 and Vice President, Inventory Management, North America from 2001
to 2004. He also served on the HIDA Supply Chain Advisory Council and as NWDA Pharmaceutical Market
Committee Chairman.
Lonnie Shoff has been Chief Executive Officer of the Global Animal Health and Strategic Partnerships Group
since 2010. Prior to joining us in 2009, Ms. Shoff was employed with Roche Diagnostics, where she held a series
of positions of increasing responsibility in the United States and Switzerland over the past 20 years, most recently
as Senior Vice President and General Manager, Applied Science.
Walter Siegel has been Senior Vice President and General Counsel since 2013. Prior to joining us, Mr. Siegel
was employed with Standard Microsystems Corporation, a publicly traded global semiconductor company from
2005 to 2012, holding positions of increasing responsibility, most recently as Senior Vice President, General
Counsel and Secretary.
18
ITEM 1A. Risk Factors
The risks described below could have a material adverse effect on our business, reputation, financial condition
or the trading price of our common stock. Although it is not possible to predict or identify all such risks and
uncertainties, they may include, but are not limited to, the factors discussed below. Our business operations could
also be affected by additional factors that are not presently known to us or that we currently consider not to be
material to our operations. You should not consider this list to be a complete statement of all risks and
uncertainties. The order in which these factors appear should not be construed to indicate their relative importance
or priority.
The health care products distribution industry is highly competitive and we may not be able to compete
successfully.
We compete with numerous companies, including several major manufacturers and distributors. Some of our
competitors have greater financial and other resources than we do, which could allow them to compete more
successfully. Most of our products are available from several sources and our customers tend to have relationships
with several distributors. Competitors could obtain exclusive rights to market particular products, which we would
then be unable to market. Manufacturers also could increase their efforts to sell directly to end-users and thereby
eliminate or reduce our role and that of other distributors. Industry consolidation among health care product
distributors, price competition, the unavailability of products, whether due to our inability to gain access to products
or to interruptions in supply from manufacturers, or the emergence of new competitors also could increase
competition. In the future, we may be unable to compete successfully and competitive pressures may reduce our
revenues.
Because substantially all of the products that we distribute are not manufactured by us, we are dependent upon
third parties for the manufacture and supply of substantially all of our products.
We obtain substantially all of our products from third-party suppliers. Generally, we do not have long-term
contracts with our suppliers committing them to supply products to us. Therefore, suppliers may not provide the
products we need in the quantities we request. While there is generally more than one source of supply for most of
the categories of products we sell, some key suppliers, in the aggregate, supply a significant portion of the products
we sell. Additionally, because we generally do not control the actual production of the products we sell, we may be
subject to delays caused by interruption in production based on conditions outside of our control, including the
failure to comply with applicable government requirements. The failure of manufacturers of products regulated by
the FDA to meet these requirements could result in product recall, cessation of sales or other market disruptions. In
the event that any of our third-party suppliers were to become unable or unwilling to continue to provide the
products in required volumes, we would need to identify and obtain acceptable replacement sources on a timely
basis. There is no guarantee that we would be able to obtain such alternative sources of supply on a timely basis, if
at all. An extended interruption in the supply of our products, especially any high sales volume product, would
have an adverse effect on our results of operations, which most likely would adversely affect the value of our
common stock.
Our revenues depend on our relationships with capable sales personnel as well as customers, suppliers and
manufacturers of the products that we distribute.
Our future operating results depend on our ability to maintain satisfactory relationships with qualified sales
personnel as well as customers, suppliers and manufacturers. If we fail to maintain our existing relationships with
such persons or fail to acquire relationships with such key persons in the future, our business may be adversely
affected.
Our future success is substantially dependent upon our senior management.
Our future success is substantially dependent upon the efforts and abilities of members of our existing senior
management, particularly Stanley M. Bergman, Chairman and Chief Executive Officer, among others. The loss of
the services of Mr. Bergman could have a material adverse effect on our business. We have an employment
agreement with Mr. Bergman. We do not currently have “key man” life insurance policies on any of our
employees. Competition for senior management is intense and we may not be successful in attracting and retaining
key personnel.
19
We experience fluctuations in quarterly earnings. As a result, we may fail to meet or exceed the expectations of
securities analysts and investors, which could cause our stock price to decline.
Our business is subject to seasonal and other quarterly fluctuations. Net sales and operating profits generally
have been higher in the third and fourth quarters due to the timing of sales of seasonal products (including influenza
vaccine, equipment and software products), purchasing patterns of office-based health care practitioners and year-
end promotions. Net sales and operating profits generally have been lower in the first quarter, primarily due to
increased sales in the prior two quarters. We expect our historical seasonality of sales to continue in the foreseeable
future. Quarterly results may also be adversely affected by a variety of other factors, including:
• timing and amount of sales and marketing expenditures;
• timing of pricing changes offered by our vendors;
• timing of the introduction of new products and services by our vendors;
• timing of the release of upgrades and enhancements to our technology-related products and services;
• changes in or availability of vendor contracts or rebate programs;
• vendor rebates based upon attaining certain growth goals;
• changes in the way vendors introduce or deliver products to market;
• costs of developing new applications and services;
• our ability to correctly identify customer needs and preferences and predict future needs and
preferences;
• exclusivity requirements with certain vendors may prohibit us from distributing competitive products
manufactured by other vendors;
• loss of sales representatives;
• costs related to acquisitions and/or integrations of technologies or businesses;
• costs associated with our self-insured medical and dental insurance programs;
• general market and economic conditions, as well as those specific to the health care industry and
related industries;
• our success in establishing or maintaining business relationships;
• unexpected difficulties in developing and manufacturing products;
• product demand and availability or recalls by manufacturers;
• exposure to product liability and other claims in the event that the use of the products we sell results in
injury;
• increases in the cost of shipping or service issues with our third-party shippers;
• fluctuations in the value of foreign currencies;
• restructuring costs; and
• changes in accounting principles.
Any change in one or more of these or other factors could cause our annual or quarterly operating results to
fluctuate. If our operating results do not meet market expectations, our stock price may decline.
20
Expansion of group purchasing organizations (“GPO”) or provider networks and the multi-tiered costing
structure may place us at a competitive disadvantage.
The medical products industry is subject to a multi-tiered costing structure, which can vary by manufacturer
and/or product. Under this structure, certain institutions can obtain more favorable prices for medical products than
we are able to obtain. The multi-tiered costing structure continues to expand as many large integrated health care
providers and others with significant purchasing power, such as GPOs, demand more favorable pricing terms.
Additionally, the formation of provider networks and GPOs may shift purchasing decisions to entities or persons
with whom we do not have a historical relationship. This may threaten our ability to compete effectively, which
would in turn negatively impact our results of operations. Although we are seeking to obtain similar terms from
manufacturers, obtain access to lower prices demanded by GPO contracts or other contracts, and develop
relationships with provider networks and new GPOs, we cannot assure that such terms will be obtained or contracts
will be executed.
Increases in the cost of shipping or service issues with our third-party shippers could harm our business.
Shipping is a significant expense in the operation of our business. We ship almost all of our orders through
third-party delivery services, and typically bear the cost of shipment. Accordingly, any significant increase in
shipping rates could have an adverse effect on our operating results. Similarly, strikes or other service interruptions
by those shippers could cause our operating expenses to rise and adversely affect our ability to deliver products on a
timely basis.
Uncertain global macro-economic and political conditions could adversely affect our results of operations and
financial condition.
Uncertain global macro-economic conditions that affect the economy and the economic outlook of the United
States, Europe and other parts of the world could adversely affect our customers and vendors, which could
adversely affect our results of operations and financial condition. These uncertainties, including, among other
things, sovereign debt levels, the inability of political institutions to effectively resolve actual or perceived
economic, currency or budgetary crises or issues, consumer confidence, unemployment levels (and a corresponding
increase in the uninsured and underinsured population), interest rates, availability of capital, fuel and energy costs,
tax rates, health care costs and the threat or outbreak of terrorism or public unrest, could adversely impact our
customers and vendors, which could adversely affect us. Government debt and/or budget crises may lead to
reductions in government spending in certain countries, which could reduce overall health care spending, and/or
higher income or corporate taxes, which could depress spending overall. Additionally, recessionary conditions and
depressed levels of consumer and commercial spending may cause customers to reduce, modify, delay or cancel
plans to purchase our products and may cause vendors to reduce their output or change their terms of sale. We
generally sell products to customers with payment terms. If customers’ cash flow or operating and financial
performance deteriorates, or if they are unable to make scheduled payments or obtain credit, they may not be able
to pay, or may delay payment to us. Likewise, for similar reasons vendors may restrict credit or impose different
payment terms. Any inability of current and/or potential customers to pay us for our products and/or services or
any demands by vendors for different payment terms may adversely affect our results of operations and financial
condition.
Disruptions in the financial markets may adversely affect the availability and cost of credit to us.
Our ability to make scheduled payments or refinance our obligations with respect to indebtedness will depend
on our operating and financial performance, which in turn is subject to prevailing economic conditions and
financial, business and other factors beyond our control. Disruptions in the financial markets may adversely affect
the availability and cost of credit to us.
21
The market price for our common stock may be highly volatile.
The market price for our common stock may be highly volatile. A variety of factors may have a significant
impact on the market price of our common stock, including:
•
the publication of earnings estimates or other research reports and speculation in the press or
investment community;
• changes in our industry and competitors;
• our financial condition, results of operations and cash flows and prospects;
• stock repurchases;
• any future issuances of our common stock, which may include primary offerings for cash, stock splits,
issuances in connection with business acquisitions, issuances of restricted stock/units and the grant or
exercise of stock options from time to time;
• general market and economic conditions; and
• any outbreak or escalation of hostilities in areas where we do business.
In addition, the NASDAQ Stock Market can experience extreme price and volume fluctuations that can be
unrelated or disproportionate to the operating performance of the companies listed on NASDAQ. Broad market
and industry factors may negatively affect the market price of our common stock, regardless of actual operating
performance. In the past, following periods of volatility in the market price of a company’s securities, securities
class action litigation has often been instituted against companies. This type of litigation, if instituted, could result
in substantial costs and a diversion of management’s attention and resources, which would have an adverse effect
on our business.
The health care industry is experiencing changes that could adversely affect our business.
The health care industry is highly regulated and subject to changing political, economic and regulatory
influences. In recent years, the health care industry has undergone, and is in the process of undergoing, significant
changes driven by various efforts to reduce costs, including: trends toward managed care; consolidation of health
care distribution companies; consolidation of health care manufacturers; collective purchasing arrangements and
consolidation among office-based health care practitioners; and changes in reimbursements to customers, as well as
growing enforcement activities (and related monetary recoveries) by governmental officials. Both our own profit
margins and the profit margins of our customers may be adversely affected by laws and regulations reducing
reimbursement rates for pharmaceuticals and/or medical treatments or services, changing the methodology by
which reimbursement levels are determined and, in the case of animal health practitioners, changes in the use of
feed additives (including, without limitation, antibiotics and growth promotants) used in the production of animal
products due to trade restrictions, animal welfare and/or government regulations; and changes in customer buying
habits (including customers purchasing animal health pharmaceuticals outside the veterinarians’ offices). If we are
unable to react effectively to these and other changes in the health care industry, our operating results could be
adversely affected. In addition, the enactment of significant health care reforms could have a material adverse
effect on our businesses.
The implementation of the Health Care Reform Law could adversely affect our business.
The United States Patient Protection and Affordable Care Act as amended by the Health Care and Education
Reconciliation Act, each enacted in March 2010, generally known as the Health Care Reform Law, significantly
expand health insurance coverage to uninsured Americans and changes the way health care is financed by both
governmental and private payers. We expect expansion of access to health insurance to increase the demand for
our products and services, but other provisions of the Health Care Reform Law could affect us adversely, and the
Health Care Reform Law may be invalidated, in whole or in part, or it may be repealed. Additionally, further
federal and state proposals for health care reform in the United States are likely, and foreign government authorities
may also adopt reforms of their health systems. We cannot predict what further reform proposals, if any, will be
adopted, when they may be adopted, or what impact they may have on us.
22
The Health Care Reform Law contains many provisions designed to generate the revenues necessary to fund
the coverage expansions and to reduce costs of Medicare and Medicaid, including imposing a 2.3% excise tax on
domestic sales of many medical devices by manufacturers and importers that began in 2013, and a fee on branded
prescription drugs and biologics that was implemented in 2011, both of which may adversely affect sales and cost
of goods sold.
The implementation of the reporting and disclosure obligations of the Physician Payment Sunshine Act
provisions of the Health Care Reform Law could adversely affect our business.
A Health Care Reform Law provision, generally referred to as the Physician Payment Sunshine Act or Open
Payments Program, has imposed new reporting and disclosure requirements for drug and device manufacturers with
regard to payments or other transfers of value made to certain practitioners (including physicians, dentists and
teaching hospitals), and for such manufacturers and for group purchasing organizations, with regard to certain
ownership interests held by physicians in the reporting entity. On February 1, 2013, CMS released the final rule to
implement the Physician Payment Sunshine Act. Under this rule, data collection activities began on August 1,
2013, and we timely filed our first disclosure reports on June 30, 2014 for the period August 1, 2013 through
December 31, 2013. As required under the Physician Payment Sunshine Act, CMS published information from
these reports on a publicly available website, including amounts transferred and physician, dentist and teaching
hospital identities on September 30, 2014.
The final rule implementing the Physician Payment Sunshine Act is complex, ambiguous and broad in scope.
CMS commentary on the final rule and more recent CMS communications indicate that wholesale drug and device
distributors which take title to such products are to be treated as “applicable manufacturers” subject to full reporting
requirements. In addition, certain of our subsidiaries manufacture drugs and devices. Accordingly, we are required
to collect and report detailed information regarding certain financial relationships we have with physicians, dentists
and teaching hospitals. It is difficult to predict how the new requirements may impact existing relationships among
manufacturers, distributors, physicians, dentists and teaching hospitals. The Physician Payment Sunshine Act
preempts similar state reporting laws, although we or our subsidiaries may be required to continue to report under
certain of such state laws in addition to Physician Payment Sunshine Act reporting, and some of these state laws are
also ambiguous. We are also subject to foreign regulations requiring transparency of certain interactions between
suppliers and their customers. While we believe we have substantially compliant programs and controls in place to
comply with the Physician Payment Sunshine Act requirements (and similar foreign requirements), our compliance
with the new final rule (and similar foreign requirements) imposes additional costs on us.
Failure to comply with existing and future regulatory requirements could adversely affect our business.
Our business is subject to requirements under various local, state, federal and international laws and regulations
applicable to the distribution of pharmaceuticals and medical devices, and human cells, tissue and cellular and
tissue-based products, also known as HCT/P products, and animal feed and supplements. Among the federal laws
with which we must comply are the Controlled Substances Act, the Federal Food, Drug, and Cosmetic Act, as
amended, and Section 361 of the Public Health Services Act. Among other things, such laws, and the regulations
promulgated thereunder:
• regulate the storage and distribution, labeling, packaging, handling, reporting, record keeping,
introduction, manufacturing and marketing of drugs, HCT/P products and medical devices;
• subject us to inspection by the FDA and the DEA;
• regulate the storage, transportation and disposal of certain of our products that are considered
hazardous materials;
• require us to advertise and promote our drugs and devices in accordance with applicable FDA
requirements;
• require registration with the FDA and the DEA and various state agencies;
• require record keeping and documentation of transactions involving drug products;
• require us to design and operate a system to identify and report suspicious orders of controlled
substances to the DEA;
23
• require us to manage returns of products that have been recalled and subject us to inspection of our
recall procedures and activities; and
•
impose reporting requirements if a pharmaceutical, HCT/P product or medical device causes serious
illness, injury or death.
Applicable federal, state, local and foreign laws and regulations also may require us to meet various standards
relating to, among other things, licensure or registration, sales and marketing practices, product integrity and supply
tracking to the manufacturer of the product, personnel, privacy and security of health or other personal information,
installation, maintenance and repair of equipment, and the importation and exportation of products. Our business
also is subject to requirements of similar and other foreign governmental laws and regulations affecting our
operations abroad. The FDA and DEA have recently increased their regulatory and enforcement activities.
The failure to comply with any of these regulations, or new interpretations of existing laws and regulations, or
the imposition of any additional laws and regulations, could negatively affect our business. There can be no
assurance that current government regulations will not adversely affect our business. The costs to us associated
with complying with the various applicable statutes and regulations, as they now exist and as they may be modified,
could be material. Allegations by a governmental body that we have not complied with these laws could have a
material adverse effect on our businesses. If it is determined that we have not complied with these laws, we are
potentially subject to penalties including warning letters, civil and criminal penalties, mandatory recall of product,
seizure of product and injunction, and suspension or limitation of product sale and distribution. If we enter into
settlement agreements to resolve allegations of non-compliance, we could be required to make settlement payments
or be subject to civil and criminal penalties, including fines and the loss of licenses. Non-compliance with
government requirements could adversely affect our ability to participate in federal and state government health
care programs, and damage our reputation.
If we fail to comply with laws and regulations relating to health care fraud or other laws and regulations, we
could suffer penalties or be required to make significant changes to our operations, which could adversely affect
our business.
We are subject to federal and state (and similar foreign) laws and regulations relating to health care fraud.
Some of these laws, referred to as “false claims laws,” prohibit the submission or causing the submission of false or
fraudulent claims for reimbursement to federal, state and other health care payers and programs. Other laws,
referred to as “anti-kickback laws,” prohibit soliciting, offering, receiving or paying remuneration in order to
induce the referral of a patient or ordering, purchasing, leasing or arranging for or recommending ordering,
purchasing or leasing, of items or services that are paid for by federal, state and other health care payers and
programs. Health care fraud measures may implicate, for example, our relationships with pharmaceutical
manufacturers, our pricing and incentive programs for physician and dental practices, and our dental and physician
practice management products that offer billing-related functionality.
The government has expressed concerns about financial relationships between suppliers on the one hand and
physicians and dentists on the other. As a result, we regularly review and revise our marketing practices as
necessary to facilitate compliance. In addition, under the reporting and disclosure obligations of the Physician
Payment Sunshine Act provisions of the Health Care Reform Law, discussed in more detail under “Government
Regulations - Health Care Reform” above, the general public and government officials are being provided with new
access to detailed information with regard to payments or other transfers of value to certain practitioners (including
physicians, dentists and teaching hospitals) by applicable drug and device manufacturers subject to such reporting
and disclosure obligations, which includes us. This information may lead to greater scrutiny, which may result in
modifications to established practices and additional costs.
The applicable requirements have been subject to varying interpretations, as well as heightened enforcement
activity, over the past few years. Also, significant enforcement activity has been the result of actions brought by
“relators,” who file complaints in the name of the United States (and if applicable, particular states) under federal
and state false claims laws, and under the federal False Claims Act can be entitled to receive up to 30% of total
recoveries. Violations of the federal False Claims Act can result in treble damages, and each false claim submitted
can be subject to a penalty of up to $11,000 per claim. The Health Care Reform Law significantly strengthened the
federal False Claims Act and federal anti-kickback law provisions, which could lead to the possibility of increased
whistleblower or relator suits, and among other things made clear that a federal anti-kickback law violation can be a
basis for federal False Claims Act liability.
24
We also are subject to certain United States and foreign laws and regulations concerning the conduct of our
foreign operations, including the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and other anti-
bribery laws and laws pertaining to the accuracy of our internal books and records, which have been the focus of
increasing enforcement activity globally in recent years.
Failure to comply with health care fraud laws and regulations could result in significant civil and criminal
penalties and costs, including the loss of licenses and the ability to participate in federal and state health care
programs, and could have a material adverse effect on our business. Also, these laws may be interpreted or applied
by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our
operations or incur substantial defense and settlement expenses. Even unsuccessful challenges by regulatory
authorities or private relators could result in reputational harm and the incurring of substantial costs. In addition,
many of these laws are vague or indefinite and have not been interpreted by the courts, and have been subject to
frequent modification and varied interpretation by prosecutorial and regulatory authorities, increasing compliance
risks.
Our businesses are generally subject to numerous other laws and regulations that could impact our financial
performance, including, without limitation, securities, antitrust and marketing laws and regulations. Failure to
comply with laws or regulations could have a material adverse effect on our business.
While we believe that we are substantially compliant with the foregoing laws and regulations promulgated
thereunder, and have adequate compliance programs and controls in place to ensure substantial compliance, we
cannot predict whether changes in applicable law, or interpretation of laws, or changes in our services or marketing
practices in response to changes in applicable law or interpretation of laws, could have a material adverse effect on
our business.
If we fail to comply with laws and regulations relating to the confidentiality of sensitive personal information or
standards in electronic health data transmissions, we could be required to make significant changes to our
products, or incur penalties or other liabilities.
State, federal and foreign laws, such as HIPAA, regulate the confidentiality of sensitive personal information
and the circumstances under which such information may be released. These measures may govern the disclosure
and use of personal and patient medical record information and may require users of such information to implement
specified security measures, and to notify individuals in the event of privacy and security breaches. Evolving laws
and regulations in this area could restrict the ability of our customers to obtain, use or disseminate patient
information, or could require us to incur significant additional costs to re-design our products in a timely manner to
reflect these legal requirements, either of which could have an adverse effect on our results of operations. Other
health information standards, such as regulations under HIPAA, establish standards regarding electronic health data
transmissions and transaction code set rules for specified electronic transactions, for example transactions involving
claims submissions to third party payers. These also continue to evolve and are often unclear and difficult to apply.
In addition, under the HITECH Act, which was passed in 2009, some of our businesses that were previously only
indirectly subject to federal HIPAA privacy and security rules became directly subject to such rules because the
businesses serve as “business associates” to our customers. On January 17, 2013, the Office for Civil Rights of the
Department of Health and Human Services released a final rule implementing the HITECH Act and making certain
other changes to HIPAA privacy and security requirements. Compliance with the rule was required by September
23, 2013, and increased the requirements applicable to some of our businesses. Failure to maintain the
confidentiality of sensitive personal information in accordance with the applicable regulatory requirements, or to
abide by electronic health data transmission standards, could expose us to breach of contract claims, fines and
penalties, costs for remediation and harm to our reputation.
In addition, federal initiatives are providing a program of incentive payments available to certain health care
providers involving the adoption and use of certain electronic health care records systems and processes. The
initiative includes providing, among others, physicians and dentists, with financial incentives if they meaningfully
use EHR in accordance with applicable requirements. In addition, Medicare-eligible providers that fail to timely
adopt certified EHR systems and meet “meaningful use” requirements for those systems in accordance with
regulatory requirements are to be subject to cumulative Medicare reimbursement reductions, which reductions for
eligible health professionals (including physicians and dentists) began on January 1, 2015. Qualification for the
incentive payments requires the use of EHRs that have certain capabilities for meaningful use pursuant to standards
adopted by the Department of Health and Human Services. Initial (“Stage 1”) standards addressed criteria for
periods beginning in 2011. CMS has also issued a final rule with more demanding “Stage 2” criteria for periods
beginning in 2014 for eligible health professionals (including physicians and dentists).
25
Recognizing difficulties encountered by some providers in acquiring and implementing 2014 edition-certified
EHR technology, CMS published a final rule on September 4, 2014 that adds flexibility to the manner in which
physicians, dentists and others may demonstrate meaningful use of EHR by extending through the 2014 reporting
period the ability, in certain circumstances, to use 2011 edition-certified technology to attest to meaningful use,
rather than requiring the use of 2014 edition-certified technology. The rule also delays for one year implementation
of more rigorous “Stage 3” measures, and under this rule eligible health professionals (including physicians and
dentists) would begin Stage 3 in calendar year 2017, as to which regulations are to be proposed in Spring 2015. In
addition, also in recognition of difficulties encountered by some providers in acquiring and implementing 2014
edition-certified EHR technology, CMS has specifically recognized that a hardship exemption may be granted,
among other reasons, where the provider’s failure to demonstrate meaningful use was caused by its EHR vendor’s
failure to timely obtain 2014 certification for its EHR technology, and extended the deadline for health care
professionals to file hardship exemption applications from July 1, 2014 to November 30, 2014. On January 29,
2015, CMS announced an intent to engage in further rulemaking under the EHR incentive program to redress the
Stage 2 reporting burden on providers. Among other things, the new rule, expected in the Spring of 2015, will tie
EHR reporting to a calendar year, modify other aspects of the program, and shorten the EHR reporting period in
2015 to 90 days. Certain of our businesses involve the manufacture and sale of certified EHR systems and other
products linked to incentive programs, and the failure to maintain compliance with these evolving governmental
criteria could have a material adverse effect on our business. In addition, the frequently changing requirements
may increase our costs in these businesses.
Our global operations are subject to inherent risks that could adversely affect our operating results.
Global operations are subject to risks that may materially adversely affect our business, results of operations
and financial condition. The risks that our global operations are subject to include, among other things:
• difficulties and costs relating to staffing and managing foreign operations;
• difficulties in establishing channels of distribution;
• fluctuations in the value of foreign currencies;
•
longer payment cycles of foreign customers and difficulty of collecting receivables in foreign
jurisdictions;
• repatriation of cash from our foreign operations to the United States;
• regulatory requirements;
• anti-bribery, anti-corruption and laws pertaining to the accuracy of our internal books and records;
• unexpected difficulties in importing or exporting our products;
•
imposition of import/export duties, quotas, sanctions or penalties;
• difficulties and delays inherent in sourcing products and contract manufacturing in foreign markets;
•
limitations on our ability under local laws to protect our intellectual property;
• unexpected regulatory, legal, economic and political changes in foreign markets;
• changes in tax regulations that influence purchases of capital equipment;
• civil disturbances, geopolitical turmoil, including terrorism, war or political or military coups; and
• public health emergencies.
26
Our expansion through acquisitions and joint ventures involves risks.
We have expanded our domestic and international markets in part through acquisitions and joint ventures, and
we expect to continue to make acquisitions and enter into joint ventures in the future. Such transactions involve
numerous risks, including possible adverse effects on our operating results or the market price of our common
stock. Some of our acquisitions and future acquisitions may also give rise to an obligation by us to make
contingent payments or to satisfy certain repurchase obligations, which payments could have an adverse effect on
our results of operations. In addition, integrating acquired businesses and joint ventures:
• may result in a loss of customers or product lines of the acquired businesses or joint ventures;
• requires significant management attention;
• may place significant demands on our operations, information systems and financial resources; and
• results in additional acquisition and integration expenses.
There can be no assurance that our future acquisitions or joint ventures will be successful. Our ability to
continue to successfully effect acquisitions and joint ventures will depend upon the following:
•
the availability of suitable acquisition or joint venture candidates at acceptable prices;
• our ability to consummate such transactions, which could potentially be prohibited due to U.S. or
foreign antitrust regulations;
•
the availability of financing on acceptable terms, in the case of non-stock transactions; and
•
the liquidity of our investments and our ability to raise capital could be affected by the financial credit
markets.
Our acquisitions may not result in the benefits and revenue growth we expect.
We are in the process of integrating companies that we acquired and including the operations, services,
products and personnel of each company within our management policies, procedures and strategies. We cannot be
sure that we will achieve the benefits of revenue growth that we expect from these acquisitions or that we will not
incur unforeseen additional costs or expenses in connection with these acquisitions. To effectively manage our
expected future growth, we must continue to successfully manage our integration of these companies and continue
to improve our operational systems, internal procedures, working capital management, and financial and
operational controls. If we fail in any of these areas, our business could be adversely affected.
We face inherent risk of exposure to product liability and other claims in the event that the use of the products
we sell results in injury.
Our business involves a risk of product liability and other claims in the ordinary course of business, and from
time to time we are named as a defendant in cases as a result of our distribution of products. Additionally, we own
interests in companies that manufacture certain dental products. As a result, we are subject to the potential risk of
product liability or other claims relating to the manufacture and distribution of products by those entities.
Additionally, as our private-label business continues to grow, purchasers of such products may increasingly seek
recourse directly from us, rather than the ultimate product manufacturer, for product-related claims. Another
potential risk we face in the distribution of our products is liability resulting from counterfeit or tainted products
infiltrating the supply chain. In addition, some of the products that we transport and sell are considered hazardous
materials. The improper handling of such materials or accidents involving the transportation of such materials
could subject us to liability. We have various insurance policies, including product liability insurance, covering
risks and in amounts that we consider adequate. In many cases in which we have been sued in connection with
products manufactured by others, the manufacturer of the product provides us with indemnification. There can be
no assurance that the insurance coverage we maintain is sufficient or will be available in adequate amounts or at a
reasonable cost, or that indemnification agreements will provide us with adequate protection. A successful claim
brought against us in excess of available insurance or not covered by indemnification agreements, or any claim that
results in significant adverse publicity against us, could have an adverse effect on our business and our reputation.
27
Our technology segment depends upon continued software and e-services product development, technical
support and successful marketing.
Competition among companies supplying practice management software and/or e-services is intense and
increasing. Our future sales of practice management software and e-services will depend on, among other factors:
•
the effectiveness of our sales and marketing programs;
• our ability to enhance our products and services to satisfy customer requirements; and
• our ability to provide ongoing technical support.
We cannot be sure that we will be successful in introducing and marketing new software, software
enhancements or e-services, or that such software, software enhancements and e-services will be released on time
or accepted by the market. Our software and applicable e-services products, like software products generally, may
contain undetected errors or bugs when introduced or as new versions are released. We cannot be sure that future
problems with post-release software errors or bugs will not occur. Any such defective software may result in
increased expenses related to the software and could adversely affect our relationships with the customers using
such software as well as our reputation. We do not have any patents on our software or e-services, and rely upon
copyright, trademark and trade secret laws, as well as contractual and common law protections. We cannot provide
assurance that such legal protections will be available or enforceable to protect our software or e-services products.
We may experience competition from third-party online commerce sites.
Traditional health care supply and distribution relationships are being challenged by electronic online
commerce solutions. The continued advancement of online commerce by third parties will require us to cost-
effectively adapt to changing technologies, to enhance existing services and to differentiate our business (including
with additional value-added services) to address changing demands of consumers and our customers on a timely
basis. The emergence of such potential competition and our inability to anticipate and effectively respond to
changes on a timely basis could have an adverse effect on our business.
Cyber-security risks generally associated with our information systems and our technology products and services
could adversely affect our business.
We rely on information systems (IS) in our business to obtain, rapidly process, analyze, manage and store data
to, among other things:
• maintain and manage worldwide systems to facilitate the purchase and distribution of thousands of
inventory items from numerous distribution centers;
• receive, process and ship orders on a timely basis;
• manage the accurate billing and collections for thousands of customers;
• process payments to suppliers; and
• maintain certain of our customers’ electronic medical records (including protected health information
of their patients).
Information security risks have generally increased in recent years, and a cyber-attack that bypasses our IS
security systems causing an IS security breach may lead to a material disruption of our IS business systems and/or
the loss of business information resulting in an adverse effect on our business. Our IS systems also utilize certain
third party service organizations that manage a portion of our information systems, and our business may be
adversely affected if these third party service organizations are subject to an IS security breach. Risks may include,
among other things:
• future results could be adversely affected due to the theft, destruction, loss, misappropriation or release
of confidential data or intellectual property;
• operational or business delays resulting from the disruption of IS systems and subsequent clean-up and
mitigation activities;
28
• procedures and safeguards must continually evolve to meet new IS challenges, and enhancing
protections, and conducting investigations and remediation, may impose additional costs on us; and
• negative publicity resulting in reputation or brand damage with our customers, partners or industry
peers.
Our results of operations could be adversely affected if our IS systems (or third-party systems we rely on) are
interrupted, damaged by unforeseen events, cyber-attacks or fail for any extended period of time.
We develop products and provide services to our customers that are technology-based. A cyber-attack that
bypasses the security systems of our products or services causing a security breach and/or perceived security
vulnerabilities in our products or services could cause significant reputational harm. Actual or perceived
vulnerabilities may lead to claims against us by our customers and/or governmental agencies. Although our
customer license agreements typically contain provisions that eliminate or limit our exposure to such liability, there
is no assurance these provisions will withstand all legal challenges.
Failure to maintain the confidentiality of sensitive customer data in accordance with applicable regulatory
requirements, or to abide by electronic health data transmission standards, could also expose us to claims, fines and
penalties and costs for remediation. Additionally, legislative or regulatory action related to cyber-security may
increase our costs to develop or implement new technology products and services.
We also deliver Internet-based services and, accordingly, depend on our ability and the ability of our customers
to access the Internet. In the event of any difficulties, outages and delays by Internet service providers, we may be
impeded from providing such services, which may have an adverse effect on our business and our reputation.
We have various insurance policies, including cyber liability insurance, covering risks and in amounts that we
consider adequate. There can be no assurance that the insurance coverage we maintain is sufficient or will be
available in adequate amounts or at a reasonable cost. Successful claims for misappropriation or release of
confidential or personal data brought against us in excess of available insurance or fines or other penalties assessed
or any claim that results in significant adverse publicity against us, could have an adverse effect on our business
and our reputation.
Certain provisions in our governing documents and other documents to which we are a party may discourage
third-party offers to acquire us that might otherwise result in our stockholders receiving a premium over the
market price of their shares.
The provisions of our certificate of incorporation and by-laws may make it more difficult for a third party to
acquire us, may discourage acquisition bids and may limit the price that certain investors might be willing to pay in
the future for shares of our common stock. These provisions, among other things:
• require the affirmative vote of the holders of at least 60% of the shares of common stock entitled to
vote to approve a merger, consolidation, or a sale, lease, transfer or exchange of all or substantially all
of our assets; and
• require the affirmative vote of the holders of at least 66 2/3% of our common stock entitled to vote to
(i) remove a director; and (ii) to amend or repeal our by-laws, with certain limited exceptions.
In addition, our 2013 Stock Incentive Plan and 1996 Non-Employee Director Stock Incentive Plan provide for
accelerated vesting of stock options upon a change in control. These incentive plans also authorize the committee
under the plans to provide for accelerated vesting of other types of equity awards in connection with a change in
control at grant or thereafter, and certain other awards made under these incentive plans (such as restricted stock
and restricted stock unit awards) accelerate upon a change in control or upon certain termination events in
connection with a change in control. Further, certain agreements between us and our executive officers provide for
increased severance payments and certain benefits if those executive officers are terminated without cause by us or
if they terminate for good reason in each case, within two years after a change in control or within ninety days prior
to the effective date of the change in control or after the first public announcement of the pendency of the change in
control.
29
Tax legislation initiatives could adversely affect our net earnings and tax liabilities.
We are subject to the tax laws and regulations of the United States federal, state and local governments, as well
as foreign jurisdictions. From time to time, various legislative initiatives may be proposed that could adversely
affect our tax positions. There can be no assurance that our effective tax rate will not be adversely affected by these
initiatives. In addition, tax laws and regulations are extremely complex and subject to varying interpretations.
Although we believe that our historical tax positions are sound and consistent with applicable laws, regulations and
existing precedent, there can be no assurance that our tax positions will not be challenged by relevant tax authorities
or that we would be successful in any such challenge.
Item 1B. Unresolved Staff Comments
We have no unresolved comments from the staff of the SEC that were issued 180 days or more preceding the
end of our 2014 fiscal year.
ITEM 2. Properties
We own or lease the following properties with more than 100,000 square feet:
Property
Corporate Headquarters ........................................
Corporate Headquarters ........................................
Location
Melville, NY
Melville, NY
Office and Distribution Center .............................
Lyssach, Switzerland
Own or
Lease
Lease
Own
Lease
Office and Distribution Center .............................
Office and Distribution Center .............................
Office and Distribution Center ............................. Gillingham, United Kingdom Lease/Own
Plymouth, MA
Tours, France
Lease
Own
Office and Distribution Center ............................. Niagara on the Lake, Canada
Office and Distribution Center .............................
Bastian, VA
Office and Distribution Center .............................
Office and Distribution Center .............................
Distribution Center ...............................................
Distribution Center ...............................................
Distribution Center ...............................................
Distribution Center ...............................................
Distribution Center ...............................................
Distribution Center ...............................................
Distribution Center ...............................................
Distribution Center ...............................................
West Allis, WI
Cuijk, Netherlands
Denver, PA
Indianapolis, IN
Sparks, NV
Indianapolis, IN
Grapevine, TX
Gallin, Germany
Jacksonville, FL
Fort Worth, TX
Lease
Own
Lease
Lease
Lease
Lease
Lease
Own
Lease
Own
Lease
Lease
Lease Expiration
N/A
N/A
Date
July 2016
September 2021
June 2020
June 2033
Approximate
Square Footage
185,000
105,000
180,000
166,000
165,000 December 2015
165,000
128,000
108,000
106,000
101,000
624,000 December 2021
380,000
February 2019
370,000 December 2016
287,000
242,000
215,000
212,000
120,000
February 2019
October 2027
May 2021
May 2022
July 2018
N/A
N/A
N/A
The properties listed in the table above are our principal properties primarily used by our health care
distribution segment. In addition, we lease numerous other distribution, office, showroom, manufacturing and sales
space in locations including the United States, Australia, Austria, Belgium, Brazil, Canada, Chile, China, the Czech
Republic, France, Germany, Hong Kong SAR, Iceland, Ireland, Israel, Italy, Japan, Luxembourg, the Netherlands,
New Zealand, Poland, Portugal, Slovakia, South Africa, Spain, Switzerland, Thailand and the United Kingdom.
We believe that our properties are in good condition, are well maintained and are suitable and adequate to carry
on our business. We have additional operating capacity at certain distribution center facilities.
30
ITEM 3. Legal Proceedings
From time to time, we may become a party to legal proceedings, including, without limitation, product liability
claims, employment matters, commercial disputes, governmental inquiries and investigations, and other matters
arising out of the ordinary course of our business. While the results of legal proceedings cannot be predicted with
certainty, in our opinion pending matters are not currently anticipated to have a material adverse effect on our
financial condition or results of operations.
As of December 27, 2014, we had accrued our best estimate of potential losses relating to claims that were
probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as
well as related expenses, was not material to our financial position, results of operations or cash flows. Our method
for determining estimated losses considers currently available facts, presently enacted laws and regulations and
other external factors, including probable recoveries from third parties.
ITEM 4. Mine Safety Disclosures
Not applicable.
PART II
ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of
Equity Securities
Our common stock is traded on the NASDAQ Global Select Market tier of the NASDAQ Stock Market, or
NASDAQ, under the symbol HSIC. On October 2, 2007, our common stock became a component of the
NASDAQ-100 stock market index. The following table sets forth, for the periods indicated, the high and low
reported sales prices of our common stock as reported on NASDAQ for each quarterly period in fiscal 2014 and
2013:
Fiscal 2014:
1st Quarter ......................................................................................................... $
2nd Quarter ........................................................................................................
3rd Quarter .........................................................................................................
4th Quarter .........................................................................................................
Fiscal 2013:
1st Quarter ......................................................................................................... $
2nd Quarter ........................................................................................................
3rd Quarter .........................................................................................................
4th Quarter .........................................................................................................
High
Low
120.72 $
120.99
121.00
139.15
92.66 $
98.28
107.75
116.07
109.68
110.99
114.54
109.34
79.57
88.90
95.94
102.50
On February 2, 2015, there were approximately 471 holders of record of our common stock and the last
reported sales price was $138.75.
31
Purchases of Equity Securities by the Issuer
Our share repurchase program, announced on June 21, 2004, originally allowed us to repurchase up to $100
million of shares of our common stock, which represented approximately 3.5% of the shares outstanding at the
commencement of the program. As summarized in the table below, subsequent additional increases totaling $1.6
billion, authorized by our Board of Directors, to the repurchase program provide for a total of $1.7 billion of shares
of our common stock to be repurchased under this program.
Date of
Amount of Additional
Authorization
Repurchases Authorized
October 31, 2005
$
March 28, 2007
November 16, 2010
August 18, 2011
April 18, 2012
November 12, 2012
December 9, 2013
December 4, 2014
100,000,000
100,000,000
100,000,000
200,000,000
200,000,000
300,000,000
300,000,000
300,000,000
As of December 27, 2014, we had repurchased approximately $1.4 billion of common stock (19,357,214
shares) under these initiatives, with $299.9 million available for future common stock share repurchases.
The following table summarizes repurchases of our common stock under our stock repurchase program during
the fiscal quarter ended December 27, 2014:
Total
Number
of Shares
Fiscal Month
Purchased (1)
09/28/14 through 11/01/14
11/02/14 through 11/29/14
11/30/14 through 12/27/14
265,874
179,616
148,940
594,430
Average
Price Paid
Per Share
$
115.19
127.25
135.80
Total Number
of Shares
Purchased as Part
Maximum Number
of Shares
that May Yet
of Our Publicly
Be Purchased Under
Announced Program
265,874
179,616
148,940
594,430
Our Program (2)
357,889
146,516
2,182,657
(1) All repurchases were executed in the open market under our existing publicly announced authorized program.
(2)
The maximum number of shares that may yet be purchased under this program is determined at the end of each month based on the
closing price of our common stock at that time.
Dividend Policy
We have not declared any cash or stock dividends on our common stock during fiscal years 2014 or 2013. We
currently do not anticipate declaring any cash or stock dividends on our common stock in the foreseeable future.
We intend to retain earnings to finance the expansion of our business and for general corporate purposes, including
our share repurchase program. Any declaration of dividends will be at the discretion of our Board of Directors and
will depend upon the earnings, financial condition, capital requirements, level of indebtedness, contractual
restrictions with respect to payment of dividends and other factors.
32
Stock Performance Graph
The graph below compares the cumulative total stockholder return on $100 invested, assuming the reinvestment
of all dividends, on December 26, 2009, the last trading day before the beginning of our 2010 fiscal year, through
the end of our 2014 fiscal year with the cumulative total return on $100 invested for the same period in the Dow
Jones U.S. Health Care Index and the NASDAQ Stock Market Composite Index.
COMPARISON OF 5-YEAR CUMULATIVE TOTAL RETURN
$300
$250
$200
$150
$100
$50
December 2009
December 2010
December 2011
December 2012
December 2013
December 2014
Henry Schein, Inc.
Dow Jones U.S. Health Care Index
NASDAQ Stock Market Composite Index
ASSUMES $100 INVESTED ON DECEMBER 26, 2009
ASSUMES DIVIDENDS REINVESTED
December 26, December 25, December 31, December 29, December 28, December 27,
2009
2010
2011
2012
2013
2014
Henry Schein, Inc. .......................... $
100.00 $
117.26 $
121.54 $
150.84 $
215.86 $
259.18
Dow Jones U.S. Health
Care Index ...................................
100.00
104.21
115.67
136.27
195.44
249.11
NASDAQ Stock Market
Composite Index .........................
100.00
117.73
116.21
133.81
190.31
222.69
33
ITEM 6. Selected Financial Data
The following selected financial data, with respect to our financial position and results of operations for each of
the five fiscal years in the period ended December 27, 2014, set forth below, has been derived from, should be read
in conjunction with and is qualified in its entirety by reference to, our consolidated financial statements and notes
thereto. The selected financial data presented below should also be read in conjunction with ITEM 7,
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” and ITEM 8,
“Financial Statements and Supplementary Data.”
December 27,
December 28,
December 29,
Years ended
2014
2013
2012
(in thousands, except per share data)
December 31,
2011
December 25,
2010
Income Statement Data:
Net sales ......................................................................... $
10,371,390 $
9,560,647 $
8,939,967 $
8,530,242 $
7,526,790
Gross profit .....................................................................
2,911,315
2,656,014
2,507,513
2,418,055
2,170,876
Selling, general and administrative expenses ................
2,196,173
1,978,960
1,873,360
1,835,906
1,637,460
12,285
521,131
(19,096)
502,035
(160,069)
10,165
-
Restructuring costs (1) ...................................................
-
Operating income ...........................................................
715,142
Other expense, net (2) ....................................................
(5,830)
-
677,054
(12,360)
15,192
618,961
(14,773)
-
582,149
(12,842)
Income before taxes and equity in earnings
of affiliates ................................................................
709,312
664,694
604,188
569,307
Income taxes (3) .............................................................
(215,610)
(190,891)
(187,858)
(180,212)
Equity in earnings of affiliates .......................................
11,734
Loss on sale of equity investment (4) ............................
-
Net income .....................................................................
505,436
10,194
(12,535)
471,462
7,058
15,561
-
-
423,388
404,656
352,131
Less: Net income attributable to
noncontrolling interests
Net income attributable to Henry Schein, Inc. .............. $
Earnings per share attributable to
Henry Schein, Inc.:
(39,359)
466,077 $
(39,908)
431,554 $
(35,312)
388,076 $
(36,995)
367,661 $
(26,342)
325,789
Basic ............................................................................ $
Diluted .........................................................................
5.53 $
5.44
5.02 $
4.93
4.44 $
4.32
4.08 $
3.97
Weighted-average common shares outstanding:
Basic ............................................................................
Diluted .........................................................................
84,265
85,740
85,926
87,622
87,499
89,823
90,120
92,620
3.62
3.49
90,097
93,268
34
December 27,
December 28,
December 29,
2014
2013
2012
December 31,
2011
December 25,
2010
Years ended
(in thousands)
Net Sales by Market Data:
Health care distribution (5):
Dental ............................................................... $
Animal health ...................................................
Medical .............................................................
Total health care distribution ........................
Technology and value-added services (6) ..........
5,381,215 $
2,898,612
1,742,685
10,022,512
348,878
4,997,972 $
2,599,461
1,643,167
9,240,600
320,047
4,774,482 $
2,321,151
1,560,921
8,656,554
283,413
Total .............................................................. $
10,371,390 $
9,560,647 $
8,939,967 $
4,764,898 $
2,010,270
1,504,454
8,279,622
250,620
8,530,242 $
4,415,469
1,537,370
1,373,999
7,326,838
199,952
7,526,790
December 27,
December 28,
December 29,
2014
2013
2012
December 31,
2011
December 25,
2010
As of
(in thousands)
Balance Sheet data:
Total assets .......................................................... $
Long-term debt ....................................................
Redeemable noncontrolling interests ..................
Stockholders' equity ............................................
6,138,807 $
542,776
564,527
2,816,445
5,624,636 $
450,233
497,539
2,788,001
5,333,997 $
488,121
435,175
2,615,864
4,740,144 $
363,524
402,050
2,433,623
4,547,471
395,309
304,140
2,412,957
(1) Restructuring costs for the year ended December 29, 2012 consist primarily of severance costs, including severance pay and benefits
of $12.8 million and facility closing costs of $2.4 million. Restructuring costs for the year ended December 25, 2010 consist
primarily of severance costs, including severance pay and benefits of $8.9 million and facility closing costs of $3.4 million. See
“Management’s Discussion and Analysis of Financial Condition and Results of Operations – Plans of Restructuring” herein and the
consolidated financial statements and related notes contained in ITEM 8.
(2)
Includes approximately $6.2 million of one-time expenses related to the refinancing of Henry Schein Animal Health debt during the
first quarter of 2013. These expenses reflect non-cash deferred financing costs.
(3) During the third quarter of 2013, there was a $13.4 million reduction of our valuation allowance related to certain deferred tax assets
related to tax loss carryforwards originating outside the United States.
(4) Represents a loss on divestiture of a noncontrolling interest in a dental wholesale distributor in the Middle East.
(5) Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and
generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
(6) Consists of practice management software and other value-added products, which are distributed primarily to health care providers,
and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other
services.
35
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Cautionary Note Regarding Forward-Looking Statements
In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we
provide the following cautionary remarks regarding important factors that, among others, could cause future results
to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein.
All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future
performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors
that may cause our actual results, performance and achievements or industry results to be materially different from
any future results, performance or achievements expressed or implied by such forward-looking statements. These
statements are identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,”
“estimate,” “forecast,” “project,” “anticipate” or other comparable terms.
Risk factors and uncertainties that could cause actual results to differ materially from current and historical
results include, but are not limited to: effects of a highly competitive market; our dependence on third parties for
the manufacture and supply of our products; our dependence upon sales personnel, customers, suppliers and
manufacturers; our dependence on our senior management; fluctuations in quarterly earnings; risks from expansion
of customer purchasing power and multi-tiered costing structures; possible increases in the cost of shipping our
products or other service issues with our third-party shippers; general global macro-economic conditions;
disruptions in financial markets; possible volatility of the market price of our common stock; changes in the health
care industry; implementation of health care laws; failure to comply with regulatory requirements and data privacy
laws; risks associated with our global operations; transitional challenges associated with acquisitions and joint
ventures, including the failure to achieve anticipated synergies; financial risks associated with acquisitions and joint
ventures; litigation risks; the dependence on our continued product development, technical support and successful
marketing in the technology segment; risks from challenges associated with the emergence of potential increased
competition by third-party online commerce sites; risks from disruption to our information systems; certain
provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax
legislation. The order in which these factors appear should not be construed to indicate their relative importance or
priority.
We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to
control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a
prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.
Where You Can Find Important Information
We may disclose important information through one or more of the following channels: SEC filings, public
conference calls and webcasts, press releases, the investor relations page of our website (www.henryschein.com)
and the social media channels identified on the investor relations page of our website.
Executive-Level Overview
We believe we are the world’s largest provider of health care products and services primarily to office-based
dental, animal health and medical practitioners. We serve more than 1 million customers worldwide including
dental practitioners and laboratories, animal health clinics and physician practices, as well as government,
institutional health care clinics and other alternate care clinics. We believe that we have a strong brand identity due
to our more than 82 years of experience distributing health care products.
We are headquartered in Melville, New York, employ more than 17,500 people (of which approximately 8,000
are based outside the United States) and have operations or affiliates in 28 countries, including the United States,
Australia, Austria, Belgium, Brazil, Canada, Chile, China, the Czech Republic, France, Germany, Hong Kong SAR,
Iceland, Ireland, Israel, Italy, Japan, Luxembourg, the Netherlands, New Zealand, Poland, Portugal, Slovakia, South
Africa, Spain, Switzerland, Thailand and the United Kingdom.
36
We have established strategically located distribution centers to enable us to better serve our customers and
increase our operating efficiency. This infrastructure, together with broad product and service offerings at
competitive prices, and a strong commitment to customer service, enables us to be a single source of supply for our
customers’ needs. Our infrastructure also allows us to provide convenient ordering and rapid, accurate and
complete order fulfillment.
We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and
value-added services. These segments offer different products and services to the same customer base.
The health care distribution reportable segment aggregates our global dental, animal health and medical
operating segments. This segment distributes consumable products, small equipment, laboratory products, large
equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic
tests, infection-control products and vitamins. Our global dental group serves office-based dental practitioners,
dental laboratories, schools and other institutions. Our global animal health group serves animal health practices
and clinics. Our global medical group serves office-based medical practitioners, ambulatory surgery centers, other
alternate-care settings and other institutions.
Our global technology and value-added services group provides software, technology and other value-added
services to health care practitioners. Our technology group offerings include practice management software
systems for dental and medical practitioners and animal health clinics. Our value-added practice solutions include
financial services on a non-recourse basis, e-services, practice technology, network and hardware services, as well
as continuing education services for practitioners.
Industry Overview
In recent years, the health care industry has increasingly focused on cost containment. This trend has benefited
distributors capable of providing a broad array of products and services at low prices. It also has accelerated the
growth of HMOs, group practices, other managed care accounts and collective buying groups, which, in addition to
their emphasis on obtaining products at competitive prices, tend to favor distributors capable of providing
specialized management information support. We believe that the trend towards cost containment has the potential
to favorably affect demand for technology solutions, including software, which can enhance the efficiency and
facilitation of practice management.
Our operating results in recent years have been significantly affected by strategies and transactions that we
undertook to expand our business, domestically and internationally, in part to address significant changes in the
health care industry, including consolidation of health care distribution companies, health care reform, trends
toward managed care, cuts in Medicare and collective purchasing arrangements.
Our current and future results have been and could be impacted by the current economic environment and
uncertainty, particularly impacting overall demand for our products and services.
Industry Consolidation
The health care products distribution industry, as it relates to office-based health care practitioners, is highly
fragmented and diverse. This industry, which encompasses the dental, animal health and medical markets, was
estimated to produce revenues of approximately $45 billion in 2014 in the global markets. The industry ranges
from sole practitioners working out of relatively small offices to group practices or service organizations ranging in
size from a few practitioners to a large number of practitioners who have combined or otherwise associated their
practices.
Due in part to the inability of office-based health care practitioners to store and manage large quantities of
supplies in their offices, the distribution of health care supplies and small equipment to office-based health care
practitioners has been characterized by frequent, small quantity orders, and a need for rapid, reliable and
substantially complete order fulfillment. The purchasing decisions within an office-based health care practice are
typically made by the practitioner or an administrative assistant. Supplies and small equipment are generally
purchased from more than one distributor, with one generally serving as the primary supplier.
37
The trend of consolidation extends to our customer base. Health care practitioners are increasingly seeking to
partner, affiliate or combine with larger entities such as hospitals, health systems, group practices or physician
hospital organizations. In many cases, purchasing decisions for consolidated groups are made at a centralized or
professional staff level; however, orders are delivered to the practitioners’ offices.
We believe that consolidation within the industry will continue to result in a number of distributors, particularly
those with limited financial, operating and marketing resources, seeking to combine with larger companies that can
provide growth opportunities. This consolidation also may continue to result in distributors seeking to acquire
companies that can enhance their current product and service offerings or provide opportunities to serve a broader
customer base.
Our trend with regard to acquisitions and joint ventures has been to expand our role as a provider of products
and services to the health care industry. This trend has resulted in our expansion into service areas that complement
our existing operations and provide opportunities for us to develop synergies with, and thus strengthen, the acquired
businesses.
As industry consolidation continues, we believe that we are positioned to capitalize on this trend, as we believe
we have the ability to support increased sales through our existing infrastructure. We also have invested in
expanding our sales/marketing infrastructure to include a focus on building relationships with decision makers who
do not reside in the office-based practitioner setting.
As the health care industry continues to change, we continually evaluate possible candidates for merger and
joint venture or acquisition and intend to continue to seek opportunities to expand our role as a provider of products
and services to the health care industry. There can be no assurance that we will be able to successfully pursue any
such opportunity or consummate any such transaction, if pursued. If additional transactions are entered into or
consummated, we would incur merger and/or acquisition-related costs, and there can be no assurance that the
integration efforts associated with any such transaction would be successful.
Aging Population and Other Market Influences
The health care products distribution industry continues to experience growth due to the aging population,
increased health care awareness, the proliferation of medical technology and testing, new pharmacology treatments
and expanded third-party insurance coverage, partially offset by the effects of unemployment on insurance
coverage. In addition, the physician market continues to benefit from the shift of procedures and diagnostic testing
from acute care settings to alternate-care sites, particularly physicians’ offices.
According to the U.S. Census Bureau’s International Data Base, in 2014 there were more than six million
Americans aged 85 years or older, the segment of the population most in need of long-term care and elder-care
services. By the year 2050, that number is projected to nearly triple to approximately 18 million. The population
aged 65 to 84 years is projected to increase over 60% during the same time period.
As a result of these market dynamics, annual expenditures for health care services continue to increase in the
United States. We believe that demand for our products and services will grow, while continuing to be impacted by
current and future operating, economic and industry conditions. The Centers for Medicare and Medicaid Services,
or CMS, published “National Health Expenditure Projections 2013-2023” indicating that total national health care
spending reached approximately $2.9 trillion in 2013, or 17.2% of the nation’s gross domestic product, the
benchmark measure for annual production of goods and services in the United States. Health care spending is
projected to reach approximately $5.2 trillion in 2023, approximately 19.3% of the nation’s gross domestic product.
38
Government
Certain of our businesses involve the distribution of pharmaceuticals and medical devices, and in this regard we
are subject to extensive local, state, federal and foreign governmental laws and regulations applicable to the
distribution of pharmaceuticals and medical devices. Additionally, government and private insurance programs
fund a large portion of the total cost of medical care, and there has been an emphasis on efforts to control medical
costs, including laws and regulations lowering reimbursement rates for pharmaceuticals, medical devices, and/or
medical treatments or services. Also, many of these laws and regulations are subject to change and may impact our
financial performance. In addition, our businesses are generally subject to numerous other laws and regulations
that could impact our financial performance, including securities, antitrust and other laws and regulations. Failure
to comply with law or regulations could have a material adverse effect on our business.
Health Care Reform
The United States Health Care Reform law adopted through the March 2010 enactment of the Patient
Protection and Affordable Care Act and the Health Care and Education Reconciliation Act increased federal
oversight of private health insurance plans and included a number of provisions designed to reduce Medicare
expenditures and the cost of health care generally, to reduce fraud and abuse, and to provide access to increased
health coverage.
The Health Care Reform Law requirements include a 2.3% excise tax on domestic sales of many medical
devices by manufacturers and importers that began in 2013 and a fee on branded prescription drugs and biologics
that was implemented in 2011, both of which may affect sales. The Healthcare Reform Law has also materially
expanded the number of individuals in the United States with health insurance. However, litigation is pending,
including before the Supreme Court of the United States, which could result in the invalidation of some of or all of
the law or the manner in which it has been interpreted, and the reduction in the expansion of health insurance
coverage. There has also been an effort by the party in control of Congress to repeal some or all of the law. The
uncertain status of the Healthcare Reform Law affects our ability to plan.
A Health Care Reform Law provision, generally referred to as the Physician Payment Sunshine Act or Open
Payments Program, has imposed new reporting and disclosure requirements for drug and device manufacturers with
regard to payments or other transfers of value made to certain practitioners (including physicians, dentists and
teaching hospitals), and for such manufacturers and for group purchasing organizations, with regard to certain
ownership interests held by physicians in the reporting entity. On February 1, 2013, CMS released the final rule to
implement the Physician Payment Sunshine Act. Under this rule, data collection activities began on August 1,
2013, and first disclosure reports were due by March 31, 2014 for the period August 1, 2013 through December 31,
2013. As required under the Physician Payment Sunshine Act, CMS published information from these reports on a
publicly available website, including amounts transferred and physician, dentist and teaching hospital identities, on
September 30, 2014.
Under the Physician Payment Sunshine Act, we are required to collect and report detailed information
regarding certain financial relationships we have with physicians, dentists and teaching hospitals. It is difficult to
predict how the new requirements may impact existing relationships among manufacturers, distributors, physicians,
dentists and teaching hospitals. The Physician Payment Sunshine Act pre-empts similar state reporting laws,
although we or our subsidiaries may be required to report under certain of such state laws in addition to Physician
Payment Sunshine Act reporting, and some of these state laws are also ambiguous. We completed the initial
Physician Payment Sunshine Act submission to CMS due March 31, 2014, covering the period August 1 to
December 31, 2013, which was released to the public September 1, 2014. Beginning from 2014 and each year
thereafter, data collection for each calendar year must be submitted by March 31 of the subsequent year. We are
also subject to foreign regulations requiring transparency of certain interactions between suppliers and their
customers. While we believe we have substantially compliant programs and controls in place to comply with the
Physician Payment Sunshine Act requirements (and similar foreign requirements), our compliance with the new
final rule (and similar foreign requirements) imposes additional costs on us.
39
Health Care Fraud
Certain of our businesses are subject to federal and state (and similar foreign) health care fraud and abuse,
referral and reimbursement laws and regulations with respect to their operations. Some of these laws, referred to as
“false claims laws,” prohibit the submission or causing the submission of false or fraudulent claims for
reimbursement to federal, state and other health care payers and programs. Other laws, referred to as “anti-
kickback laws,” prohibit soliciting, offering, receiving or paying remuneration in order to induce the referral of a
patient or ordering, purchasing, leasing or arranging for, or recommending ordering, purchasing or leasing of, items
or services that are paid for by federal, state and other health care payers and programs.
The fraud and abuse laws and regulations have been subject to varying interpretations, as well as heightened
enforcement activity over the past few years, and significant enforcement activity has been the result of “relators,”
who serve as whistleblowers by filing complaints in the name of the United States (and if applicable, particular
states) under federal and state false claims laws. Under the federal False Claims Act relators can be entitled to
receive up to 30% of total recoveries. Also, violations of the federal False Claims Act can result in treble damages,
and each false claim submitted can be subject to a penalty of up to $11,000 per claim. The Health Care Reform
Law significantly strengthened the federal False Claims Act and the federal Anti-Kickback Law provisions, which
could lead to the possibility of increased whistleblower or relator suits, and among other things made clear that a
federal Anti-Kickback Law violation can be a basis for federal False Claims Act liability.
The United States government (among others) has expressed concerns about financial relationships between
suppliers on the one hand and physicians and dentists on the other. As a result, we regularly review and revise our
marketing practices as necessary to facilitate compliance.
We also are subject to certain United States and foreign laws and regulations concerning the conduct of our
foreign operations, including the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act and other anti-bribery
laws and laws pertaining to the accuracy of our internal books and records, which have been the focus of increasing
enforcement activity globally in recent years.
Failure to comply with fraud and abuse laws and regulations could result in significant civil and criminal
penalties and costs, including the loss of licenses and the ability to participate in federal and state health care
programs, and could have a material adverse effect on our business. Also, these measures may be interpreted or
applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our
operations or incur substantial defense and settlement expenses. Even unsuccessful challenges by regulatory
authorities or private relators could result in reputational harm and the incurring of substantial costs. In addition,
many of these laws are vague or indefinite and have not been interpreted by the courts, and have been subject to
frequent modification and varied interpretation by prosecutorial and regulatory authorities, increasing the risk of
noncompliance.
While we believe that we are substantially compliant with applicable fraud and abuse laws and regulations, and
have adequate compliance programs and controls in place to ensure substantial compliance, we cannot predict
whether changes in applicable law, or interpretation of laws, or changes in our services or marketing practices in
response to changes in applicable law or interpretation of laws, could have a material adverse effect on our
business.
Operating and Security Standards
The Federal Food, Drug, and Cosmetic Act (“FDC Act”) and similar foreign laws generally regulate the
introduction, manufacture, advertising, labeling, packaging, storage, handling, reporting, marketing and distribution
of, and record keeping for, pharmaceuticals and medical devices shipped in interstate commerce, and states may
similarly regulate such activities within the state.
40
The Federal Drug Quality and Security Act of 2013 brings about significant changes with respect to
pharmaceutical supply chain requirements and pre-empts state law. Title II of this measure, known as the Drug
Supply Chain Security Act (“DSCSA”), will be phased in over 10 years, and is intended to build a national
electronic, interoperable system to identify and trace certain prescription drugs as they are distributed in the United
States. The law began to take effect in January 2015, and on that date specific product tracing requirements for
manufacturers, wholesalers, repackagers and dispensers (e.g., pharmacies) of prescription drugs took effect,
although the FDA, in a Final Guidance issued on December 23, 2014, stated that in order to minimize possible
disruptions in the distribution of prescription drugs in the United States, it would not take action for noncompliance
with these track and trace requirements prior to May 1, 2015. These new product tracing requirements replace the
former FDA drug pedigree requirements and pre-empt state requirements that are inconsistent with, more stringent
than, or in addition to, the DSCSA requirements. Also in January 2015, the DSCSA required manufacturers and
wholesale distributors to have systems in place by which they can identify whether a product in their possession or
control is a “suspect” or “illegitimate” product, and handle it accordingly.
The DSCSA also establishes certain requirements for the licensing and operation of prescription drug
wholesalers and third party logistics providers (“3PLs”), and includes the creation of national wholesaler and 3PL
licenses in cases where states do not license such entities. The DSCSA requires that wholesalers and 3PLs
distribute drugs in accordance with certain standards regarding the recordkeeping, storage and handling of
prescription drugs. Wholesalers and 3PLs are also required to submit annual reports to the FDA beginning on
January 1, 2015, which include information regarding each state where the wholesaler or 3PL is licensed, the name
and address of each facility and contact information. According to FDA guidance, states are pre-empted from
imposing any licensing requirements that are inconsistent with, less stringent than, directly related to, or covered by
the standards established by Federal law in this area. Current state licensing requirements will likely remain in
effect until the FDA issues new regulations as directed by the DSCSA.
We are in the process of analyzing the impact of the DSCSA on our business.
Regulated Software; Electronic Health Records
The FDA has become increasingly active in addressing the regulation of computer software intended for use in
health care settings, and has developed policies on regulating clinical decision support tools and other types of
software as medical devices. Certain of our businesses involve the development and sale of software and related
products to support physician and dental practice management, and it is possible that the FDA or foreign
government authorities could determine that one or more of our products is a medical device, which could subject
us or one or more of our businesses to substantial additional requirements with respect to these products.
Certain of our businesses involve access to personal health, medical, financial and other information of
individuals, and are accordingly directly or indirectly subject to numerous federal, state, local and foreign laws and
regulations that protect the privacy and security of such information, such as the privacy and security provisions of
the federal Health Insurance Portability and Accountability Act of 1996, as amended, and implementing regulations
(“HIPAA”). HIPAA requires, among other things, the implementation of various recordkeeping, operational,
notice and other practices intended to safeguard that information, limit its use to allowed purposes and notify
individuals in the event of privacy and security breaches. Failure to comply with these laws and regulations can
result in substantial penalties and other liabilities.
In addition, federal initiatives are providing a program of incentive payments available to certain health care
providers involving the adoption and use of certain electronic health care records systems and processes. The
initiative includes providing, among others, physicians and dentists, with financial incentives if they meaningfully
use certified electronic health record technology (“EHR”) in accordance with applicable requirements. In addition,
Medicare-eligible providers that fail to timely adopt certified EHR systems and meet “meaningful use”
requirements for those systems in accordance with regulatory requirements are to be subject to cumulative
Medicare reimbursement reductions, which reductions for eligible health professionals (including physicians and
dentists) began on January 1, 2015. Qualification for the incentive payments requires the use of EHRs that have
certain capabilities for meaningful use pursuant to standards adopted by the Department of Health and Human
Services. Initial (“Stage 1”) standards addressed criteria for periods beginning in 2011. CMS has also issued a
final rule with more demanding “Stage 2” criteria for periods beginning in 2014 for eligible health professionals
(including physicians and dentists).
41
Recognizing difficulties encountered by some providers in acquiring and implementing 2014 edition-certified
EHR technology, CMS published a final rule on September 4, 2014 that adds flexibility to the manner in which
physicians, dentists and others may demonstrate meaningful use of EHR by extending through the 2014 reporting
period the ability, in certain circumstances, to use 2011 edition-certified technology to attest to meaningful use,
rather than requiring the use of 2014 edition-certified technology. The rule also delays for one year implementation
of more rigorous “Stage 3” measures, and under this rule eligible health professionals (including physicians and
dentists) would begin Stage 3 in calendar year 2017, as to which regulations are to be proposed in Spring 2015. In
addition, also in recognition of difficulties encountered by some providers in acquiring and implementing 2014
edition-certified EHR technology, CMS has specifically recognized that a hardship exemption may be granted,
among other reasons, where the provider’s failure to demonstrate meaningful use was caused by its EHR vendor’s
failure to timely obtain 2014 certification for its EHR technology, and extended the deadline for health care
professionals to file hardship exemption applications from July 1, 2014 to November 30, 2014. On January 29,
2015, CMS announced an intent to engage in further rulemaking under the EHR incentive program to redress the
Stage 2 reporting burden on providers. Among other things, the new rule, expected in the Spring of 2015, will tie
EHR reporting to a calendar year, modify other aspects of the program and shorten the EHR reporting period in
2015 to 90 days. Certain of our businesses involve the manufacture and sale of certified EHR systems and other
products linked to incentive programs, and so must maintain compliance with, and are affected by, these evolving
governmental criteria.
Also, HIPAA requires certain health care providers, such as physicians, to use certain transaction and code set
rules for specified electronic transactions, such as transactions involving claims submissions. Commencing July 1,
2012, CMS required that electronic claim submissions and related electronic transactions be conducted under a new
HIPAA transaction standard, called Version 5010. CMS has required this upgrade in connection with another new
requirement applicable to the industry, the implementation of new diagnostic code sets to be used in claims
submission. The new diagnostic code sets are called the ICD-10-CM. They were originally to be implemented on
October 1, 2013 (and CMS delayed the implementation date until October 1, 2014), but as part of the Protecting
Access to Medicare Act of 2014, enacted on April 1, 2014, Congress prohibited the Secretary of Health and Human
Services from implementing ICD-10-CM any earlier than October 1, 2015. CMS published a final rule on
August 4, 2014 adopting the October 1, 2015 compliance date and requiring the use of ICD-9-CM code sets
through September 30, 2015, and there is no suggestion that implementation will be further delayed. Certain of our
businesses provide electronic practice management products that must meet those requirements, and while we
believe that we are prepared to timely adopt the new standards, it is possible that the transition to these new
standards, particularly the transition to ICD-10-CM, may result in a degree of disruption and confusion, thus
potentially increasing the costs associated with supporting this product.
There may be additional legislative initiatives in the future impacting health care.
E-Commerce
Electronic commerce solutions have become an integral part of traditional health care supply and distribution
relationships. Our distribution business is characterized by rapid technological developments and intense
competition. The continuing advancement of online commerce requires us to cost-effectively adapt to changing
technologies, to enhance existing services and to develop and introduce a variety of new services to address the
changing demands of consumers and our customers on a timely basis, particularly in response to competitive
offerings.
Through our proprietary, technologically based suite of products, we offer customers a variety of competitive
alternatives. We believe that our tradition of reliable service, our name recognition and large customer base built
on solid customer relationships, position us well to participate in this significant aspect of the distribution business.
We continue to explore ways and means to improve and expand our Internet presence and capabilities, including
our online commerce offerings and our use of various social media outlets.
42
Results of Operations
The following tables summarize the significant components of our operating results and cash flows for each of
the three years ended December 27, 2014, December 28, 2013 and December 29, 2012 (in thousands):
Years Ended
December 27, December 28,
December 29,
2014
2013
2012
Operating results:
Net sales .................................................................................................. $
Cost of sales ............................................................................................
Gross profit .........................................................................................
Operating expenses:
Selling, general and administrative .....................................................
Restructuring costs ..............................................................................
Operating income ........................................................................... $
10,371,390 $
7,460,075
2,911,315
9,560,647 $
6,904,633
2,656,014
2,196,173
-
715,142 $
1,978,960
-
677,054 $
8,939,967
6,432,454
2,507,513
1,873,360
15,192
618,961
Other expense, net ................................................................................... $
Net income ..............................................................................................
Net income attributable to Henry Schein, Inc. ........................................
(5,830) $
505,436
466,077
(12,360) $
471,462
431,554
(14,773)
423,388
388,076
Years Ended
December 27, December 28,
December 29,
2014
2013
2012
Cash flows:
Net cash provided by operating activities ............................................... $
Net cash used in investing activities ........................................................
Net cash used in financing activities .......................................................
592,504 $
(516,639)
(154,647)
664,175 $
(266,605)
(335,974)
408,099
(269,604)
(170,601)
Plans of Restructuring
On November 6, 2014, we announced a corporate initiative to rationalize our operations and provide expense
efficiencies, which will occur throughout fiscal 2015. This initiative is expected to include the elimination of
approximately 2% to 3% of our workforce and the closing of certain facilities. The costs associated with all actions
to complete this restructuring are expected to be in the range of $35 million to $40 million pre-tax (approximately
$0.29 to $0.33 per diluted share). We plan to reduce our cost structure to fund new initiatives to drive future
growth as our 2015 – 2017 strategic planning cycle begins. At this time, we are unable to make a determination of
the estimated amount or range of amounts to be included for each major type of cost associated with this
restructuring (including associated cash expenditures). We will provide further details in a future Securities and
Exchange Commission filing at such time as we are able to determine the costs we expect to incur in connection
with this restructuring.
The costs associated with this restructuring will be included in a separate line item, “Restructuring costs”
within our consolidated statements of income.
During the year ended December 29, 2012, we incurred restructuring costs of approximately $15.2 million
(approximately $10.5 million after taxes) consisting of employee severance pay and benefits related to the
elimination of approximately 200 positions; facility closing costs, representing primarily lease terminations and
asset write-off costs; and outside professional and consulting fees directly related to the restructuring plan. This
restructuring program is complete and we do not expect any additional costs from this program.
43
2014 Compared to 2013
Net Sales
Net sales for 2014 and 2013 were as follows (in thousands):
2014
% of
Total
2013
% of
Total
Increase
$
%
Health care distribution (1):
Dental ..................................................... $
Animal health .........................................
Medical ...................................................
Total health care distribution ...............
Technology and value-added services (2) .......
Total .................................................... $
5,381,215
2,898,612
1,742,685
10,022,512
348,878
10,371,390
51.9 % $
27.9
16.8
96.6
3.4
100.0 % $
4,997,972
2,599,461
1,643,167
9,240,600
320,047
9,560,647
52.3 % $
27.2
17.2
96.7
3.3
100.0 % $
383,243
299,151
99,518
781,912
28,831
810,743
7.7 %
11.5
6.1
8.5
9.0
8.5
(1) Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and
generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
(2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers,
and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other
services.
The $810.7 million, or 8.5%, increase in net sales for the year ended December 27, 2014 includes an increase of
8.6% local currency growth (4.6% increase in internally generated revenue and 4.0% growth from acquisitions) as
well as a decrease of 0.1% related to foreign currency exchange.
The $383.2 million, or 7.7%, increase in dental net sales for the year ended December 27, 2014 includes an
increase of 8.2% in local currencies (3.3% increase in internally generated revenue and 4.9% growth from
acquisitions) as well as a decrease of 0.5% related to foreign currency exchange. The 8.2% increase in local
currency sales was due to increases in dental equipment sales and service revenues of 6.8% (3.3% increase in
internally generated revenue and 3.5% growth from acquisitions) and dental consumable merchandise sales growth
of 8.7% (3.3% increase in internally generated revenue and 5.4% growth from acquisitions).
The $299.2 million, or 11.5%, increase in animal health net sales for the year ended December 27, 2014
includes an increase of 11.2% local currency growth (6.3% increase in internally generated revenue and 4.9%
growth from acquisitions) as well as an increase of 0.3% related to foreign currency exchange.
The $99.5 million, or 6.1%, increase in medical net sales for the year ended December 27, 2014 includes an
increase of 6.0% local currency growth (5.9% increase in internally generated revenue and 0.1% growth from
acquisitions) as well as an increase of 0.1% related to foreign currency exchange.
The $28.8 million, or 9.0%, increase in technology and value-added services net sales for the year ended
December 27, 2014 includes an increase of 8.8% local currency growth (5.7% increase in internally generated
revenue and 3.1% growth from acquisitions) as well as an increase of 0.2% related to foreign currency exchange.
44
Gross Profit
Gross profit and gross margins for 2014 and 2013 by segment and in total were as follows (in thousands):
Health care distribution ............................. $
Technology and value-added services .......
Total ..................................................... $
2014
2,680,190
231,125
2,911,315
Gross
Margin %
26.7 % $
66.2
28.1
$
2013
2,451,334
204,680
2,656,014
Gross
Margin %
26.5 % $
64.0
27.8
$
Increase
$
228,856
26,445
255,301
%
9.3 %
12.9
9.6
Gross profit increased $255.3 million, or 9.6%, for the year ended December 27, 2014 compared to the prior
year period. As a result of different practices of categorizing costs associated with distribution networks throughout
our industry, our gross margins may not necessarily be comparable to other distribution companies. Additionally,
we realize substantially higher gross margin percentages in our technology segment than in our health care
distribution segment. These higher gross margins result from being both the developer and seller of software
products and services, as well as certain financial services. The software industry typically realizes higher gross
margins to recover investments in research and development.
Within our health care distribution segment, gross profit margins may vary from one period to the next.
Changes in the mix of products sold as well as changes in our customer mix have been the most significant drivers
affecting our gross profit margin. For example, sales of pharmaceutical products are generally at lower gross profit
margins than other products. Conversely, sales of our private label products achieve gross profit margins that are
higher than average. With respect to customer mix, sales to our large-group customers are typically completed at
lower gross margins due to the higher volumes sold as opposed to the gross margin on sales to office-based
practitioners who normally purchase lower volumes at greater frequencies.
Health care distribution gross profit increased $228.9 million, or 9.3%, for the year ended December 27, 2014
compared to the prior year period. Health care distribution gross profit margin increased to 26.7% for the year
ended December 27, 2014 from 26.5% for the comparable prior year period. The slight increase in our health care
distribution gross profit margin reflects stable margins in each of the segment’s operating units.
Technology and value-added services gross profit increased $26.4 million, or 12.9%, for the year ended
December 27, 2014 compared to the prior year period. Technology and value-added services gross profit margin
increased to 66.2% for the year ended December 27, 2014 from 64.0% for the comparable prior year period,
primarily due to changes in the product sales mix.
Selling, General and Administrative
Selling, general and administrative expenses by segment and in total for 2014 and 2013 were as follows (in
thousands):
Health care distribution ............................. $
Technology and value-added services .......
Total .................................................... $
% of
Respective
Net Sales
2014
2,068,419
127,754
2,196,173
20.6 % $
36.6
21.2
$
2013
1,860,670
118,290
1,978,960
% of
Respective
Net Sales
20.1 % $
37.0
20.7
$
Increase
$
207,749
9,464
217,213
%
11.2 %
8.0
11.0
Selling, general and administrative expenses increased $217.2 million, or 11.0%, for the year ended December
27, 2014 from the comparable prior year period. As a percentage of net sales, selling, general and administrative
expenses increased to 21.2% from 20.7% for the comparable prior year period.
45
As a component of total selling, general and administrative expenses, selling expenses increased $118.6
million, or 9.3%, for the year ended December 27, 2014 from the comparable prior year period. As a percentage of
net sales, selling expenses increased to 13.4% from 13.3% for the comparable prior year period.
As a component of total selling, general and administrative expenses, general and administrative expenses
increased $98.6 million, or 13.9%, for the year ended December 27, 2014 from the comparable prior year period.
As a percentage of net sales, general and administrative expenses increased to 7.8% from 7.4% for the comparable
prior year period.
Other Expense, Net
Other expense, net for the years ended 2014 and 2013 was as follows (in thousands):
Interest income .................................................................... $
Interest expense ...................................................................
Other, net .............................................................................
Other expense, net ....................................................... $
13,655 $
(24,057)
4,572
(5,830) $
12,853 $
(27,538)
2,325
(12,360) $
2014
2013
$
Variance
802
3,481
2,247
6,530
%
6.2 %
12.6
96.6
52.8
Other expense, net decreased $6.5 million to $5.8 million for the year ended December 27, 2014 from the
comparable prior year period. Interest income increased $0.8 million. Interest expense decreased $3.5 million
primarily due to the $6.2 million accelerated amortization of deferred financing costs resulting from the early
repayment of our Henry Schein Animal Health (“HSAH”) debt during February 2013, partially offset by an
increase in borrowings under our bank credit lines and our private placement facilities. Other, net increased by $2.2
million due primarily to a contractual payment from an animal health supplier in Europe related to a change to a
non-exclusive sales model.
Income Taxes
For the year ended December 27, 2014, our effective tax rate was 30.4% compared to 28.7% for the prior year
period. During the third quarter of 2013, we concluded that it is more likely than not that certain deferred tax assets
related to tax loss carryforwards originating outside the United States, which had been previously reserved, will be
realized. As a result, our provision for income taxes for the year ended December 28, 2013 included a $13.4
million reduction of the valuation allowance which was based on an estimate of future taxable income available to
be offset by the tax loss carryforwards.
Absent the effects of the reduction of this valuation allowance in the third quarter of 2013, our effective tax rate
for the year ended December 28, 2013 would have been 30.7% as compared to our actual effective tax rate of
28.7%. The remaining difference between our effective tax rates and the federal statutory tax rates for both periods
primarily relates to state and foreign income taxes and interest expense. For 2015, we expect our effective tax rate
to be in the range of 30%.
Loss on Sale of Equity Investment
On July 10, 2013, we divested our investment in a dental wholesale distributor in the Middle East that had
primarily served as an importer that distributed products largely to other distributors. The divestiture resulted in a
one-time loss of $12.5 million, or $0.14 per diluted share, in the third quarter of 2013. Pursuant to the terms of this
divestiture, we made cash payments to this distributor in the aggregate amount of $13.4 million, which it was
required to use to reduce its debt, pay certain trade payables and provide working capital. The investment in this
distributor had been fully impaired as of the end of 2012. There was no tax benefit related to the loss on this
divestiture.
Net Income
Net income increased $34.0 million, or 7.2%, for the year ended December 27, 2014, compared to the prior
year period due to the factors noted above.
46
2013 Compared to 2012
Net Sales
Net sales for 2013 and 2012 were as follows (in thousands):
Health care distribution (1):
Dental ..................................................... $
Animal health .........................................
Medical ...................................................
Total health care distribution ...............
Technology and value-added services (2) ......
Total .................................................... $
2013
% of
Total
2012
% of
Total
Increase
$
%
4,997,972
2,599,461
1,643,167
9,240,600
320,047
9,560,647
52.3 % $
27.2
17.2
96.7
3.3
100.0 % $
4,774,482
2,321,151
1,560,921
8,656,554
283,413
8,939,967
53.4 % $
26.0
17.4
96.8
3.2
100.0 % $
223,490
278,310
82,246
584,046
36,634
620,680
4.7 %
12.0
5.3
6.7
12.9
6.9
(1) Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and
generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
(2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers,
and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other
services.
The $620.7 million, or 6.9%, increase in net sales for the year ended December 28, 2013 includes an increase of
6.8% local currency growth (3.6% increase in internally generated revenue and 3.2% growth from acquisitions) as
well as an increase of 0.1% related to foreign currency exchange.
The $223.5 million, or 4.7%, increase in dental net sales for the year ended December 28, 2013 includes an
increase of 4.3% in local currencies (2.1% increase in internally generated revenue and 2.2% growth from
acquisitions) as well as an increase of 0.4% related to foreign currency exchange. The 4.3% increase in local
currency sales was due to increases in dental equipment sales and service revenues of 3.6% (3.0% increase in
internally generated revenue and 0.6% growth from acquisitions) and dental consumable merchandise sales growth
of 4.5% (1.8% increase in internally generated revenue and 2.7% growth from acquisitions).
The $278.3 million, or 12.0%, increase in animal health net sales for the year ended December 28, 2013
includes an increase of 12.3% local currency growth (5.5% increase in internally generated revenue and 6.8%
growth from acquisitions) as well as a decrease of 0.3% related to foreign currency exchange.
The $82.2 million, or 5.3%, increase in medical net sales for the year ended December 28, 2013 includes an
increase of 5.1% local currency growth (4.6% increase in internally generated revenue and 0.5% growth from
acquisitions) as well as an increase of 0.2% related to foreign currency exchange.
The $36.6 million, or 12.9%, increase in technology and value-added services net sales for the year ended
December 28, 2013 includes an increase of 13.3% local currency growth (9.5% increase in internally generated
revenue and 3.8% growth from acquisitions) as well as a decrease of 0.4% related to foreign currency exchange.
47
Gross Profit
Gross profit and gross margins for 2013 and 2012 by segment and in total were as follows (in thousands):
Health care distribution ............................. $
Technology and value-added services .......
Total ..................................................... $
2013
2,451,334
204,680
2,656,014
Gross
Margin %
26.5 % $
64.0
27.8
$
2012
2,323,913
183,600
2,507,513
Gross
Margin %
26.8 % $
64.8
28.0
$
Increase
$
127,421
21,080
148,501
%
5.5 %
11.5
5.9
Gross profit increased $148.5 million, or 5.9%, for the year ended December 28, 2013 compared to the prior
year period. As a result of different practices of categorizing costs associated with distribution networks throughout
our industry, our gross margins may not necessarily be comparable to other distribution companies. Additionally,
we realize substantially higher gross margin percentages in our technology segment than in our health care
distribution segment. These higher gross margins result from being both the developer and seller of software
products and services, as well as certain financial services. The software industry typically realizes higher gross
margins to recover investments in research and development.
Within our health care distribution segment, gross profit margins may vary from one period to the
next. Changes in the mix of products sold as well as changes in our customer mix have been the most significant
drivers affecting our gross profit margin. For example, sales of pharmaceutical products are generally at lower
gross profit margins than other products. Conversely, sales of our private label products achieve gross profit
margins that are higher than average. With respect to customer mix, sales to our large-group customers are
typically completed at lower gross margins due to the higher volumes sold as opposed to the gross margin on sales
to office-based practitioners who normally purchase lower volumes at greater frequencies.
Health care distribution gross profit increased $127.4 million, or 5.5%, for the year ended December 28, 2013
compared to the prior year period. Health care distribution gross profit margin decreased to 26.5% for the year
ended December 28, 2013 from 26.8% for the comparable prior year period. The decrease in our health care
distribution gross profit margin is primarily due to growth in sales within our animal health businesses, which
typically include a greater percentage of lower-margin pharmaceutical products than our other operating units.
Technology and value-added services gross profit increased $21.1 million, or 11.5%, for the year ended
December 28, 2013 compared to the prior year period. Technology and value-added services gross profit margin
decreased to 64.0% for the year ended December 28, 2013 from 64.8% for the comparable prior year period,
primarily due to changes in the product sales mix.
Selling, General and Administrative
Selling, general and administrative expenses by segment and in total for 2013 and 2012 were as follows (in
thousands):
Health care distribution ............................. $
Technology and value-added services .......
Total ..................................................... $
% of
Respective
Net Sales
2013
1,860,670
118,290
1,978,960
20.1 % $
37.0
20.7
$
2012
1,767,265
106,095
1,873,360
% of
Respective
Net Sales
20.4 % $
37.4
21.0
$
Increase
$
93,405
12,195
105,600
%
5.3 %
11.5
5.6
Selling, general and administrative expenses increased $105.6 million, or 5.6%, for the year ended December
28, 2013 from the comparable prior year period. As a percentage of net sales, selling, general and administrative
expenses decreased to 20.7% from 21.0% for the comparable prior year period.
48
As a component of total selling, general and administrative expenses, selling expenses increased $70.4 million,
or 5.9%, for the year ended December 28, 2013 from the comparable prior year period. As a percentage of net
sales, selling expenses decreased to 13.3% from 13.5% for the comparable prior year period.
As a component of total selling, general and administrative expenses, general and administrative expenses
increased $35.2 million, or 5.2%, for the year ended December 28, 2013 from the comparable prior year period. As
a percentage of net sales, general and administrative expenses decreased to 7.4% from 7.5% for the comparable
prior year period.
Other Expense, Net
Other expense, net for the years ended 2013 and 2012 was as follows (in thousands):
Interest income .................................................................... $
Interest expense ...................................................................
Other, net .............................................................................
Other expense, net ....................................................... $
12,853 $
(27,538)
2,325
(12,360) $
13,394 $
(30,902)
2,735
(14,773) $
2013
2012
$
Variance
(541)
3,364
(410)
2,413
%
(4.0)%
10.9
(15.0)
16.3
Other expense, net decreased $2.4 million to $12.4 million for the year ended December 28, 2013 from the
comparable prior year period. Interest income decreased $0.5 million primarily due to lower investment income.
Interest expense decreased $3.4 million primarily due to a reduction in borrowings under our HSAH debt, partially
offset by an increase in borrowings under our private placement facilities and increased borrowings based on the
securitization of our U.S. trade accounts receivable. Other, net decreased by $0.4 million due primarily to the
impact of foreign currency exchange.
Income Taxes
For the year ended December 28, 2013, our effective tax rate was 28.7% compared to 31.1% for the prior year
period. During the third quarter of 2013, we concluded that it is more likely than not that certain deferred tax assets
related to tax loss carryforwards originating outside the United States, which had been previously reserved, will be
realized. As a result, our provision for income taxes for the year ended December 28, 2013 included a $13.4
million reduction of the valuation allowance which was based on an estimate of future taxable income available to
be offset by the tax loss carryforwards.
Absent the effects of the reduction of this valuation allowance in the third quarter of 2013, our effective tax rate
for the year ended December 28, 2013 would have been 30.7% as compared to our actual effective tax rate of
28.7% The remaining difference between our effective tax rates and the federal statutory tax rates for both periods
primarily relates to state and foreign income taxes and interest expense.
Loss on Sale of Equity Investment
On July 10, 2013, we divested our investment in a dental wholesale distributor in the Middle East that had
primarily served as an importer that distributed products largely to other distributors. The divestiture resulted in a
one-time loss of $12.5 million, or $0.14 per diluted share, in the third quarter of 2013. Pursuant to the terms of this
divestiture, we made cash payments to this distributor in the aggregate amount of $13.4 million, which it was
required to use to reduce its debt, pay certain trade payables and provide working capital. The investment in this
distributor had been fully impaired as of the end of 2012. There was no tax benefit related to the loss on this
divestiture.
Net Income
Net income increased $48.1 million, or 11.4%, for the year ended December 28, 2013 compared to the prior
year period due to the factors noted above.
49
Liquidity and Capital Resources
Our principal capital requirements include funding of acquisitions, purchases of additional noncontrolling
interests, repayments of debt principal, the funding of working capital needs, purchases of fixed assets and
repurchases of common stock. Working capital requirements generally result from increased sales, special
inventory forward buy-in opportunities and payment terms for receivables and payables. Historically, sales have
tended to be stronger during the third and fourth quarters and special inventory forward buy-in opportunities have
been most prevalent just before the end of the year, and have caused our working capital requirements to have been
higher from the end of the third quarter to the end of the first quarter of the following year.
We finance our business primarily through cash generated from our operations, revolving credit facilities and
debt placements. Our ability to generate sufficient cash flows from operations is dependent on the continued
demand of our customers for our products and services, and access to products and services from our suppliers.
Our business requires a substantial investment in working capital, which is susceptible to fluctuations during
the year as a result of inventory purchase patterns and seasonal demands. Inventory purchase activity is a function
of sales activity, special inventory forward buy-in opportunities and our desired level of inventory. We anticipate
future increases in our working capital requirements.
We finance our business to provide adequate funding for at least 12 months. Funding requirements are based
on forecasted profitability and working capital needs, which, on occasion, may change. Consequently, we may
change our funding structure to reflect any new requirements.
We believe that our cash and cash equivalents, our ability to access private debt markets and public equity
markets, and our available funds under existing credit facilities provide us with sufficient liquidity to meet our
currently foreseeable short-term and long-term capital needs. We have no off-balance sheet arrangements.
Net cash provided by operating activities was $592.5 million for the year ended December 27, 2014, compared
to $664.2 million for the prior year. The net change of $71.7 million was primarily attributable to unfavorable
working capital changes, partially offset by net income improvements. The prior year’s change in working capital
was favorably affected by reductions in inventory related to the medical device excise tax.
Net cash used in investing activities was $516.6 million for the year ended December 27, 2014, compared to
$266.6 million for the prior year. The net change of $250.0 million was primarily due to increased payments for
equity investments and business acquisitions and increased purchases of fixed assets.
Net cash used in financing activities was $154.6 million for the year ended December 27, 2014, compared to
$336.0 million for the prior year. The net change of $181.4 million was primarily due to decreased net payments
for long-term debt, partially offset by an increase in acquisitions of noncontrolling interests in subsidiaries.
The following table summarizes selected measures of liquidity and capital resources (in thousands):
Cash and cash equivalents ................................................................................................... $
Working capital ...................................................................................................................
89,474 $
1,133,055
2014
2013
188,616
1,284,002
December 27, December 28,
Debt:
Bank credit lines ............................................................................................................. $
Current maturities of long-term debt ..............................................................................
Long-term debt ...............................................................................................................
Total debt ................................................................................................................... $
182,899 $
5,815
542,776
731,490 $
29,508
5,441
450,233
485,182
Our cash and cash equivalents consist of bank balances and investments in money market funds representing
overnight investments with a high degree of liquidity.
50
Accounts receivable days sales outstanding and inventory turns
Our accounts receivable days sales outstanding from operations decreased to 39.9 days as of December 27,
2014 from 40.0 days as of December 28, 2013. During the years ended December 27, 2014 and December 28,
2013, we wrote off approximately $8.1 million and $8.3 million, respectively, of fully reserved accounts receivable
against our trade receivable reserve. Our inventory turns from operations remained constant at 5.9 as of December
27, 2014 compared to the comparable prior year period. Our working capital accounts may be impacted by current
and future economic conditions.
Contractual obligations
The following table summarizes our contractual obligations related to fixed and variable rate long-term debt,
including interest (assuming an average long-term rate of interest of 2.3%), as well as operating and capital lease
obligations, inventory purchase commitments and fixed asset obligations as of December 27, 2014:
Payments due by period (in thousands)
< 1 year
2 - 3 years
4 - 5 years
> 5 years
Total
Contractual obligations:
Long-term debt, including interest .......................$
19,170 $
205,293 $
59,718 $
346,259 $
630,440
Inventory purchase commitments .........................
215,148
Operating lease obligations ..................................
78,898
Capital lease obligations, including interest .........
Fixed asset purchase commitments ......................
1,782
4,766
594,592
106,755
2,502
-
594,469
63,397
1,420
-
889,600
2,293,809
80,778
329,828
2,814
-
8,518
4,766
Total .....................................................................$
319,764 $
909,142 $
719,004 $
1,319,451 $
3,267,361
Credit Facilities
On September 12, 2012, we entered into a new $500 million revolving credit agreement (the “Credit
Agreement”) with a $200 million expansion feature, which was originally set to expire on September 12, 2017,
however, on September 22, 2014, we extended the expiration date of the Credit Agreement to September 22, 2019.
The interest rate is based on the USD LIBOR plus a spread based on our leverage ratio at the end of each financial
reporting quarter. The Credit Agreement provides, among other things, that we are required to maintain maximum
leverage ratios, and contains customary representations, warranties and affirmative covenants. The Credit
Agreement also contains customary negative covenants, subject to negotiated exceptions on liens, indebtedness,
significant corporate changes (including mergers), dispositions and certain restrictive agreements. There was no
balance outstanding under this revolving credit facility as of December 27, 2014. As of December 27, 2014, there
were $10.1 million of letters of credit provided to third parties under the credit facility.
As of December 27, 2014, we had various other short-term bank credit lines available, of which $182.9 million
was outstanding. At December 27, 2014, borrowings under all of our credit lines had a weighted average interest
rate of 1.26%. In July 2014, we extended credit lines with various financial institutions for an additional year.
51
Private Placement Facilities
On August 10, 2010, we entered into $400 million private placement facilities with two insurance companies.
On April 30, 2012, we increased our available credit facilities by $375 million by entering into a new agreement
with one insurance company and amending our existing agreements with two insurance companies. On September
22, 2014, we increased our available private placement facilities by $200 million to a total facility amount of $975
million, and extended the expiration date to September 22, 2017. These facilities are available on an uncommitted
basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time through September
22, 2017. The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed
upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be
selected by us and can range from five to 15 years (with an average life no longer than 12 years). The proceeds of
any issuances under the facilities will be used for general corporate purposes, including working capital and capital
expenditures, to refinance existing indebtedness and/or to fund potential acquisitions. The agreements provide,
among other things, that we maintain certain maximum leverage ratios, and contain restrictions relating to
subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These
facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates.
The components of our private placement facility borrowings as of December 27, 2014 are presented in the
following table (in thousands):
Date of
Borrowing
September 2, 2010
January 20, 2012
January 20, 2012 (1)
December 24, 2012
June 2, 2014
Amount of
Borrowing
Outstanding
Borrowing
Rate
$
$
100,000
50,000
50,000
50,000
100,000
350,000
3.79 %
3.45
3.09
3.00
3.19
Due Date
September 2, 2020
January 20, 2024
January 20, 2022
December 24, 2024
June 2, 2021
(1) Annual repayments of approximately $7.1 million for this borrowing will commence on January 20, 2016.
U.S. Trade Accounts Receivable Securitization
On April 17, 2013, we entered into a facility agreement of up to $300 million with a bank, as agent, based on
the securitization of our U.S. trade accounts receivable. The new facility allowed us to replace public debt
(approximately $220 million), which had a higher interest rate at HSAH during February 2013 and provided
funding for working capital and general corporate purposes. The financing was structured as an asset-backed
securitization program with pricing committed for up to three years. On September 22, 2014, we extended the
expiration date of this facility agreement to April 15, 2017. The borrowings outstanding under this securitization
facility were $150.0 million as of December 27, 2014. At December 27, 2014, the interest rate on borrowings
under this facility was based on the average asset-backed commercial paper rate of 20 basis points plus 75 basis
points, for a combined rate of 0.95%.
We are required to pay a commitment fee of 30 basis points on the daily balance of the unused portion of the
facility if our usage is greater than or equal to 50% of the facility limit or a commitment fee of 35 basis points on
the daily balance of the unused portion of the facility if our usage is less than 50% of the facility limit.
Borrowings under this facility are presented as a component of Long-term debt within our consolidated balance
sheet.
52
Henry Schein Animal Health
During February 2013, we repaid the then outstanding debt related to the HSAH (formerly Butler Schein
Animal Health) transaction using our existing Credit Agreement. As part of this transaction, we recorded a one-
time interest expense charge of $6.2 million related to the accelerated amortization of deferred financing costs.
Long-term debt
Long-term debt consisted of the following:
December 27, December 28,
2014
2013
Private placement facilities ............................................................................................... $
U.S. trade accounts receivable securitization ....................................................................
Notes payable to banks at a weighted-average interest rate of 8.5% .................................
Various collateralized and uncollateralized loans payable with interest,
in varying installments through 2018 at interest rates ranging
from 2.17% to 5.41% ...............................................................................................
Capital lease obligations (see Note 17) .............................................................................
Total ..................................................................................................................................
Less current maturities ......................................................................................................
350,000 $
150,000
30
250,000
160,000
73
41,259
7,302
548,591
(5,815)
44,091
1,510
455,674
(5,441)
450,233
Total long-term debt ................................................................................................. $
542,776 $
Divestiture of an Equity Affiliate
On July 10, 2013, we divested our investment in a dental wholesale distributor in the Middle East that had
primarily served as an importer that distributed products largely to other distributors. The divestiture resulted in a
one-time loss of $12.5 million, or $0.14 per diluted share, in the third quarter of 2013. Pursuant to the terms of this
divestiture, we made cash payments to this distributor in the aggregate amount of $13.4 million, which it was
required to use to reduce its debt, pay certain trade payables and provide working capital. The investment in this
distributor had been fully impaired as of the end of 2012. There was no tax benefit related to the loss on this
divestiture.
Stock repurchases
From June 21, 2004 through December 27, 2014, we repurchased approximately $1.4 billion, or 19,357,214
shares, under our common stock repurchase programs, with $299.9 million available as of December 27, 2014 for
future common stock share repurchases.
53
Redeemable noncontrolling interests
Some minority shareholders in certain of our subsidiaries have the right, at certain times, to require us to
acquire their ownership interest in those entities at fair value. Accounting Standards Codification Topic 480-10 is
applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the
outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put
option contained in contractual agreements. The components of the change in the Redeemable noncontrolling
interests for the years ended December 27, 2014, December 28, 2013 and December 29, 2012 are presented in the
following table:
December 27,
2014
December 28, December 29,
2013
2012
Balance, beginning of period ................................................................. $
Decrease in redeemable noncontrolling interests due to
redemptions .......................................................................................
Increase in redeemable noncontrolling interests due to
business acquisitions ...........................................................................
Net income attributable to redeemable noncontrolling interests ............
Dividends declared .................................................................................
Effect of foreign currency translation gain (loss) attributable to
redeemable noncontrolling interests ..................................................
Change in fair value of redeemable securities .......................................
Other adjustment to redeemable noncontrolling interests ......................
Balance, end of period ............................................................................ $
497,539 $
435,175 $
402,050
(105,383)
(9,028)
(23,637)
120,220
38,741
(23,346)
(4,080)
40,836
-
564,527 $
11,542
39,430
(19,965)
(654)
41,039
-
497,539 $
30,935
34,803
(21,013)
904
53,769
(42,636)
435,175
Changes in the estimated redemption amounts of the noncontrolling interests subject to put options are adjusted
at each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the
carrying amounts are subject to a floor amount that is equal to the fair value of the redeemable noncontrolling
interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests
cannot go below the floor level. These adjustments do not impact the calculation of earnings per share.
Additionally, some prior owners of such acquired subsidiaries are eligible to receive additional purchase price
cash consideration if certain financial targets are met. Any adjustments to these accrual amounts are recorded in
our consolidated statement of income.
Unrecognized tax benefits
As more fully disclosed in Note 12 of “Notes to Consolidated Financial Statements,” we cannot reasonably
estimate the timing of future cash flows related to the unrecognized tax benefits, including accrued interest, of
$80.6 million as of December 27, 2014.
54
Critical Accounting Policies and Estimates
The preparation of consolidated financial statements requires us to make estimates and judgments that affect
the reported amounts of assets, liabilities, revenues and expenses and related disclosures of contingent assets and
liabilities. We base our estimates on historical data, when available, experience, industry and market trends, and on
various other assumptions that are believed to be reasonable under the circumstances, the combined results of
which form the basis for making judgments about the carrying values of assets and liabilities that are not readily
apparent from other sources. However, by their nature, estimates are subject to various assumptions and
uncertainties. Reported results are therefore sensitive to any changes in our assumptions, judgments and estimates,
including the possibility of obtaining materially different results if different assumptions were to be applied.
We believe that the following critical accounting policies, which have been discussed with our audit committee,
affect the significant estimates and judgments used in the preparation of our financial statements:
Revenue Recognition
We generate revenue from the sale of dental, animal health and medical consumable products, as well as
equipment, software products and services and other sources. Provisions for discounts, rebates to customers,
customer returns and other contra-revenue adjustments are recorded based upon historical data and estimates and
are provided for in the period in which the related sales are recognized.
Revenue derived from the sale of consumable products is recognized when products are shipped or made
available to customers. Such sales typically entail high-volume, low-dollar orders shipped using third-party
common carriers. We believe that the shipment date is the most appropriate point in time indicating the completion
of the earnings process because we have no post-shipment obligations, the product price is fixed and determinable,
collection of the resulting receivable is reasonably assured and product returns are reasonably estimable.
Revenue derived from the sale of equipment is recognized when products are delivered to customers. Such
sales typically entail scheduled deliveries of large equipment primarily by equipment service technicians. Some
equipment sales require minimal installation, which is typically completed at the time of delivery.
Revenue derived from the sale of software products is recognized when products are shipped to customers.
Such software is generally installed by customers and does not require extensive training due to the nature of its
design. Revenue derived from post-contract customer support for software, including annual support and/or
training, is recognized over the period in which the services are provided.
Revenue derived from multiple element arrangements, and the related deferral of such revenue (which is
insignificant to our financial statements), is recognized as follows. When we sell software products together with
related services (i.e., training and technical support) we allocate revenue to the delivered elements using the
residual method, based upon vendor-specific objective evidence (“VSOE”) of the fair value of the undelivered
elements, or defer it until such time as vendor-specific evidence of fair value is obtained. Multiple element
arrangements that include elements that are not considered software consist primarily of equipment and the related
installation service. We allocate revenue for such arrangements based on the relative selling prices of the elements
applying the following hierarchy: first VSOE, then third-party evidence (“TPE”) of selling price if VSOE is not
available, and finally our estimate of the selling price if neither VSOE nor TPE is available. VSOE exists when we
sell the deliverables separately and represents the actual price charged by us for each deliverable. Estimated selling
price reflects our best estimate of what the selling prices of each deliverable would be if it were sold regularly on a
standalone basis taking into consideration the cost structure of our business, technical skill required, customer
location and other market conditions. Each element that has standalone value is accounted for as a separate unit of
accounting. Revenue allocated to each unit of accounting is recognized when the service is provided or the product
is delivered.
Revenue derived from other sources including freight charges, equipment repairs and financial services, is
recognized when the related product revenue is recognized or when the services are provided.
55
Accounts Receivable and Reserves
The carrying amount of accounts receivable is reduced by a valuation allowance that reflects our best estimate
of the amounts that will not be collected. The reserve for accounts receivable is comprised of allowance for
doubtful accounts and sales returns. In addition to reviewing delinquent accounts receivable, we consider many
factors in estimating our reserve, including historical data, experience, customer types, credit worthiness and
economic trends. From time to time, we may adjust our assumptions for anticipated changes in any of these or
other factors expected to affect collectability. Although we believe our judgments, estimates and/or assumptions
related to accounts receivable and reserves are reasonable, making material changes to such judgments, estimates
and/or assumptions could materially affect our financial results.
Inventories and Reserves
Inventories consist primarily of finished goods and are valued at the lower of cost or market. Cost is
determined by the first-in, first-out method for merchandise or actual cost for large equipment and high tech
equipment. In accordance with our policy for inventory valuation, we consider many factors including the
condition and salability of the inventory, historical sales, forecasted sales and market and economic trends.
From time to time, we may adjust our assumptions for anticipated changes in any of these or other factors
expected to affect the value of inventory. Although we believe our judgments, estimates and/or assumptions related
to inventory and reserves are reasonable, making material changes to such judgments, estimates and/or assumptions
could materially affect our financial results.
Goodwill and Other Indefinite-Lived Intangible Assets
Goodwill and other indefinite-lived intangible assets (primarily trademarks) are not amortized, but are subject
to impairment analysis at least once annually. Such impairment analyses for goodwill require a comparison of the
fair value to the carrying value of reporting units. We regard our reporting units to be our operating segments:
health care distribution (global dental, animal health and medical) and technology and value-added services.
We test goodwill impairment under the provisions of Accounting Standards Update 2011-08, “Intangibles-
Goodwill and Other (Topic 350): Testing Goodwill for Impairment,” which allows us to use qualitative factors to
determine whether it is more likely than not that the fair values of our reporting units are less than their carrying
values. The factors that we consider in developing our qualitative assessment include:
• Macroeconomic conditions consisting of the overall sales growth of our business and the overall sales
growth of each of our operating segments. We also consider our growth in market share in the markets in
which we compete;
• Credit markets and our ability to access debt facilities at favorable terms;
• Key personnel and management expertise, as well as our growth strategies for the next several years; and
• Our expectations of selling or disposing all, or a portion, of a reporting unit.
Goodwill was allocated to such reporting units, for the purposes of preparing our impairment analyses, based
on a specific identification basis. Our impairment analysis for indefinite-lived intangibles consists of a comparison
of the fair value to the carrying value of the assets. This comparison is made based on a review of historical,
current and forecasted sales and gross profit levels, as well as a review of any factors that may indicate potential
impairment. For certain indefinite-lived intangible assets, a present value technique, such as estimates of future
cash flows, is utilized. We assessed the potential impairment of goodwill and other indefinite-lived intangible
assets annually (at the beginning of our fourth quarter) and on an interim basis whenever events or changes in
circumstances indicate that the carrying value may not be recoverable.
Some factors we consider important that could trigger an interim impairment review include:
•
•
•
significant underperformance relative to expected historical or projected future operating results;
significant changes in the manner of our use of acquired assets or the strategy for our overall business
(e.g., decision to divest a business); or
significant negative industry or economic trends.
If we determine through the impairment review process that goodwill or other indefinite-lived intangible assets
are impaired, we record an impairment charge in our consolidated statements of income.
56
For the years ended December 27, 2014, December 28, 2013 and December 29, 2012, the results of our
goodwill impairment analysis did not result in any impairments.
Supplier Rebates
Supplier rebates are included as a reduction of cost of sales and are recognized over the period they are earned.
The factors we consider in estimating supplier rebate accruals include forecasted inventory purchases and sales in
conjunction with supplier rebate contract terms which generally provide for increasing rebates based on either
increased purchase or sales volume. Although we believe our judgments, estimates and/or assumptions related to
supplier rebates are reasonable, making material changes to such judgments, estimates and/or assumptions could
materially affect our financial results.
Long-Lived Assets
Long-lived assets, other than goodwill and other indefinite-lived intangibles, are evaluated for impairment
whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable
through the estimated undiscounted future cash flows to be derived from such assets.
Definite-lived intangible assets primarily consist of non-compete agreements, trademarks, trade names,
customer lists, customer relationships and intellectual property. For long-lived assets used in operations,
impairment losses are only recorded if the asset’s carrying amount is not recoverable through its undiscounted,
probability-weighted future cash flows. We measure the impairment loss based on the difference between the
carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to
fair value. Although we believe our judgments, estimates and/or assumptions used in estimating cash flows and
determining fair value are reasonable, making material changes to such judgments, estimates and/or assumptions
could materially affect such impairment analyses and our financial results.
Stock-Based Compensation
We measure stock-based compensation at the grant date, based on the estimated fair value of the award. Prior
to March 2009, awards principally included a combination of at-the-money stock options and restricted stock/units.
Since March 2009, equity-based awards have been granted solely in the form of restricted stock/units, with the
exception of providing stock options to employees pursuant to certain pre-existing contractual obligations.
We estimated the fair value of stock options using the Black-Scholes valuation model which required us to
make assumptions about the expected life of options, stock price volatility, risk-free interest rates and dividend
yields.
Grants of restricted stock/units are stock-based awards granted to recipients with specified vesting provisions.
In the case of restricted stock, common stock is delivered on the date of grant, subject to vesting conditions. In the
case of restricted stock units, common stock is generally delivered on or following satisfaction of vesting
conditions. Prior to February 2014, we issued restricted stock/units that vest solely based on the recipient’s
continued service over time (primarily four-year cliff) and restricted stock/units that vest based on our achieving
specified performance measurements and the recipient’s continued service over time (primarily three-year cliff
vesting). Since February 2014, we have issued restricted stock/units that vest solely based on the recipient’s
continued service over time (primarily four-year cliff vesting under our 2013 Stock Incentive Plan and primarily
13-month cliff vesting under our 1996 Non-Employee Director Stock Incentive Plan) and restricted stock/units that
vest based on our achieving specified performance measurements and the recipient’s continued service over time
(primarily three-year cliff vesting under our 2013 Stock Incentive Plan).
57
With respect to time-based restricted stock/units, we estimate the fair value on the date of grant based on our
closing stock price. With respect to performance-based restricted stock/units, the number of shares that ultimately
vest and are received by the recipient is based upon our performance as measured against specified targets over a
three-year period as determined by the Compensation Committee of the Board of Directors. Although there is no
guarantee that performance targets will be achieved, we estimate the fair value of performance-based restricted
stock/units based on our closing stock price at time of grant. Adjustments to the performance-based restricted
stock/units targets are provided for significant events such as acquisitions, divestitures, new business ventures,
share repurchases and certain foreign exchange fluctuations. Over the performance period, the number of shares of
common stock that will ultimately vest and be issued and the related compensation expense is adjusted upward or
downward based upon our estimation of achieving such performance targets. The ultimate number of shares
delivered to recipients and the related compensation cost recognized as an expense will be based on our actual
performance metrics as defined.
Although we believe our judgments, estimates and/or assumptions related to stock-based compensation are
reasonable, making material changes to such judgments, estimates and/or assumptions could materially affect our
financial results.
Recently Issued Accounting Standards
In May 2014, the FASB issued Accounting Standards Update No. 2014-09, “Revenue from Contracts with
Customers” (“ASU 2014-09”), which supersedes nearly all existing revenue recognition guidance under accounting
principles generally accepted in United States (“U.S. GAAP”). The core principle of ASU 2014-09 is to recognize
revenues when promised goods or services are transferred to customers in an amount that reflects the consideration
to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to
achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue
recognition process than are required under existing U.S. GAAP.
The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein,
using either of the following transition methods: (i) a full retrospective approach reflecting the application of the
standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective
approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which
includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU
2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt
the standard in 2017.
58
ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to market risks as well as changes in foreign currency exchange rates as measured against the
U.S. dollar and each other, and changes to the credit markets. We attempt to minimize these risks by primarily
using foreign currency forward contracts and by maintaining counter-party credit limits. These hedging activities
provide only limited protection against currency exchange and credit risks. Factors that could influence the
effectiveness of our hedging programs include currency markets and availability of hedging instruments and
liquidity of the credit markets. All foreign currency forward contracts that we enter into are components of hedging
programs and are entered into for the sole purpose of hedging an existing or anticipated currency exposure. We do
not enter into such contracts for speculative purposes and we manage our credit risks by diversifying our
investments, maintaining a strong balance sheet and having multiple sources of capital.
Foreign Currency Agreements
The value of certain foreign currencies as compared to the U.S. dollar may affect our financial results.
Fluctuations in exchange rates may positively or negatively affect our revenues, gross margins, operating expenses
and retained earnings, all of which are expressed in U.S. dollars. Where we deem it prudent, we engage in hedging
programs using primarily foreign currency forward contracts aimed at limiting the impact of foreign currency
exchange rate fluctuations on earnings. We purchase short-term (i.e., 18 months or less) foreign currency forward
contracts to protect against currency exchange risks associated with intercompany loans due from our international
subsidiaries and the payment of merchandise purchases to foreign suppliers. We do not hedge the translation of
foreign currency profits into U.S. dollars, as we regard this as an accounting exposure, not an economic exposure.
As of December 27, 2014, we have foreign currency exchange agreements, which expire through July 29, 2015,
which include a mark-to-market gain of $1.2 million as determined by quoted market prices. A hypothetical 5%
change in the value of the U.S. dollar would change the notional value of our foreign currency exchange
agreements by a reduction $0.1 million.
Short-Term Investments
We limit our credit risk with respect to our cash equivalents, short-term investments and derivative instruments,
by monitoring the credit worthiness of the financial institutions who are the counter-parties to such financial
instruments. As a risk management policy, we limit the amount of credit exposure by diversifying and utilizing
numerous investment grade counter-parties.
59
Item 8. Financial Statements and Supplementary Data
INDEX TO FINANCIAL STATEMENTS
HENRY SCHEIN, INC.
Page
Report of Independent Registered Public Accounting Firm ........................................................................................
61
Consolidated Financial Statements:
Balance Sheets as of December 27, 2014 and December 28, 2013 ......................................................................
62
Statements of Income for the years ended December 27, 2014,
December 28, 2013 and December 29, 2012 ..............................................................................................
63
Statements of Comprehensive Income for the years ended December 27, 2014,
December 28, 2013 and December 29, 2012 ..............................................................................................
64
Statements of Changes in Stockholders’ Equity for the years ended
December 27, 2014, December 28, 2013 and December 29, 2012 .............................................................
65
Statements of Cash Flows for the years ended December 27, 2014,
December 28, 2013 and December 29, 2012 ..............................................................................................
Notes to Consolidated Financial Statements ........................................................................................................
66
67
Report of Independent Registered Public Accounting Firm ........................................................................................
108
Schedule II - Valuation and Qualifying Accounts for the years ended December 27, 2014,
December 28, 2013 and December 29, 2012 .......................................................................................................
109
All other schedules are omitted because the required information is either inapplicable or is included in the consolidated
financial statements or the notes thereto.
60
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Board of Directors and Stockholders
Henry Schein, Inc.
Melville, New York
We have audited the accompanying consolidated balance sheets of Henry Schein, Inc. as of December 27, 2014
and December 28, 2013 and the related consolidated statements of income, comprehensive income, changes in
stockholders’ equity, and cash flows for each of the three years in the period ended December 27, 2014. These
financial statements are the responsibility of the Company’s management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board
(United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles
used and significant estimates made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects,
the financial position of Henry Schein, Inc. at December 27, 2014 and December 28, 2013, and the results of its
operations and its cash flows for each of the three years in the period ended December 27, 2014, in conformity with
accounting principles generally accepted in the United States of America.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board
(United States), Henry Schein, Inc.’s internal control over financial reporting as of December 27, 2014, based on
criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO) and our report dated February 11, 2015 expressed an
unqualified opinion thereon.
/s/ BDO USA, LLP
New York, NY
February 11, 2015
61
HENRY SCHEIN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
December 27,
2014
December 28,
2013
ASSETS
Current assets:
Cash and cash equivalents ................................................................................................... $
Accounts receivable, net of reserves of $80,671 and $78,298 .............................................
Inventories, net ....................................................................................................................
Deferred income taxes .........................................................................................................
Prepaid expenses and other ..................................................................................................
Total current assets .....................................................................................................
Property and equipment, net .....................................................................................................
Goodwill ...................................................................................................................................
Other intangibles, net ...............................................................................................................
Investments and other ...............................................................................................................
Total assets ................................................................................................................. $
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable ................................................................................................................. $
Bank credit lines ..................................................................................................................
Current maturities of long-term debt ...................................................................................
Accrued expenses:
Payroll and related ..........................................................................................................
Taxes ...............................................................................................................................
Other ...............................................................................................................................
Total current liabilities ...............................................................................................
Long-term debt .........................................................................................................................
Deferred income taxes ..............................................................................................................
Other liabilities .........................................................................................................................
Total liabilities ...........................................................................................................
$
89,474
1,127,517
1,327,796
56,591
311,788
2,913,166
311,496
1,884,123
643,736
386,286
6,138,807 $
$
860,996
182,899
5,815
237,511
151,162
341,728
1,780,111
542,776
253,118
181,830
2,757,835
188,616
1,055,216
1,250,403
63,865
276,565
2,834,665
275,888
1,635,005
417,133
461,945
5,624,636
824,495
29,508
5,441
216,629
145,161
329,429
1,550,663
450,233
198,674
139,526
2,339,096
Redeemable noncontrolling interests .......................................................................................
Commitments and contingencies
564,527
497,539
Stockholders' equity:
Preferred stock, $.01 par value, 1,000,000 shares authorized,
none outstanding .............................................................................................................
-
-
Common stock, $.01 par value, 240,000,000 shares authorized,
84,008,537 outstanding on December 27, 2014 and
85,622,452 outstanding on December 28, 2013 ..............................................................
Additional paid-in capital ....................................................................................................
Retained earnings ................................................................................................................
Accumulated other comprehensive income (loss) ...............................................................
Total Henry Schein, Inc. stockholders' equity .................................................................
Noncontrolling interests ......................................................................................................
Total stockholders' equity ...........................................................................................
Total liabilities, redeemable noncontrolling interests and stockholders' equity .............. $
840
265,363
2,642,523
(95,132)
2,813,594
2,851
2,816,445
6,138,807 $
856
318,225
2,398,267
67,849
2,785,197
2,804
2,788,001
5,624,636
See accompanying notes.
62
HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)
Years Ended
December 27, December 28, December 29,
2014
2013
2012
Net sales ................................................................................................................ $
Cost of sales ..........................................................................................................
Gross profit ......................................................................................................
Operating expenses:
Selling, general and administrative .....................................................................
Restructuring costs ..............................................................................................
Operating income ............................................................................................
Other income (expense):
Interest income ....................................................................................................
Interest expense ..................................................................................................
Other, net ............................................................................................................
Income before taxes and equity in earnings of affiliates ..................................
Income taxes ..........................................................................................................
Equity in earnings of affiliates ..............................................................................
Loss on sale of equity investment .........................................................................
Net income ............................................................................................................
Less: Net income attributable to noncontrolling interests ...................................
Net income attributable to Henry Schein, Inc. ...................................................... $
10,371,390 $
7,460,075
2,911,315
9,560,647 $
6,904,633
2,656,014
2,196,173
-
715,142
1,978,960
-
677,054
13,655
(24,057)
4,572
709,312
(215,610)
11,734
-
505,436
(39,359)
466,077 $
12,853
(27,538)
2,325
664,694
(190,891)
10,194
(12,535)
471,462
(39,908)
431,554 $
8,939,967
6,432,454
2,507,513
1,873,360
15,192
618,961
13,394
(30,902)
2,735
604,188
(187,858)
7,058
-
423,388
(35,312)
388,076
Earnings per share attributable to Henry Schein, Inc.:
Basic ................................................................................................................... $
Diluted ................................................................................................................ $
5.53 $
5.44 $
5.02 $
4.93 $
4.44
4.32
Weighted-average common shares outstanding:
Basic ...................................................................................................................
Diluted ................................................................................................................
84,265
85,740
85,926
87,622
87,499
89,823
See accompanying notes.
63
HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(in thousands)
December 27, December 28, December 29,
2014
2013
2012
Net income .......................................................................................................... $
505,436 $
471,462 $
423,388
Other comprehensive income (loss), net of tax:
Foreign currency translation gain (loss) ...........................................................
(157,698)
9,474
33,347
Unrealized gain (loss) from foreign currency hedging activities .....................
(2,337)
Unrealized investment gain (loss) ....................................................................
379
95
(100)
2,865
414
Pension adjustment gain (loss) .........................................................................
(7,441)
4,871
(5,451)
Other comprehensive income (loss), net of tax ..................................................
(167,097)
14,340
31,175
Comprehensive income .......................................................................................
338,339
485,802
454,563
Comprehensive income attributable to noncontrolling interests:
Net income ....................................................................................................
Foreign currency translation (gain) loss ........................................................
(39,359)
4,116
(39,908)
654
(35,312)
(904)
Comprehensive income attributable to noncontrolling interests ................
(35,243)
(39,254)
(36,216)
Comprehensive income attributable to Henry Schein, Inc. ................................. $
303,096 $
446,548 $
418,347
See accompanying notes.
64
HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(In thousands, except share and per share data)
Common Stock
$.01 Par Value
Shares
Amount
Additional
Paid-in
Capital
Retained
Earnings
Accumulated
Other
Total
Comprehensive Noncontrolling Stockholders'
Income (Loss)
Interests
Equity
2,433,623
Balance, December 31, 2011 ........................................................... 89,928,082 $
Net income (excluding $34,803 attributable to Redeemable
899 $
401,262 $
2,007,477 $
22,584 $
1,401 $
noncontrolling interests) ............................................................
Foreign currency translation gain (excluding $904
attributable to Redeemable noncontrolling interests) ...............
Unrealized gain from foreign currency hedging activities,
net of tax of $654 ......................................................................
Unrealized investment gain, net of tax of $310 ...............................
Pension adjustment loss, net of tax benefit of $2,187 .....................
Dividends paid .................................................................................
Initial noncontrolling interests and adjustments related to
-
-
-
-
-
-
-
business acquisitions .................................................................
Change in fair value of redeemable securities .................................
-
Repurchase and retirement of common stock .................................. (3,937,054)
Stock issued upon exercise of stock options,
including tax benefit of $31,638 ............................................... 1,889,872
277,339
(307,568)
-
Stock-based compensation expense .................................................
Shares withheld for payroll taxes ....................................................
Liability for cash settlement stock-based compensation awards .....
Balance, December 29, 2012 ........................................................... 87,850,671 $
Net income (excluding $39,430 attributable to Redeemable
noncontrolling interests) ............................................................
Foreign currency translation gain (excluding $654
attributable to Redeemable noncontrolling interests) ...............
Unrealized gain from foreign currency hedging activities,
net of tax benefit of $26 ............................................................
Unrealized investment loss, net of tax benefit of $66 .....................
Pension adjustment gain, net of tax of $1,336 .................................
Dividends paid .................................................................................
Other adjustments ............................................................................
Initial noncontrolling interests and adjustments related to
-
-
-
-
-
-
-
-
business acquisitions .................................................................
Change in fair value of redeemable securities .................................
-
Repurchase and retirement of common stock .................................. (3,072,942)
Stock issued upon exercise of stock options,
including tax benefit of $18,410 ...............................................
Stock-based compensation expense .................................................
Shares withheld for payroll taxes ....................................................
Liability for cash settlement stock-based compensation awards .....
743,651
349,804
(248,732)
-
Balance, December 28, 2013 ........................................................... 85,622,452 $
Net income (excluding $38,741 attributable to Redeemable
noncontrolling interests) ............................................................
Foreign currency translation loss (excluding $4,080
attributable to Redeemable noncontrolling interests) ...............
Unrealized loss from foreign currency hedging activities,
net of tax benefit of $155 ..........................................................
Unrealized investment gain, net of tax of $250 ...............................
Pension adjustment loss, net of tax benefit of $2,781 .....................
Dividends paid .................................................................................
Initial noncontrolling interests and adjustments related to
-
-
-
-
-
-
-
business acquisitions .................................................................
Change in fair value of redeemable securities .................................
-
Repurchase and retirement of common stock .................................. (2,528,209)
Stock issued upon exercise of stock options,
including tax benefit of $11,161 ...............................................
Stock-based compensation expense .................................................
Shares withheld for payroll taxes ....................................................
Liability for cash settlement stock-based compensation awards .....
637,014
464,124
(186,844)
-
-
-
-
-
-
-
-
-
(39)
19
3
(3)
-
-
-
-
-
-
-
(1,189)
(53,769)
(88,196)
104,103
37,310
(23,024)
(551)
388,076
-
509
388,585
-
-
-
-
-
-
-
(211,648)
-
-
-
-
32,443
-
32,443
2,865
414
(5,451)
-
-
-
-
-
-
-
-
-
-
-
(430)
799
-
-
-
-
-
-
2,865
414
(5,451)
(430)
(390)
(53,769)
(299,883)
104,122
37,313
(23,027)
(551)
879 $
375,946 $
2,183,905 $
52,855 $
2,279 $
2,615,864
-
-
-
-
-
-
-
-
-
(31)
7
3
(2)
-
-
-
-
-
-
-
(90)
-
(41,039)
(83,028)
53,955
35,524
(22,498)
(545)
431,554
-
478
432,032
-
-
-
-
-
-
-
-
(217,192)
-
-
-
-
10,128
-
10,128
95
(100)
4,871
-
-
-
-
-
-
-
-
-
-
-
-
(487)
-
534
-
-
-
-
-
-
95
(100)
4,871
(487)
(90)
534
(41,039)
(300,251)
53,962
35,527
(22,500)
(545)
856 $
318,225 $
2,398,267 $
67,849 $
2,804 $
2,788,001
-
-
-
-
-
-
-
-
(25)
6
5
(2)
-
-
-
-
-
-
-
466,077
-
-
-
-
-
-
(153,582)
(2,337)
379
(7,441)
-
744
(40,836)
(78,143)
42,646
45,871
(22,570)
(574)
-
-
(221,821)
-
-
-
-
-
-
-
-
-
-
-
618
(36)
-
-
-
(544)
9
-
-
-
-
-
-
466,695
(153,618)
(2,337)
379
(7,441)
(544)
753
(40,836)
(299,989)
42,652
45,876
(22,572)
(574)
Balance, December 27, 2014 ........................................................... 84,008,537 $
840 $
265,363 $
2,642,523 $
(95,132) $
2,851 $
2,816,445
See accompanying notes.
65
HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
Years Ended
December 27,
2014
December 28, December 29,
2013
2012
Cash flows from operating activities:
Net income ....................................................................................................... $
Adjustments to reconcile net income to net cash provided by
operating activities:
Depreciation and amortization ................................................................
Accelerated amortization of deferred financing costs .............................
Loss on sale of equity investment ...........................................................
Stock-based compensation expense ........................................................
Provision for losses on trade and other accounts receivable ...................
Provision for (benefit from) deferred income taxes ................................
Equity in earnings of affiliates ................................................................
Distributions from equity affiliates .........................................................
Changes in unrecognized tax benefits .....................................................
Other .......................................................................................................
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable ............................................................................
Inventories ..........................................................................................
Other current assets ............................................................................
Accounts payable and accrued expenses ............................................
Net cash provided by operating activities ..............................................................
Cash flows from investing activities:
Purchases of fixed assets ..................................................................................
Payments related to equity investments and business
acquisitions, net of cash acquired ................................................................
Payments related to sale of equity investment ..................................................
Proceeds from sales of available-for-sale securities .........................................
Proceeds from maturities of available-for-sale securities .................................
Other .................................................................................................................
Net cash used in investing activities ......................................................................
Cash flows from financing activities:
Proceeds from (repayments of) bank borrowings .............................................
Proceeds from issuance of long-term debt ........................................................
Debt issuance costs ...........................................................................................
Principal payments for long-term debt .............................................................
Proceeds from issuance of stock upon exercise of stock options ......................
Payments for repurchases of common stock .....................................................
Excess tax benefits related to stock-based compensation .................................
Distributions to noncontrolling shareholders ....................................................
Acquisitions of noncontrolling interests in subsidiaries ...................................
Net cash used in financing activities .....................................................................
505,436 $
471,462 $
423,388
152,238
-
-
45,876
4,619
4,699
(11,734)
15,727
22,597
3,303
(81,441)
(71,899)
(40,407)
43,490
592,504
128,035
6,203
12,535
35,527
5,189
(11,514)
(10,194)
16,529
10,500
10,290
(45,110)
(48,087)
15,747
67,063
664,175
125,322
-
-
37,313
4,407
10,072
(7,058)
14,499
13,500
693
(73,925)
(193,585)
(62,390)
115,863
408,099
(82,116)
(60,215)
(51,237)
(424,283)
-
-
3,250
(13,490)
(516,639)
152,641
314,787
(687)
(228,407)
31,491
(299,989)
5,886
(24,986)
(105,383)
(154,647)
(182,363)
(13,364)
-
-
(10,663)
(266,605)
2,175
678,781
(1,372)
(729,977)
35,553
(300,251)
8,141
(19,224)
(9,800)
(335,974)
(220,238)
-
9,225
-
(7,354)
(269,604)
(32,185)
155,132
(1,482)
(40,722)
72,485
(299,883)
17,819
(21,284)
(20,481)
(170,601)
6,902
(25,204)
147,284
122,080
Effect of exchange rate changes on cash and cash equivalents .............................
Net change in cash and cash equivalents ...............................................................
Cash and cash equivalents, beginning of period ....................................................
Cash and cash equivalents, end of period .............................................................. $
(20,360)
(99,142)
188,616
89,474 $
4,940
66,536
122,080
188,616 $
See accompanying notes.
66
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
Note 1 – Significant Accounting Policies
Nature of Operations
We distribute health care products and services primarily to office-based health care practitioners with
operations or affiliates in the United States, Australia, Austria, Belgium, Brazil, Canada, Chile, China, the Czech
Republic, France, Germany, Hong Kong SAR, Iceland, Ireland, Israel, Italy, Japan, Luxembourg, the Netherlands,
New Zealand, Poland, Portugal, Slovakia, South Africa, Spain, Switzerland, Thailand and the United Kingdom.
Principles of Consolidation
Our consolidated financial statements include the accounts of Henry Schein, Inc. and all of our controlled
subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Investments in
unconsolidated affiliates, which are greater than or equal to 20% and less than or equal to 50% owned or
investments in unconsolidated affiliates of less than 20% in which we have the ability to influence the operating or
financial decisions, are accounted for under the equity method. See Note 6 for accounting treatment of Redeemable
noncontrolling interests. Certain prior period amounts have been reclassified to conform to the current period
presentation.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the
United States requires us to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Fiscal Year
We report our results of operations and cash flows on a 52-53 week basis ending on the last Saturday of
December. The years ended December 27, 2014, December 28, 2013 and December 29, 2012 consisted of 52
weeks.
Revenue Recognition
We generate revenue from the sale of dental, animal health and medical consumable products, as well as
equipment, software products and services and other sources. Provisions for discounts, rebates to customers,
customer returns and other contra-revenue adjustments are recorded based upon historical data and estimates and
are provided for in the period in which the related sales are recognized.
Revenue derived from the sale of consumable products is recognized when products are shipped or made
available to customers. Such sales typically entail high-volume, low-dollar orders shipped using third-party
common carriers. We believe that the shipment date is the most appropriate point in time indicating the completion
of the earnings process because we have no post-shipment obligations, the product price is fixed and determinable,
collection of the resulting receivable is reasonably assured and product returns are reasonably estimable.
67
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 1 – Significant Accounting Policies – (Continued)
Revenue derived from the sale of equipment is recognized when products are delivered to customers. Such
sales typically entail scheduled deliveries of large equipment primarily by equipment service technicians. Some
equipment sales require minimal installation, which is typically completed at the time of delivery.
Revenue derived from the sale of software products is recognized when products are shipped to customers.
Such software is generally installed by customers and does not require extensive training due to the nature of its
design. Revenue derived from post-contract customer support for software, including annual support and/or
training, is recognized over the period in which the services are provided.
Revenue derived from multiple element arrangements, and the related deferral of such revenue (which is
insignificant to our financial statements), is recognized as follows. When we sell software products together with
related services (i.e., training and technical support) we allocate revenue to the delivered elements using the
residual method, based upon vendor-specific objective evidence (“VSOE”) of the fair value of the undelivered
elements, or defer it until such time as vendor-specific evidence of fair value is obtained. Multiple element
arrangements that include elements that are not considered software consist primarily of equipment and the related
installation service. We allocate revenue for such arrangements based on the relative selling prices of the elements
applying the following hierarchy: first VSOE, then third-party evidence (“TPE”) of selling price if VSOE is not
available, and finally our estimate of the selling price if neither VSOE nor TPE is available. VSOE exists when we
sell the deliverables separately and represents the actual price charged by us for each deliverable. Estimated selling
price reflects our best estimate of what the selling prices of each deliverable would be if it were sold regularly on a
standalone basis taking into consideration the cost structure of our business, technical skill required, customer
location and other market conditions. Each element that has standalone value is accounted for as a separate unit of
accounting. Revenue allocated to each unit of accounting is recognized when the service is provided or the product
is delivered.
Revenue derived from other sources including freight charges, equipment repairs and financial services, is
recognized when the related product revenue is recognized or when the services are provided.
Cash and Cash Equivalents
We consider all highly liquid short-term investments with an original maturity of three months or less to be
cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable
estimate of fair value. Outstanding checks in excess of funds on deposit of $50.4 million and $39.6 million,
primarily related to payments for inventory, were classified as accounts payable as of December 27, 2014 and
December 28, 2013.
Accounts Receivable and Reserves
The carrying amount of accounts receivable is reduced by a valuation allowance that reflects our best estimate
of the amounts that will not be collected. The reserve for accounts receivable is comprised of allowance for
doubtful accounts and sales returns. In addition to reviewing delinquent accounts receivable, we consider many
factors in estimating our reserve, including historical data, experience, customer types, credit worthiness and
economic trends. From time to time, we adjust our assumptions for anticipated changes in any of these or other
factors expected to affect collectability.
68
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 1 – Significant Accounting Policies – (Continued)
Inventories and Reserves
Inventories consist primarily of finished goods and are valued at the lower of cost or market. Cost is
determined by the first-in, first-out method for merchandise or actual cost for large equipment and high tech
equipment. In accordance with our policy for inventory valuation, we consider many factors including the
condition and salability of the inventory, historical sales, forecasted sales and market and economic trends. From
time to time, we adjust our assumptions for anticipated changes in any of these or other factors expected to affect
the value of inventory.
Direct Shipping and Handling Costs
Freight and other direct shipping costs are included in cost of sales. Direct handling costs, which represent
primarily direct compensation costs of employees who pick, pack and otherwise prepare, if necessary, merchandise
for shipment to our customers are reflected in selling, general and administrative expenses. Direct shipping and
handling costs were $78.4 million, $69.1 million and $64.5 million for the years ended December 27, 2014,
December 28, 2013 and December 29, 2012.
Advertising and Promotional Costs
We generally expense advertising and promotional costs as incurred. Total advertising and promotional
expenses were $18.4 million, $12.2 million and $10.4 million for the years ended December 27, 2014, December
28, 2013 and December 29, 2012. Additionally, advertising and promotional costs incurred in connection with
direct marketing, including product catalogs and printed material, are deferred and amortized on a straight-line
basis over the period which is benefited, generally not exceeding one year. As of December 27, 2014 and
December 28, 2013, we had $4.6 million and $3.9 million of deferred direct marketing expenses included in other
current assets.
Supplier Rebates
Supplier rebates are included as a reduction of cost of sales and are recognized over the period they are earned.
The factors we consider in estimating supplier rebate accruals include forecasted inventory purchases and sales, in
conjunction with supplier rebate contract terms, which generally provide for increasing rebates based on either
increased purchase or sales volume.
Property and Equipment
Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is
computed primarily under the straight-line method (see Note 2 - Property and Equipment, Net for estimated useful
lives). Amortization of leasehold improvements is computed using the straight-line method over the lesser of the
useful life of the assets or the lease term.
Capitalized software costs consist of costs to purchase and develop software. Costs incurred during the
application development stage for software bought and further customized by outside suppliers for our use and
software developed by a supplier for our proprietary use are capitalized. Costs incurred for our own personnel who
are directly associated with software development are capitalized.
Income Taxes
We account for income taxes under an asset and liability approach that requires the recognition of deferred
income tax assets and liabilities for the expected future tax consequences of events that have been recognized in our
financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future
events other than enactments of changes in tax laws or rates. The effect on deferred income tax assets and
liabilities of a change in tax rates will be recognized as income or expense in the period that includes the enactment
date. We file a consolidated U.S. federal income tax return with our 80% or greater owned U.S. subsidiaries.
69
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 1 – Significant Accounting Policies – (Continued)
Foreign Currency Translation and Transactions
The financial position and results of operations of our foreign subsidiaries are determined using local currency
as the functional currency. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at
each year-end. Income statement accounts are translated at the average rate of exchange prevailing during the year.
Translation adjustments arising from the use of differing exchange rates from period to period are included in
Accumulated other comprehensive income in stockholders’ equity. Gains and losses resulting from foreign
currency transactions are included in earnings.
Risk Management and Derivative Financial Instruments
We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates.
Our objective is to manage the impact that foreign currency exchange rate fluctuations could have on recognized
asset and liability fair values, earnings and cash flows. Our risk management policy requires that derivative
contracts used as hedges be effective at reducing the risks associated with the exposure being hedged and be
designated as a hedge at the inception of the contract. We do not enter into derivative instruments for speculative
purposes. Our derivative instruments primarily include foreign currency forward agreements related to certain
intercompany loans and certain forecasted inventory purchase commitments with foreign suppliers.
Our foreign currency forward agreements related to forecasted inventory purchase commitments are designated
as cash flow hedges. Our foreign currency forward agreements related to foreign currency balance sheet exposure
provide economic hedges but are not designated as hedges for accounting purposes.
For agreements not designated as hedges, changes in the value of the derivative, along with the transaction gain
or loss on the hedged item, are recorded in earnings. For cash flow hedges, the effective portion of the changes in
the fair value of the derivative, along with any gain or loss on the hedged item, is recorded as a component of
Accumulated other comprehensive income in stockholders’ equity and subsequently reclassified into earnings in the
period(s) during which the hedged transaction affects earnings.
We classify the cash flows related to our hedging activities in the same category on our consolidated statements
of cash flows as the cash flows related to the hedged item.
Acquisitions
The net assets of businesses purchased are recorded at their fair value at the acquisition date and our
consolidated financial statements include their results of operations from that date. Any excess of acquisition
consideration over the fair value of identifiable net assets acquired is recorded as goodwill. The major classes of
assets and liabilities that we generally allocate purchase price to, excluding goodwill, include identifiable intangible
assets (i.e., trademarks and trade names, customer relationships and lists and non-compete agreements), property,
plant and equipment, deferred taxes and other current and long-term assets and liabilities. The estimated fair value
of identifiable intangible assets is based on critical estimates, judgments and assumptions derived from: analysis of
market conditions; discount rate; discounted cash flows; customer retention rates; and estimated useful lives. Some
prior owners of such acquired subsidiaries are eligible to receive additional purchase price cash consideration if
certain financial targets are met. For the years ended December 27, 2014, December 28, 2013 and December 29,
2012, there were no material adjustments recorded in our consolidated statement of income relating to changes in
estimated contingent purchase price liabilities.
70
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 1 – Significant Accounting Policies – (Continued)
Redeemable Noncontrolling Interests
Some minority shareholders in certain of our subsidiaries have the right, at certain times, to require us to
acquire their ownership interest in those entities at fair value. Their interests in these subsidiaries are classified
outside permanent equity on our consolidated balance sheets and are carried at the estimated redemption amounts.
The redemption amounts have been estimated based on expected future earnings and cash flow and, if such
earnings and cash flow are not achieved, the value of the redeemable noncontrolling interests might be impacted.
Changes in the estimated redemption amounts of the noncontrolling interests subject to put options are reflected at
each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the
carrying amounts are subject to a “floor” amount that is equal to the fair value of the redeemable noncontrolling
interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests
cannot go below the floor level. These adjustments do not impact the calculation of earnings per share.
Goodwill and Other Indefinite-Lived Intangible Assets
Goodwill and other indefinite-lived intangible assets (primarily trademarks) are not amortized, but are subject
to impairment analysis at least once annually. Such impairment analyses for goodwill require a comparison of the
fair value to the carrying value of reporting units. We regard our reporting units to be our operating segments:
health care distribution (global dental, animal health and medical) and technology and value-added services.
We test goodwill for impairment under the provisions of Accounting Standards Update 2011-08, “Intangibles-
Goodwill and Other (Topic 350): Testing Goodwill for Impairment,” which allows us to use qualitative factors to
determine whether it is more likely than not that the fair values of our reporting units are less than their carrying
values. The factors that we consider in developing our qualitative assessment include:
• Macroeconomic conditions consisting of the overall sales growth of our business and the overall sales
growth of each of our operating segments. We also consider our growth in market share in the markets in
which we compete;
• Credit markets and our ability to access debt facilities at favorable terms;
• Key personnel and management expertise, as well as our growth strategies for the next several years; and
• Our expectations of selling or disposing all, or a portion, of a reporting unit.
Goodwill was allocated to such reporting units, for the purposes of preparing our impairment analyses, based
on a specific identification basis. Our impairment analysis for indefinite-lived intangibles consists of a comparison
of the fair value to the carrying value of the assets. This comparison is made based on a review of historical,
current and forecasted sales and gross profit levels, as well as a review of any factors that may indicate potential
impairment. For certain indefinite-lived intangible assets, a present value technique, such as estimates of future
cash flows, is utilized. We assessed the potential impairment of goodwill and other indefinite-lived intangible
assets annually (at the beginning of our fourth quarter) and on an interim basis whenever events or changes in
circumstances indicate that the carrying value may not be recoverable.
Some factors we consider important that could trigger an interim impairment review include:
•
•
•
significant underperformance relative to expected historical or projected future operating results;
significant changes in the manner of our use of acquired assets or the strategy for our overall business
(e.g., decision to divest a business); or
significant negative industry or economic trends.
If we determine through the impairment review process that goodwill or other indefinite-lived intangible assets
are impaired, we record an impairment charge in our consolidated statements of income.
71
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 1 – Significant Accounting Policies – (Continued)
For the years ended December 27, 2014, December 28, 2013 and December 29, 2012, the results of our
goodwill impairment analysis did not result in any impairments.
Long-Lived Assets
Long-lived assets, other than goodwill and other indefinite-lived intangibles, are evaluated for impairment
whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable
through the estimated undiscounted future cash flows to be derived from such assets.
Definite-lived intangible assets primarily consist of non-compete agreements, trademarks, trade names,
customer lists, customer relationships and intellectual property. For long-lived assets used in operations,
impairment losses are only recorded if the asset’s carrying amount is not recoverable through its undiscounted,
probability-weighted future cash flows. We measure the impairment loss based on the difference between the
carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to
fair value.
Cost of Sales
The primary components of cost of sales include the cost of the product (net of purchase discounts, supplier
chargebacks and rebates) and inbound and outbound freight charges. Costs related to purchasing, receiving,
inspections, warehousing, internal inventory transfers and other costs of our distribution network are included in
selling, general and administrative expenses along with other operating costs.
As a result of different practices of categorizing costs associated with distribution networks throughout our
industry, our gross margins may not necessarily be comparable to other distribution companies. Total distribution
network costs were $64.5 million, $62.2 million and $59.5 million for the years ended December 27, 2014,
December 28, 2013 and December 29, 2012.
Comprehensive Income
Comprehensive income includes certain gains and losses that, under accounting principles generally accepted in
the United States, are excluded from net income as such amounts are recorded directly as an adjustment to
stockholders’ equity. Our comprehensive income is primarily comprised of net income, foreign currency
translation gain (loss), unrealized gain (loss) on foreign currency hedging activities, unrealized investment gain
(loss) and pension adjustment gain (loss).
72
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 2 – Property and Equipment, Net
Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed primarily
under the straight-line method over the estimated useful life. Depreciation of leasehold improvements is computed
using the straight-line method over the lesser of the useful life of the assets or the lease term. Property and
equipment, including related estimated useful lives, consisted of the following:
December 27,
December 28,
2014
2013
Land ............................................................................................................................... $
Buildings and permanent improvements ........................................................................
Leasehold improvements ................................................................................................
Machinery and warehouse equipment ............................................................................
Furniture, fixtures and other ...........................................................................................
Computer equipment and software .................................................................................
Less accumulated depreciation .......................................................................................
19,170 $
119,057
84,649
98,551
121,485
306,227
749,139
(437,643)
Property and equipment, net ................................................................................... $
311,496 $
19,981
112,514
73,974
71,129
118,806
279,831
676,235
(400,347)
275,888
Estimated Useful
Lives (in years)
Buildings and permanent improvements .......................................
Machinery and warehouse equipment ...........................................
Furniture, fixtures and other ..........................................................
Computer equipment and software ................................................
40
5-10
3-10
3-10
Property and equipment related depreciation expense for the years ended December 27, 2014, December 28,
2013 and December 29, 2012 was $57.6 million, $52.9 million and $52.2 million.
73
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 3 – Goodwill and Other Intangibles, Net
The changes in the carrying amount of goodwill for the years ended December 27, 2014 and December 28,
2013 were as follows:
Balance as of December 29, 2012 .................................................. $
Adjustments to goodwill:
Acquisitions ...........................................................................
Foreign currency translation ..................................................
Balance as of December 28, 2013 ..................................................
Adjustments to goodwill:
Health Care
Distribution
Technology and
Value-Added
Services
Total
1,452,761 $
148,285 $
1,601,046
22,055
4,361
1,479,177
6,369
1,174
155,828
28,424
5,535
1,635,005
Acquisitions ...........................................................................
Foreign currency translation ..................................................
279,400
(48,023)
24,457
(6,716)
303,857
(54,739)
Balance as of December 27, 2014 .................................................. $
1,710,554 $
173,569 $
1,884,123
Other intangible assets consisted of the following:
December 27, 2014
Accumulated
December 28, 2013
Accumulated
Cost
Amortization
Net
Cost
Amortization
Net
Non-compete agreements ................................$
44,156 $
(10,702) $
33,454 $
44,162 $
(9,666) $
Trademarks / trade names - definite lived .......
123,207
(41,301)
81,906
77,134
(27,794)
Trademarks / trade names - indefinite lived ....
3,287
-
3,287
3,717
-
34,496
49,340
3,717
Customer relationships and lists ......................
616,367
(188,335)
428,032
478,852
(193,263)
285,589
Other ...............................................................
127,383
(30,326)
97,057
68,844
(24,853)
43,991
Total ..........................................................$
914,400 $
(270,664) $
643,736 $
672,709 $
(255,576) $
417,133
Non-compete agreements represent amounts paid primarily to key employees and prior owners of acquired
businesses, as well as certain sales persons, in exchange for placing restrictions on their ability to pose a
competitive risk to us. Such amounts are amortized, on a straight-line basis over the respective non-compete
period, which generally commences upon termination of employment or separation from us. The weighted-average
non-compete period for agreements currently being amortized was approximately 4.8 years as of December 27,
2014.
Trademarks, trade names, customer lists and customer relationships were established through business
acquisitions. Definite-lived trademarks and trade names are amortized on a straight-line basis over a weighted-
average period of approximately 9.4 years as of December 27, 2014. Customer relationships and customer lists are
definite-lived intangible assets that are amortized on a straight-line basis over a weighted-average period of
approximately 10.9 years as of December 27, 2014.
Amortization expense related to definite-lived intangible assets for the years ended December 27, 2014,
December 28, 2013 and December 29, 2012 was $89.6 million, $69.2 million and $68.5 million. The annual
amortization expense expected to be recorded for existing intangibles assets for the years 2015 through 2019 is
$91.6 million, $86.3 million, $83.2 million, $77.4 million and $69.5 million.
74
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 4 – Investments and Other
Investments and other consisted of the following:
December 27, December 28,
2014
2013
Investment in unconsolidated affiliates ............................................................................ $
Non-current deferred foreign, state and local income taxes .............................................
Notes receivable (1) .........................................................................................................
Distribution rights and exclusivity agreements, net of amortization ................................
Security deposits ..............................................................................................................
Debt issuance costs, net of amortization ..........................................................................
Acquisition related indemnification .................................................................................
Acquisition related loan receivable (2) ............................................................................
Other long-term assets ......................................................................................................
Total ........................................................................................................................ $
261,471 $
57,254
18,095
3,157
2,639
1,918
13,471
-
28,281
386,286 $
206,178
48,470
10,836
3,321
3,341
2,011
13,880
145,000
28,908
461,945
(1) Long-term notes receivable carry interest rates ranging from 2.15% to 12.0% and are due in varying installments through
December 31, 2020.
(2) See Note 9 - Business Acquisitions, Divestiture and Other Transaction for additional details of the loan receivable from
BioHorizons, Inc.
Amortization expense related to other long-term assets for the years ended December 27, 2014, December 28,
2013 and December 29, 2012 was $5.0 million, $6.0 million and $4.6 million.
Note 5 – Debt
Credit Facilities
On September 12, 2012, we entered into a new $500 million revolving credit agreement (the “Credit
Agreement”) with a $200 million expansion feature, which was originally set to expire on September 12, 2017,
however, on September 22, 2014, we extended the expiration date of the Credit Agreement to September 22, 2019.
The interest rate is based on the USD LIBOR plus a spread based on our leverage ratio at the end of each financial
reporting quarter. The Credit Agreement provides, among other things, that we are required to maintain maximum
leverage ratios, and contains customary representations, warranties and affirmative covenants. The Credit
Agreement also contains customary negative covenants, subject to negotiated exceptions on liens, indebtedness,
significant corporate changes (including mergers), dispositions and certain restrictive agreements. There was no
balance outstanding under this revolving credit facility as of December 27, 2014. As of December 27, 2014, there
were $10.1 million of letters of credit provided to third parties under the credit facility.
As of December 27, 2014, we had various other short-term bank credit lines available, of which $182.9 million
was outstanding. At December 27, 2014, borrowings under all of our credit lines had a weighted average interest
rate of 1.26%. In July 2014, we extended credit lines with various financial institutions for an additional year.
75
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 5 – Debt – (Continued)
Private Placement Facilities
On August 10, 2010, we entered into $400 million private placement facilities with two insurance companies.
On April 30, 2012, we increased our available credit facilities by $375 million by entering into a new agreement
with one insurance company and amending our existing agreements with two insurance companies. On September
22, 2014, we increased our available private placement facilities by $200 million to a total facility amount of $975
million, and extended the expiration date to September 22, 2017. These facilities are available on an uncommitted
basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time through September
22, 2017. The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed
upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be
selected by us and can range from five to 15 years (with an average life no longer than 12 years). The proceeds of
any issuances under the facilities will be used for general corporate purposes, including working capital and capital
expenditures, to refinance existing indebtedness and/or to fund potential acquisitions. The agreements provide,
among other things, that we maintain certain maximum leverage ratios, and contain restrictions relating to
subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These
facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates.
The components of our private placement facility borrowings as of December 27, 2014 are presented in the
following table:
Date of Borrowing
September 2, 2010
January 20, 2012
January 20, 2012 (1)
December 24, 2012
June 2, 2014
Amount of
Borrowing
Outstanding
Borrowing
Rate
$
$
100,000
50,000
50,000
50,000
100,000
350,000
3.79 %
3.45
3.09
3.00
3.19
Due Date
September 2, 2020
January 20, 2024
January 20, 2022
December 24, 2024
June 2, 2021
(1) Annual repayments of approximately $7.1 million for this borrowing will commence on January 20, 2016.
U.S. Trade Accounts Receivable Securitization
On April 17, 2013, we entered into a facility agreement of up to $300 million with a bank, as agent, based on
the securitization of our U.S. trade accounts receivable. The new facility allowed us to replace public debt
(approximately $220 million), which had a higher interest rate at Henry Schein Animal Health (“HSAH”) during
February 2013 and provided funding for working capital and general corporate purposes. The financing was
structured as an asset-backed securitization program with pricing committed for up to three years. On September
22, 2014, we extended the expiration date of this facility agreement to April 15, 2017. The borrowings outstanding
under this securitization facility were $150.0 million as of December 27, 2014. At December 27, 2014, the interest
rate on borrowings under this facility was based on the average asset-backed commercial paper rate of 20 basis
points plus 75 basis points, for a combined rate of 0.95%.
We are required to pay a commitment fee of 30 basis points on the daily balance of the unused portion of the
facility if our usage is greater than or equal to 50% of the facility limit or a commitment fee of 35 basis points on
the daily balance of the unused portion of the facility if our usage is less than 50% of the facility limit.
76
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 5 – Debt – (Continued)
Borrowings under this facility are presented as a component of Long-term debt within our consolidated balance
sheet.
Henry Schein Animal Health
During February 2013, we repaid the then outstanding debt related to the HSAH (formerly Butler Schein
Animal Health) transaction using our existing Credit Agreement. As part of this transaction, we recorded a one-
time interest expense charge of $6.2 million related to the accelerated amortization of deferred financing costs.
Long-term debt
Long-term debt consisted of the following:
December 27, December 28,
2014
2013
Private placement facilities ............................................................................................... $
U.S. trade accounts receivable securitization ....................................................................
Notes payable to banks at a weighted-average interest rate of 8.5% .................................
Various collateralized and uncollateralized loans payable with interest,
in varying installments through 2018 at interest rates ranging
from 2.17% to 5.41% ...............................................................................................
Capital lease obligations (see Note 17) .............................................................................
Total ..................................................................................................................................
Less current maturities ......................................................................................................
350,000 $
150,000
30
250,000
160,000
73
41,259
7,302
548,591
(5,815)
44,091
1,510
455,674
(5,441)
450,233
Total long-term debt ................................................................................................. $
542,776 $
As of December 27, 2014, the aggregate amounts of long-term debt, including capital lease obligations,
maturing in each of the next five years and thereafter are as follows:
2015 ...........................................................................$
2016 ...........................................................................
2017 ...........................................................................
2018 ...........................................................................
2019 ...........................................................................
Thereafter ..................................................................
Total ..................................................................$
5,815
11,225
168,987
30,959
7,642
323,963
548,591
77
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 6 – Redeemable Noncontrolling Interests
Some minority shareholders in certain of our subsidiaries have the right, at certain times, to require us to
acquire their ownership interest in those entities at fair value. Accounting Standards Codification (“ASC”) Topic
480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the
outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put
option contained in contractual agreements. The components of the change in the Redeemable noncontrolling
interests for the years ended December 27, 2014, December 28, 2013 and December 29, 2012 are presented in the
following table:
December 27, December 28, December 29,
2013
2014
2012
Balance, beginning of period ........................................................................ $
Decrease in redeemable noncontrolling interests due to
redemptions ..............................................................................................
Increase in redeemable noncontrolling interests due to
business acquisitions ..................................................................................
Net income attributable to redeemable noncontrolling interests ...................
Dividends declared ........................................................................................
Effect of foreign currency translation gain (loss) attributable to
redeemable noncontrolling interests .........................................................
Change in fair value of redeemable securities ..............................................
Other adjustment to redeemable noncontrolling interests .............................
Balance, end of period ................................................................................... $
497,539 $
435,175 $
402,050
(105,383)
(9,028)
(23,637)
120,220
38,741
(23,346)
(4,080)
40,836
-
564,527 $
11,542
39,430
(19,965)
(654)
41,039
-
497,539 $
30,935
34,803
(21,013)
904
53,769
(42,636)
435,175
Changes in the estimated redemption amounts of the noncontrolling interests subject to put options are adjusted
at each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the
carrying amounts are subject to a “floor” amount that is equal to the fair value of the redeemable noncontrolling
interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests
cannot go below the floor level. These adjustments do not impact the calculation of earnings per share.
78
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 7 – Comprehensive Income
Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income
as such amounts are recorded directly as an adjustment to stockholders’ equity. Our comprehensive income is
primarily comprised of net income, foreign currency translation gain (loss), unrealized gain (loss) on foreign
currency hedging activities, unrealized investment gain (loss) and pension adjustment gain (loss).
The following table summarizes our Accumulated other comprehensive income, net of applicable taxes as of:
December 27, December 28, December 29,
2013
2012
2014
Attributable to Redeemable noncontrolling interests:
Foreign currency translation adjustment .................................................. $
(5,583) $
(1,503) $
(849)
Attributable to noncontrolling interests:
Foreign currency translation adjustment .................................................. $
(36) $
- $
-
Attributable to Henry Schein, Inc.:
Foreign currency translation gain (loss) ....................................................... $
Unrealized gain (loss) from foreign currency hedging activities ..................
Unrealized investment loss ...........................................................................
Pension adjustment loss ................................................................................
Accumulated other comprehensive income (loss) .................................... $
(71,294) $
(1,055)
(136)
(22,647)
(95,132) $
82,288 $
1,282
(515)
(15,206)
67,849 $
72,160
1,187
(415)
(20,077)
52,855
Total Accumulated other comprehensive income (loss) ................................... $
(100,751) $
66,346 $
52,006
The following table summarizes the components of comprehensive income, net of applicable taxes as follows:
December 27, December 28, December 29,
2013
2014
2012
Net income .................................................................................................... $
505,436 $
471,462 $
423,388
Foreign currency translation gain (loss) ........................................................
Tax effect ......................................................................................................
(157,698)
-
Foreign currency translation gain (loss) ........................................................
(157,698)
Unrealized gain (loss) from foreign currency hedging activities ..................
Tax effect ......................................................................................................
Unrealized gain (loss) from foreign currency hedging activities ..................
Unrealized investment gain (loss) .................................................................
Tax effect ......................................................................................................
Unrealized investment gain (loss) .................................................................
(2,492)
155
(2,337)
629
(250)
379
9,474
-
9,474
69
26
95
(166)
66
(100)
Pension adjustment gain (loss) ......................................................................
Tax effect ......................................................................................................
Pension adjustment gain (loss) ......................................................................
(10,222)
2,781
(7,441)
6,207
(1,336)
4,871
33,347
-
33,347
3,519
(654)
2,865
724
(310)
414
(7,638)
2,187
(5,451)
Comprehensive income ................................................................................. $
338,339 $
485,802 $
454,563
79
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 7 – Comprehensive Income – (Continued)
The following table summarizes our total comprehensive income, net of applicable taxes as follows:
December 27,
2014
December 28, December 29,
2013
2012
Comprehensive income attributable to
Henry Schein, Inc. ............................................................................... $
Comprehensive income attributable to
noncontrolling interests .......................................................................
Comprehensive income attributable to
Redeemable noncontrolling interests ...................................................
Comprehensive income ............................................................................ $
303,096 $
446,548 $
418,347
582
478
509
34,661
338,339 $
38,776
485,802 $
35,707
454,563
Note 8 – Fair Value Measurements
ASC Topic 820 “Fair Value Measurements and Disclosures” (“ASC Topic 820”) provides a framework for
measuring fair value in generally accepted accounting principles.
ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a
liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes
a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market
data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market
participant assumptions developed based on the best information available in the circumstances (unobservable
inputs).
The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted
prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs
(Level 3). The three levels of the fair value hierarchy under ASC Topic 820 are described as follows:
• Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the
measurement date.
• Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability,
either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets;
quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted
prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by
observable market data by correlation or other means.
• Level 3— Inputs that are unobservable for the asset or liability.
The following section describes the valuation methodologies that we used to measure different financial
instruments at fair value.
Investments and notes receivable
There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable;
however, we believe the carrying amounts are a reasonable estimate of fair value.
Debt
The fair value of our debt as of December 27, 2014 and December 28, 2013 was estimated at $731.5 million
and $485.2 million, respectively. Factors that we considered when estimating the fair value of our debt include
market conditions, prepayment and make-whole provisions, liquidity levels in the private placement market,
variability in pricing from multiple lenders and term of debt.
80
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 8 – Fair Value Measurements – (Continued)
Derivative contracts
Derivative contracts are valued using quoted market prices and significant other observable and unobservable
inputs. We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates.
Our derivative instruments primarily include foreign currency forward agreements related to intercompany loans
and certain forecasted inventory purchase commitments with suppliers.
The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our
contract rate to a published forward price of the underlying market rates, which is based on market rates for
comparable transactions and are classified within Level 2 of the fair value hierarchy.
Redeemable noncontrolling interests
Some minority shareholders in certain of our subsidiaries have the right, at certain times, to require us to
acquire their ownership interest in those entities at fair value based on third-party valuations. The primary factor
affecting the future value of redeemable noncontrolling interests is expected earnings and, if such earnings are not
achieved, the value of the redeemable noncontrolling interests might be impacted. The noncontrolling interests
subject to put options are adjusted to their estimated redemption amounts each reporting period with a
corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a
“floor” amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were
originally recorded. The recorded value of the redeemable noncontrolling interests cannot go below the floor level.
These adjustments do not impact the calculation of earnings per share. The values for Redeemable noncontrolling
interests are classified within Level 3 of the fair value hierarchy. The details of the changes in Redeemable
noncontrolling interests are presented in Note 6.
The following table presents our assets and liabilities that are measured and recognized at fair value on a
recurring basis classified under the appropriate level of the fair value hierarchy as of December 27, 2014 and
December 28, 2013:
Level 1
December 27, 2014
Level 2
Level 3
Total
Assets:
Derivative contracts ................................................... $
Total assets ............................................................ $
Liabilities:
Derivative contracts ................................................... $
Total liabilities ....................................................... $
Redeemable noncontrolling interests ............................... $
Assets:
Derivative contracts ................................................... $
Total assets ............................................................ $
Liabilities:
Derivative contracts ................................................... $
Total liabilities ....................................................... $
Redeemable noncontrolling interests ............................... $
- $
- $
- $
- $
- $
- $
- $
- $
- $
- $
2,472 $
2,472 $
1,307 $
1,307 $
- $
- $
- $
- $
2,472
2,472
1,307
1,307
- $
564,527 $
564,527
December 28, 2013
Level 2
Level 3
Total
1,235 $
1,235 $
1,142 $
1,142 $
- $
- $
- $
- $
1,235
1,235
1,142
1,142
- $
497,539 $
497,539
Level 1
81
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 9 – Business Acquisitions and Divestiture
Acquisitions
The operating results of all acquisitions are reflected in our financial statements from their respective
acquisition dates.
On December 30, 2013, we completed the acquisition of approximately 60% of the equity interest in
BioHorizons, Inc., a U.S.-based manufacturer of advanced dental implants with annual revenues of approximately
$115 million. Prior to completion of the acquisition, we funded BioHorizons, Inc. $145 million, which was
recorded as a long-term loan included in Investments and Other within our consolidated balance sheet at December
28, 2013. This long-term loan was subsequently recorded as an intercompany loan upon completion of the
acquisition and has been eliminated from our consolidated balance sheet as of December 27, 2014. As a result of
this acquisition, we recorded $143.7 million of initial goodwill.
On February 3, 2014, we completed the acquisition of 100% ownership of five businesses in three European
countries from Arseus NV. The businesses combine for annual sales of approximately $97 million and include a
dental practice management software company in France and distributors of dental products in France, the
Netherlands and Belgium. As a result of this acquisition, we recorded $21.4 million of initial goodwill.
On April 2, 2014, we completed our previously announced acquisition of an 80% ownership position in
Medivet S.A., a privately held distributor of animal health products and services in Poland. Medivet has annual
sales of approximately $80 million. As a result of this acquisition, we recorded $18.7 million of initial goodwill.
On June 30, 2014, we completed our previously announced acquisition by our U.S. Animal Health business,
Butler Animal Health Supply LLC, together with our wholly-owned subsidiary, W.A. Butler Company, of a 60%
ownership position in SmartPak Equine, LLC (“SmartPak”), a privately held provider of equine supplements and
horse supplies in the United States. SmartPak had sales of approximately $105 million in 2013. As a result of this
acquisition, we recorded $59.7 million of initial goodwill.
On November 20, 2014, we entered into a long-term strategic agreement with Cardinal Health, Inc. Under the
terms of the agreement, the physician office-focused commercial organization of Cardinal Health’s Medical
segment was acquired and will be consolidated into the commercial organization of our Medical Group. The
physician office sales team and physician office distribution business of Cardinal Health’s Medical segment, with
annual sales of more than $300 million, will be integrated into our Medical Group. Cardinal Health will provide
transitional customer order fulfillment and distribution services on our behalf until integrated, which we expect to
occur during the second quarter of 2015. Additionally, we have committed to purchase Cardinal Health™ Brand
products and utilize Cardinal Health as a primary source for various medical products. There was no goodwill
recorded on this transaction.
We completed certain other acquisitions during the year ended December 27, 2014, which were immaterial to
our financial statements individually and in the aggregate and resulted in the recording of approximately $16.4
million of initial goodwill through preliminary purchase price allocations. Total acquisition transaction costs
incurred in the year ended December 27, 2014 were immaterial to our financial results.
We completed certain acquisitions during the year ended December 28, 2013, which were immaterial to our
financial statements individually and in the aggregate and resulted in the recording of approximately $14.7 million
of initial goodwill through preliminary purchase price allocations.
We completed certain acquisitions during the year ended December 29, 2012, which were immaterial to our
financial statements individually and in the aggregate and resulted in the recording of approximately $128.0 million
of initial goodwill through preliminary purchase price allocations.
82
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 9 – Business Acquisitions and Divestiture – (Continued)
Divestiture of an Equity Affiliate
On July 10, 2013, we divested our investment in a dental wholesale distributor in the Middle East that had
primarily served as an importer that distributed products largely to other distributors. The divestiture resulted in a
one-time loss, which is recorded in a separate line item, “Loss on sale of equity investment” within our
consolidated statements of income and within the cash flows from operating activities section of our consolidated
statements of cash flows, of $12.5 million, or $0.14 per diluted share, in the third quarter of 2013. Pursuant to the
terms of this divestiture, we made cash payments, which are recorded in a separate line item, “Payments related to
sale of equity investment”, within the cash flows from investing activities section of our consolidated statements of
cash flows, to this distributor in the aggregate amount of $13.4 million, which it was required to use to
reduce its debt, pay certain trade payables and provide working capital. The investment in this distributor had been
fully impaired as of the end of 2012. There was no tax benefit related to the loss on this divestiture.
Note 10 – Plans of Restructuring
On November 6, 2014, we announced a corporate initiative to rationalize our operations and provide expense
efficiencies, which will occur throughout fiscal 2015. This initiative is expected to include the elimination of
approximately 2% to 3% of our workforce and the closing of certain facilities. The costs associated with all actions
to complete this restructuring are expected to be in the range of $35 million to $40 million pre-tax (approximately
$0.29 to $0.33 per diluted share). We plan to reduce our cost structure to fund new initiatives to drive future
growth as our 2015 – 2017 strategic planning cycle begins. At this time, we are unable to make a determination of
the estimated amount or range of amounts to be included for each major type of cost associated with this
restructuring (including associated cash expenditures). We will provide further details in a future Securities and
Exchange Commission filing at such time as we are able to determine the costs we expect to incur in connection
with this restructuring.
During the year ended December 29, 2012, we incurred restructuring costs of approximately $15.2 million pre-
tax ($0.12 per diluted share) consisting of employee severance pay and benefits related to the elimination of
approximately 200 positions; facility closing costs, representing primarily lease terminations and property and
equipment write-off costs; and outside professional and consulting fees directly related to the restructuring plan.
This restructuring program is complete and we do not expect any additional costs from this program.
The costs associated with these restructurings have been and will be included in a separate line item,
“Restructuring costs” within our consolidated statements of income.
The following table shows the amounts expensed and paid for restructuring costs that were incurred during our
2014, 2013 and 2012 fiscal years and the remaining accrued balance of restructuring costs as of December 27,
2014, which is included in Accrued expenses: Other and Other liabilities within our consolidated balance sheet:
Severance
Costs
Facility
Closing
Costs
Balance, December 31, 2011 .......................................................... $
Provision ........................................................................................
Payments and other adjustments ....................................................
Balance, December 29, 2012 .......................................................... $
Provision ........................................................................................
Payments and other adjustments ....................................................
Balance, December 28, 2013 .......................................................... $
Provision ........................................................................................
Payments and other adjustments ....................................................
Balance, December 27, 2014 .......................................................... $
569 $
12,841
(11,584)
1,826 $
-
(1,599)
227 $
-
(107)
120 $
551 $
2,351
(1,671)
1,231 $
-
(747)
484 $
-
(183)
301 $
Total
1,120
15,192
(13,255)
3,057
-
(2,346)
711
-
(290)
421
83
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 10 – Plans of Restructuring – (Continued)
The following table shows, by reportable segment, the amounts expensed and paid for restructuring costs that
were incurred during our 2014, 2013 and 2012 fiscal years and the remaining accrued balance of restructuring costs
as of December 27, 2014:
Health Care
Distribution
Technology and
Value-Added
Services
Total
Balance, December 31, 2011 .......................................................... $
Provision ........................................................................................
Payments and other adjustments ....................................................
Balance, December 29, 2012 .......................................................... $
Provision ........................................................................................
Payments and other adjustments ....................................................
Balance, December 28, 2013 .......................................................... $
Provision ........................................................................................
Payments and other adjustments ....................................................
Balance, December 27, 2014 .......................................................... $
1,120 $
14,981
(13,058)
3,043 $
-
(2,332)
711 $
-
(290)
421 $
- $
211
(197)
14 $
-
(14)
- $
-
-
- $
1,120
15,192
(13,255)
3,057
-
(2,346)
711
-
(290)
421
Note 11 – Earnings Per Share
Basic earnings per share is computed by dividing net income attributable to Henry Schein, Inc. by the
weighted-average number of common shares outstanding for the period. Our diluted earnings per share is
computed similarly to basic earnings per share, except that it reflects the effect of common shares issuable for
presently unvested restricted stock and restricted stock units and upon exercise of stock options, using the treasury
stock method in periods in which they have a dilutive effect.
A reconciliation of shares used in calculating earnings per basic and diluted share follows:
Basic ..............................................................................................................
Effect of dilutive securities:
Stock options, restricted stock and restricted stock units ..........................
Diluted ......................................................................................................
84,265
1,475
85,740
85,926
1,696
87,622
87,499
2,324
89,823
Years Ended
December 27,
2014
December 28, December 29,
2013
2012
84
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 12 – Income Taxes
Income before taxes and equity in earnings of affiliates was as follows:
Years ended
December 27,
2014
December 28,
December 29,
2013
2012
Domestic .................................................................................................$
Foreign ....................................................................................................
Total ..................................................................................................$
543,433 $
165,879
709,312 $
517,950 $
146,744
664,694 $
466,457
137,731
604,188
The provisions for income taxes were as follows:
Years ended
December 27,
December 28,
December 29,
2014
2013
2012
Current income tax expense:
U.S. Federal .............................................................................. $
State and local ..........................................................................
Foreign .....................................................................................
Total current .........................................................................
Deferred income tax expense (benefit):
U.S. Federal ..............................................................................
State and local ..........................................................................
Foreign .....................................................................................
Total deferred .......................................................................
Total provision ................................................................ $
151,888 $
27,985
31,038
210,911
2,678
(1,958)
3,979
4,699
139,253 $
27,272
35,880
202,405
10,325
(4,531)
(17,308)
(11,514)
215,610 $
190,891 $
121,591
23,279
32,916
177,786
9,242
946
(116)
10,072
187,858
85
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 12 – Income Taxes – (Continued)
The tax effects of temporary differences that give rise to our deferred income tax asset (liability) were as
follows:
Years Ended
December 27,
December 28,
2014
2013
Current deferred income tax assets:
Inventory, premium coupon redemptions and accounts receivable
valuation allowances ..................................................................................... $
Uniform capitalization adjustments to inventories .................................................
Other current assets ................................................................................................
Current deferred income tax asset (1) ....................................................................
31,429 $
10,061
10,025
51,515
Non-current deferred income tax asset (liability):
Property and equipment .........................................................................................
Stock-based compensation .....................................................................................
Intangibles amortization .........................................................................................
Other non-current liabilities ...................................................................................
Net operating losses of domestic subsidiaries ........................................................
Net operating losses of foreign subsidiaries ...........................................................
Total non-current deferred tax liability ..........................................................
Valuation allowance for non-current deferred tax assets (2) .....................
Net non-current deferred tax liability (1) ...............................................................
(8,121)
30,837
(234,987)
(5,853)
12,763
37,133
(168,228)
(27,636)
(195,864)
Net deferred income tax liability .................................................................................... $
(144,349) $
31,016
7,318
21,351
59,685
(5,571)
35,995
(205,139)
(6,041)
693
45,254
(134,809)
(16,285)
(151,094)
(91,409)
(1) Certain deferred tax amounts do not have a right of offset and are therefore reflected on a gross basis in current assets
and non-current liabilities in our consolidated balance sheets.
(2) Primarily relates to operating losses of acquired subsidiaries, the benefits of which are uncertain. Any future reductions
of such valuation allowances will be reflected as a reduction of income tax expense in accordance with the provisions of
ASC Topic 805, “Business Combinations.”
The assessment of the amount of value assigned to our deferred tax assets under the applicable accounting rules
is judgmental. We are required to consider all available positive and negative evidence in evaluating the likelihood
that we will be able to realize the benefit of our deferred tax assets in the future. Such evidence includes scheduled
reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and the results of recent
operations. Since this evaluation requires consideration of events that may occur some years into the future, there
is an element of judgment involved. Realization of our deferred tax assets is dependent on generating sufficient
taxable income in future periods. We believe that it is more likely than not that future taxable income will be
sufficient to allow us to recover substantially all of the value assigned to our deferred tax assets. However, if future
events cause us to conclude that it is not more likely than not that we will be able to recover all of the value
assigned to our deferred tax assets, we will be required to adjust our valuation allowance accordingly.
86
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 12 – Income Taxes – (Continued)
As of December 27, 2014, we have federal net operating loss carryforwards of $37.2 million relating to our
domestic subsidiaries, which can be used against future income through December 31, 2029. As of December 27,
2014, we have state net operating loss carryforwards of $18.6 million relating to our domestic subsidiaries, which
can be utilized against future state income through December 31, 2029. As of December 27, 2014, we have foreign
net operating loss carryforwards of $9.9 million, which can be utilized against future foreign income through
December 31, 2021. Additionally, as of December 27, 2014, there were foreign net operating loss carryforwards of
$126.7 million that have an indefinite life.
The tax provisions differ from the amount computed using the federal statutory income tax rate as follows:
Years ended
December 27,
December 28,
December 29,
2014
2013
2012
Income tax provision at federal statutory rate ................................ $
State income tax provision, net of federal income tax effect .........
Foreign income tax benefit .............................................................
Valuation allowance .......................................................................
Interest expense related to loans .....................................................
Other ..............................................................................................
Total income tax provision .................................................... $
248,260 $
19,774
(21,424)
(770)
(24,043)
(6,187)
215,610 $
232,644 $
20,134
(19,635)
(14,026)
(23,723)
(4,503)
190,891 $
211,466
21,665
(17,979)
1,502
(21,018)
(7,778)
187,858
For the year ended December 27, 2014, our effective tax rate was 30.4% compared to 28.7% for the prior year
period. During the third quarter of 2013, we concluded that it was more likely than not that certain deferred tax
assets related to tax loss carryforwards originating outside the United States, which had been previously reserved,
would be realized. As a result, our provision for income taxes included a $13.4 million reduction of the valuation
allowance which was based on an estimate of future taxable income available to be offset by the tax loss
carryforwards.
Absent the effects of the reduction of this valuation allowance in the third quarter of 2013, our effective tax rate
for the year ended December 28, 2013 would have been 30.7% as compared to our actual effective tax rate of
28.7%. The remaining difference between our effective tax rates and the federal statutory tax rates for both periods
primarily relates to state and foreign income taxes and interest expense.
Provision has not been made for U.S. or additional foreign taxes on undistributed earnings of foreign
subsidiaries, which have been, and will continue to be reinvested. These earnings could become subject to
additional tax if they were remitted as dividends, if foreign earnings were loaned to us or a U.S. affiliate, or if we
should sell, transfer or dispose of our stock in the foreign subsidiaries. It is not practicable to determine the amount
of additional tax, if any, that might be payable on the foreign earnings because if we were to repatriate these
earnings, we believe there would be various methods available to us, each with different U.S. tax consequences. As
of December 27, 2014, the cumulative amount of reinvested earnings was approximately $826.0 million.
ASC Topic 740 clarifies the accounting for uncertainty in income taxes recognized in the financial statements
in accordance with other provisions contained within this guidance. This topic prescribes a recognition threshold
and a measurement attribute for the financial statement recognition and measurement of tax positions taken or
expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not
to be sustained upon examination by the taxing authorities. The amount recognized is measured as the largest
amount of benefit that is greater than 50% likely of being realized upon ultimate audit settlement. In the normal
course of business, our tax returns are subject to examination by various taxing authorities. Such examinations may
result in future tax and interest assessments by these taxing authorities for uncertain tax positions taken in respect to
certain tax matters.
87
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 12 – Income Taxes – (Continued)
The total amount of unrecognized tax benefits as of December 27, 2014 was approximately $80.6 million, of
which $60.7 million would affect the effective tax rate if recognized. It is expected that the amount of
unrecognized tax benefits will change in the next 12 months; however, we do not expect the change to have a
material impact on our consolidated financial statements.
The total amounts of interest and penalties, which are classified as a component of the provision for income
taxes, were approximately $14.8 million and $0, respectively, as of December 27, 2014.
The tax years subject to examination by major tax jurisdictions include the years 2009 and forward by the U.S.
Internal Revenue Service, the years 2005 and forward for certain states and the years 2005 and forward for certain
foreign jurisdictions. In December 2014, the IRS issued a Statutory Notice of Deficiency for 2009, 2010 and 2011.
We do not expect this to have a significant effect on our consolidated financial position, liquidity or the results of
operations.
The following table provides a reconciliation of unrecognized tax benefits excluding the effects of deferred
taxes, interest and penalties:
December 27,
December 28,
2014
2013
Balance, beginning of period ......................................................................................... $
Additions based on current year tax positions ................................................................
Additions based on prior year tax positions ...................................................................
Reductions based on prior year tax positions .................................................................
Reductions resulting from settlements with taxing authorities .......................................
Reductions resulting from lapse in statutes of limitations ..............................................
Balance, end of period .................................................................................................... $
43,200 $
13,500
13,400
(900)
(1,700)
(1,700)
65,800 $
32,700
6,000
9,600
(1,100)
(800)
(3,200)
43,200
88
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 13 – Concentrations of Risk
Certain financial instruments potentially subject us to concentrations of credit risk. These financial instruments
consist primarily of cash equivalents, trade receivables, long-term investments, notes receivable and derivative
instruments. In all cases, our maximum exposure to loss from credit risk equals the gross fair value of the financial
instruments. We continuously assess the need for reserves for such losses, which have been within our
expectations. We do not require collateral or other security to support financial instruments subject to credit risk,
except for long-term notes receivable.
We limit our credit risk with respect to our cash equivalents, short-term and long-term investments and
derivative instruments, by monitoring the credit worthiness of the financial institutions who are the counter-parties
to such financial instruments. As a risk management policy, we limit the amount of credit exposure by diversifying
and utilizing numerous investment grade counter-parties.
With respect to our trade receivables, our credit risk is somewhat limited due to a relatively large customer base
and its dispersion across different types of health care professionals and geographic areas. No single customer
accounted for more than 0.8% of our net sales in 2014. With respect to our sources of supply, our top 10 health
care distribution suppliers and our single largest supplier accounted for approximately 36% and 7%, respectively, of
our aggregate purchases in 2014.
Our long-term notes receivable primarily represent strategic financing arrangements with certain industry
affiliates and amounts owed to us from sales of certain businesses. Generally, these notes are secured by certain
assets of the counter-party; however, in most cases our security is subordinate to other commercial financial
institutions. While we have exposure to credit loss in the event of non-performance by these counter-parties, we
conduct ongoing assessments of their financial and operational performance.
Note 14 – Derivatives and Hedging Activities
We are exposed to market risks as well as changes in foreign currency exchange rates as measured against the
U.S. dollar and each other, and changes to the credit markets. We attempt to minimize these risks by primarily
using foreign currency forward contracts and by maintaining counter-party credit limits. These hedging activities
provide only limited protection against currency exchange and credit risks. Factors that could influence the
effectiveness of our hedging programs include currency markets and availability of hedging instruments and
liquidity of the credit markets. All foreign currency forward contracts that we enter into are components of hedging
programs and are entered into for the sole purpose of hedging an existing or anticipated currency exposure. We do
not enter into such contracts for speculative purposes and we manage our credit risks by diversifying our
investments, maintaining a strong balance sheet and having multiple sources of capital.
Fluctuations in the value of certain foreign currencies as compared to the U.S. dollar may positively or
negatively affect our revenues, gross margins, operating expenses and retained earnings, all of which are expressed
in U.S. dollars. Where we deem it prudent, we engage in hedging programs using primarily foreign currency
forward contracts aimed at limiting the impact of foreign currency exchange rate fluctuations on earnings. We
purchase short-term (i.e., 18 months or less) foreign currency forward contracts to protect against currency
exchange risks associated with intercompany loans due from our international subsidiaries and the payment of
merchandise purchases to our foreign suppliers. We do not hedge the translation of foreign currency profits into
U.S. dollars, as we regard this as an accounting exposure, not an economic exposure. Our hedging activities have
historically not had a material impact on our consolidated financial statements. Accordingly, additional disclosures
related to derivatives and hedging activities required by ASC Topic 815 have been omitted.
89
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 15 – Segment and Geographic Data
We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and
value-added services. These segments offer different products and services to the same customer base.
The health care distribution reportable segment aggregates our global dental, animal health and medical
operating segments. This segment distributes consumable products, small equipment, laboratory products, large
equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic
tests, infection-control products and vitamins. Our global dental group serves office-based dental practitioners,
dental laboratories, schools and other institutions. Our global animal health group serves animal health practices
and clinics. Our global medical group serves office-based medical practitioners, ambulatory surgery centers, other
alternate-care settings and other institutions. Our global dental, animal health and medical groups serve
practitioners in 28 countries worldwide.
Our global technology and value-added services group provides software, technology and other value-added
services to health care practitioners. Our technology group offerings include practice management software
systems for dental and medical practitioners and animal health clinics. Our value-added practice solutions include
financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting
and other services.
The following tables present information about our reportable and operating segments:
Years Ended
December 27,
2014
December 28, December 29,
2013
2012
Net Sales:
Health care distribution (1):
Dental ...................................................................................... $
Animal health ..........................................................................
Medical ....................................................................................
Total health care distribution ..............................................
Technology and value-added services (2) ......................................
Total ........................................................................................ $
5,381,215 $
2,898,612
1,742,685
10,022,512
348,878
10,371,390 $
4,997,972 $
2,599,461
1,643,167
9,240,600
320,047
9,560,647 $
4,774,482
2,321,151
1,560,921
8,656,554
283,413
8,939,967
(1)
(2)
Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and
generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Consists of practice management software and other value-added products, which are distributed primarily to health care providers,
and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other
services.
90
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 15 – Segment and Geographic Data – (Continued)
Years ended
December 27,
December 28,
December 29,
2014
2013
2012
Operating Income:
Health care distribution ............................................................ $
Technology and value-added services ......................................
Total ................................................................................... $
Income before taxes and equity in earnings of affiliates:
Health care distribution ............................................................ $
Technology and value-added services ......................................
Total ................................................................................... $
611,771 $
103,371
715,142 $
609,619 $
99,693
709,312 $
590,664 $
86,390
677,054 $
581,759 $
82,935
664,694 $
Depreciation and Amortization:
Health care distribution ............................................................ $
Technology and value-added services ......................................
Total ................................................................................... $
136,126 $
16,112
152,238 $
113,670 $
14,365
128,035 $
Income Tax Expense:
Health care distribution ............................................................ $
Technology and value-added services ......................................
Total ................................................................................... $
185,649 $
29,961
215,610 $
165,869 $
25,022
190,891 $
Interest Income:
Health care distribution ............................................................ $
Technology and value-added services ......................................
Total ................................................................................... $
Interest Expense:
Health care distribution ............................................................ $
Technology and value-added services ......................................
Total ................................................................................... $
Purchases of Fixed Assets:
Health care distribution ............................................................ $
Technology and value-added services ......................................
Total ................................................................................... $
13,585 $
70
13,655 $
23,916 $
141
24,057 $
74,955 $
7,161
82,116 $
12,816 $
37
12,853 $
27,375 $
163
27,538 $
57,364 $
2,851
60,215 $
541,667
77,294
618,961
529,236
74,952
604,188
113,688
11,634
125,322
165,346
22,512
187,858
13,293
101
13,394
30,790
112
30,902
47,057
4,180
51,237
As of
December 27,
December 28,
December 29,
2014
2013
2012
Total Assets:
Health care distribution ............................................................ $
Technology and value-added services ......................................
Total ................................................................................... $
5,741,160 $
397,647
6,138,807 $
5,277,354 $
347,282
5,624,636 $
5,001,188
332,809
5,333,997
91
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 15 – Segment and Geographic Data – (Continued)
The following table presents information about our operations by geographic area as of and for the three years
ended December 27, 2014. Net sales by geographic area are based on the respective locations of our subsidiaries.
No country, except for the United States, generated net sales greater than 10% of consolidated net sales. There
were no material amounts of sales or transfers among geographic areas and there were no material amounts of
export sales.
2014
2013
2012
Net Sales
Long-Lived
Assets
Net Sales
Long-Lived
Assets
Net Sales
Long-Lived
Assets
United States ............................ $ 6,247,056 $
Other ........................................
4,124,334
Consolidated total ............... $ 10,371,390 $
1,771,719 $
1,067,636
5,813,512 $
3,747,135
1,272,683 $ 5,496,969 $
3,442,998
1,055,343
1,313,866
1,022,820
2,839,355 $
9,560,647 $
2,328,026 $ 8,939,967 $
2,336,686
Note 16 – Employee Benefit Plans
Stock-based Compensation
Our accompanying consolidated statements of income reflect pre-tax share-based compensation expense of
$45.9 million ($31.9 million after-tax), $35.5 million ($24.6 million after-tax) and $37.3 million ($25.7 million
after-tax) for the years ended December 27, 2014, December 28, 2013 and December 29, 2012.
Our accompanying consolidated statements of cash flows present our stock-based compensation expense as an
adjustment to reconcile net income to net cash provided by operating activities for all periods presented. In the
accompanying consolidated statements of cash flows, we presented $5.9 million, $8.1 million and $17.8 million of
benefits associated with tax deductions in excess of recognized compensation as a cash inflow from financing
activities for the years ended December 27, 2014, December 28, 2013 and December 29, 2012.
Stock-based compensation represents the cost related to stock-based awards granted to employees and non-
employee directors. We measure stock-based compensation at the grant date, based on the estimated fair value of
the award, and recognize the cost (net of estimated forfeitures) as compensation expense on a straight-line basis
over the requisite service period. Our stock-based compensation expense is reflected in selling, general and
administrative expenses in our consolidated statements of income.
Stock-based awards are provided to certain employees and non-employee directors under the terms of our 2013
Stock Incentive Plan, as amended, and our 1996 Non-Employee Director Stock Incentive Plan, as amended
(together, the “Plans”). The Plans are administered by the Compensation Committee of the Board of Directors.
Prior to March 2009, awards under the Plans principally included a combination of at-the-money stock options and
restricted stock/units. Since March 2009, equity-based awards have been granted solely in the form of restricted
stock/units, with the exception of providing stock options to employees pursuant to certain pre-existing contractual
obligations. As of December 27, 2014, there were 31,229 shares authorized and 5,923 shares available to be
granted under the 2013 Stock Incentive Plan and 800 shares authorized and 84 shares available to be granted under
the 1996 Non-Employee Director Stock Incentive Plan.
92
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 16 – Employee Benefit Plans – (Continued)
Grants of restricted stock/units are stock-based awards granted to recipients with specified vesting provisions.
In the case of restricted stock, common stock is delivered on the date of grant, subject to vesting conditions. In the
case of restricted stock units, common stock is generally delivered on or following satisfaction of vesting
conditions. Prior to February 2014, we issued restricted stock/units that vest solely based on the recipient’s
continued service over time (primarily four-year cliff) and restricted stock/units that vest based on our achieving
specified performance measurements and the recipient’s continued service over time (primarily three-year cliff
vesting). Since February 2014, we have issue restricted stock/units that vest solely based on the recipient’s
continued service over time (primarily four-year cliff vesting under our 2013 Stock Incentive Plan and primarily
13-month cliff vesting under our 1996 Non-Employee Director Stock Incentive Plan) and restricted stock/units that
vest based on our achieving specified performance measurements and the recipient’s continued service over time
(primarily three-year cliff vesting under our 2013 Stock Incentive Plan).
With respect to time-based restricted stock/units, we estimate the fair value on the date of grant based on our
closing stock price. With respect to performance-based restricted stock/units, the number of shares that ultimately
vest and are received by the recipient is based upon our performance as measured against specified targets over a
three-year period as determined by the Compensation Committee of the Board of Directors. Although there is no
guarantee that performance targets will be achieved, we estimate the fair value of performance-based restricted
stock/units based on our closing stock price at time of grant.
The Plans provide for adjustments to the performance-based restricted stock/units targets for significant events
such as acquisitions, divestitures, new business ventures, share repurchases and certain foreign exchange
fluctuations. Over the performance period, the number of shares of common stock that will ultimately vest and be
issued and the related compensation expense is adjusted upward or downward based upon our estimation of
achieving such performance targets. The ultimate number of shares delivered to recipients and the related
compensation cost recognized as an expense will be based on our actual performance metrics as defined under the
Plans.
We record deferred income tax assets for awards that will result in future deductions on our income tax returns
based on the amount of compensation cost recognized and our statutory tax rate in the jurisdiction in which we will
receive a deduction. Differences between the deferred income tax assets recognized for financial reporting
purposes and the actual tax deduction reported on our income tax return are recorded in additional paid-in capital (if
the tax deduction exceeds the deferred income tax asset) or in earnings (if the deferred income tax asset exceeds the
tax deduction and no additional paid-in capital exists from previous awards).
Stock-based compensation grants for the three years ended December 27, 2014 primarily consisted of restricted
stock/unit grants. Certain stock-based compensation granted may require us to settle in the form of a cash payment.
During the year ended December 27, 2014, we recorded a liability of $0.6 million relating to the grant date fair
value of stock-based compensation to be settled in cash, as well as an expense of $0.7 million relating to the change
in the fair value of these grants. The weighted-average grant date fair value of stock-based awards granted before
forfeitures was $119.45, $89.97 and $73.42 per share during the years ended December 27, 2014, December 28,
2013 and December 29, 2012.
Total unrecognized compensation cost related to non-vested awards as of December 27, 2014 was $84.5
million, which is expected to be recognized over a weighted-average period of approximately 2.1 years.
93
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 16 – Employee Benefit Plans – (Continued)
A summary of the stock option activity under the Plans is presented below:
December 27,
2014
Weighted
Average
Exercise
Price
Shares
Outstanding at beginning of year ...........
Granted ...................................................
Exercised ................................................
Forfeited .................................................
Outstanding at end of year .....................
1,323 $
-
(639)
-
684 $
51.53
-
49.51
-
53.41
Years Ended
December 28,
2013
December 29,
2012
Weighted
Average
Exercise
Price
Weighted
Average
Exercise
Price
Shares
Shares
2,138 $
-
(815)
-
1,323 $
48.61
-
43.86
-
51.53
4,059 $
-
(1,890)
(31)
2,138 $
44.53
-
40.06
36.02
48.61
Options exercisable at end of year .........
684 $
53.41
1,323 $
51.53
2,137 $
48.62
During the years ended December 27, 2014, December 28, 2013 and December 29, 2012, we did not grant any
stock options.
The following table represents the intrinsic values of:
As of
December 27,
December 28,
2014
2013
December 29,
2012
Stock options outstanding ................................................................ $
Stock options exercisable .................................................................
57,421 $
57,421
83,252 $
83,252
67,044
66,964
The total cash received as a result of stock option exercises for the years ended December 27, 2014, December
28, 2013 and December 29, 2012 was approximately $31.5 million, $35.6 million and $72.5 million. In connection
with these exercises, the tax benefits that we realized for the years ended December 27, 2014, December 28, 2013
and December 29, 2012 were $11.2 million, $18.4 million and $31.6 million. We settle employee stock option
exercises with newly issued common shares.
94
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 16 – Employee Benefit Plans – (Continued)
The total intrinsic value per share of restricted stock/units that vested was $119.36, $98.99 and $75.98 during
the years ended December 27, 2014, December 28, 2013 and December 29, 2012. The following table summarizes
the status of our non-vested restricted stock/units for the year ended December 27, 2014:
Time-Based Restricted Stock/Units
Weighted Average
Grant Date Fair
Value Per Share
Shares/Units
Intrinsic Value
Per Share
Outstanding at beginning of period ...........................................
Granted ......................................................................................
Vested ........................................................................................
Forfeited ....................................................................................
Outstanding at end of period .....................................................
926 $
177
(229)
(38)
836 $
70.70
119.32
57.69
86.47
83.86 $
137.39
Performance-Based Restricted Stock/Units
Weighted Average
Grant Date Fair
Value Per Share
Shares/Units
Intrinsic Value
Per Share
Outstanding at beginning of period ...........................................
Granted ......................................................................................
Vested ........................................................................................
Forfeited ....................................................................................
Outstanding at end of period .....................................................
1,078 $
343
(264)
(30)
1,127 $
59.85
114.06
69.89
90.77
77.19 $
137.39
401(k) Plans
We offer qualified 401(k) plans to substantially all our domestic full-time employees. As determined by our
Board of Directors, matching contributions to these plans generally do not exceed 100% of the participants’
contributions up to 7% of their base compensation, subject to applicable legal limits. Matching contributions
consist of cash and were allocated entirely to the participants’ investment elections on file, subject to a 20%
allocation limit to the Henry Schein Stock Fund. Forfeitures attributable to participants whose employment
terminates prior to becoming fully vested are used to reduce our matching contributions and offset administrative
expenses of the 401(k) plans.
Assets of the 401(k) and other defined contribution plans are held in self-directed accounts enabling
participants to choose from various investment fund options. Matching contributions and administrative expenses
related to these plans charged to operations during the years ended December 27, 2014, December 28, 2013 and
December 29, 2012 amounted to $28.6 million, $25.3 million and $23.8 million.
Supplemental Executive Retirement Plan
We offer an unfunded, non-qualified supplemental executive retirement plan to eligible employees. This plan
generally covers officers and certain highly-compensated employees after they have reached the maximum IRS
allowed pre-tax 401(k) contribution limit. Our contributions to this plan are equal to the 401(k) employee-elected
contribution percentage applied to base compensation for the portion of the year in which such employees are not
eligible to make pre-tax contributions to the 401(k) plan. The amounts charged to operations during the years
ended December 27, 2014, December 28, 2013 and December 29, 2012 amounted to $1.9 million, $4.1 million and
$2.1 million.
95
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 16 – Employee Benefit Plans – (Continued)
Deferred Compensation Plan
During 2011, we began to offer a deferred compensation plan to a select group of management or highly
compensated employees of the Company and certain associated companies. This plan allows for the elective
deferral of base salary, bonus and/or commission compensation by eligible employees. The amounts charged to
operations during the years ended December 27, 2014, December 28, 2013 and December 29, 2012 were
approximately $0.7 million, $1.1 million and $0.3 million, respectively.
Note 17 – Commitments and Contingencies
Operating Leases
We lease facilities and equipment under non-cancelable operating leases expiring through 2033. We expect
that in the normal course of business, leases will be renewed or replaced by other leases.
Future minimum annual rental payments under our non-cancelable operating leases as of December 27, 2014
were:
2015 ...............................................................................$
2016 ...............................................................................
2017 ...............................................................................
2018 ...............................................................................
2019 ...............................................................................
Thereafter ......................................................................
Total minimum operating lease payments ...............$
78,898
61,781
44,974
35,534
27,863
80,778
329,828
Total rental expense for the years ended December 27, 2014, December 28, 2013 and December 29, 2012 was
$76.1 million, $70.8 million and $68.2 million.
Capital Leases
We lease certain equipment under capital leases. Future minimum annual lease payments under our capital
leases together with the present value of the minimum capital lease payments as of December 27, 2014 were:
2015 ..................................................................................................$
2016 ..................................................................................................
2017 ..................................................................................................
2018 ..................................................................................................
2019 ..................................................................................................
Thereafter ..........................................................................................
Total minimum capital lease payments .............................................
Less: Amount representing interest at 2.00% to 13.00%
Total present value of minimum capital lease payments ..............$
1,782
1,435
1,067
803
617
2,814
8,518
(1,216)
7,302
96
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 17 – Commitments and Contingencies – (Continued)
Capital Expenditures
We sometimes enter into certain commitments regarding capital expenditures. As of December 27, 2014, we
have capital expenditure commitments of $4.8 million due within one year.
Purchase Commitments
In our health care distribution business, we sometimes enter into long-term purchase commitments to ensure the
availability of products for distribution. Future minimum annual payments for inventory purchase commitments as
of December 27, 2014 were:
2015 .................................................................................................$
2016 .................................................................................................
2017 .................................................................................................
2018 .................................................................................................
2019 .................................................................................................
Thereafter ........................................................................................
Total minimum inventory purchase commitment payments .......$
215,148
288,787
305,805
309,669
284,800
889,600
2,293,809
Litigation
From time to time, we may become a party to legal proceedings, including, without limitation, product liability
claims, employment matters, commercial disputes, governmental inquiries and investigations, and other matters
arising out of the ordinary course of our business. While the results of legal proceedings cannot be predicted with
certainty, in our opinion pending matters are not currently anticipated to have a material adverse effect on our
financial condition or results of operations.
As of December 27, 2014, we had accrued our best estimate of potential losses relating to claims that were
probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as
well as related expenses, was not material to our financial position, results of operations or cash flows. Our method
for determining estimated losses considers currently available facts, presently enacted laws and regulations and
other external factors, including probable recoveries from third parties.
Employment, Consulting and Non-Compete Agreements
We have definite-lived employment, consulting and non-compete agreements that have varying base aggregate
annual payments for the years 2015 through 2019 and thereafter of approximately $15.7 million, $3.1 million, $3.4
million, $0.4 million, $0.4 million and $1.7 million. We also have lifetime consulting agreements that provide for
current compensation of $0.5 million per year, increasing $25 every fifth year with the next increase in 2017. In
addition, some agreements have provisions for additional incentives and compensation.
97
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 18 – Quarterly Information (Unaudited)
The following tables present certain quarterly financial data:
Quarters ended
March 29,
2014
June 28,
2014
September 27,
2014
December 27,
2014
Net sales ............................................................ $
Gross profit .......................................................
Operating income ..............................................
Net income ........................................................
2,430,159 $
696,713
157,268
110,128
2,615,406 $
728,472
180,844
127,117
2,623,729 $
721,666
174,088
124,236
2,702,096
764,464
202,942
143,955
Amounts attributable to
Henry Schein, Inc.:
Net income ........................................................
Earnings per share attributable to
Henry Schein, Inc.:
102,099
116,236
114,776
132,966
Basic ............................................................ $
Diluted .........................................................
1.20 $
1.18
1.37 $
1.35
1.36 $
1.34
1.59
1.56
Quarters ended
March 30,
2013 (1)
June 29,
2013
September 28,
2013 (2) (3)
December 28,
2013
Net sales ............................................................ $
Gross profit .......................................................
Operating income ..............................................
Net income ........................................................
2,293,511 $
646,991
153,629
98,686
2,391,810 $
669,856
176,065
121,435
2,348,956 $
639,647
160,477
116,372
2,526,370
699,520
186,883
134,969
Amounts attributable to
Henry Schein, Inc.:
Net income ........................................................
Earnings per share attributable to
Henry Schein, Inc.:
91,478
108,430
107,378
124,268
Basic ............................................................ $
Diluted .........................................................
1.06 $
1.03
1.26 $
1.23
1.25 $
1.23
1.46
1.43
(1) See Note 5 - "Debt" for details of expenses related to the refinancing of HSAH debt incurred during the first quarter
of 2013.
(2) See Note 9 - "Business Acquisitions, Divestiture and Other Transaction" for details of the loss on sale of equity
investment incurred during the third quarter of 2013.
(3) See Note 12 - "Incomes Taxes" for details of the reduction of our valuation allowance related to certain deferred tax
assets incurred during the third quarter of 2013.
98
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 18 – Quarterly Information (Unaudited) – (Continued)
We experience fluctuations in quarterly earnings. As a result, we may fail to meet or exceed the expectations
of securities analysts and investors, which could cause our stock price to decline.
Our business is subject to seasonal and other quarterly fluctuations. Net sales and operating profits generally
have been higher in the third and fourth quarters due to the timing of sales of seasonal products (including influenza
vaccine, equipment and software products), purchasing patterns of office-based health care practitioners and year-
end promotions. Net sales and operating profits generally have been lower in the first quarter, primarily due to
increased sales in the prior two quarters. We expect our historical seasonality of sales to continue in the foreseeable
future. Quarterly results may also be adversely affected by a variety of other factors, including:
• timing and amount of sales and marketing expenditures;
• timing of pricing changes offered by our vendors;
• timing of the introduction of new products and services by our vendors;
• timing of the release of upgrades and enhancements to our technology-related products and services;
• changes in or availability of vendor contracts or rebate programs;
• vendor rebates based upon attaining certain growth goals;
• changes in the way vendors introduce or deliver products to market;
• costs of developing new applications and services;
• our ability to correctly identify customer needs and preferences and predict future needs and preferences;
• exclusivity requirements with certain vendors may prohibit us from distributing competitive products
manufactured by other vendors;
• loss of sales representatives;
• costs related to acquisitions and/or integrations of technologies or businesses;
• costs associated with our self-insured medical and dental insurance programs;
• general market and economic conditions, as well as those specific to the health care industry and related
industries;
• our success in establishing or maintaining business relationships;
• unexpected difficulties in developing and manufacturing products;
• product demand and availability or recalls by manufacturers;
• exposure to product liability and other claims in the event that the use of the products we sell results in
injury;
• increases in the cost of shipping or service issues with our third-party shippers;
• fluctuations in the value of foreign currencies;
• restructuring costs; and
• changes in accounting principles.
Any change in one or more of these or other factors could cause our annual or quarterly operating results to
fluctuate. If our operating results do not meet market expectations, our stock price may decline.
99
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
(in thousands, except per share data)
Note 19 – Supplemental Cash Flow Information
Cash paid for interest and income taxes was:
Years ended
December 27,
December 28, December 29,
2014
2013
2012
Interest ............................................................................................. $
Income taxes ...................................................................................
22,285 $
208,272
19,893 $
146,593
23,358
196,765
There was approximately $3.3 million, $0.1 million and $8.3 million of debt assumed as a part of the
acquisitions for the years ended December 27, 2014, December 28, 2013 and December 29, 2012, respectively.
Debt assumed during the year ended December 27, 2014 relates to the acquisitions of BioHorizons, Inc. and
Medivet S.A., and debt assumed during the year ended December 29, 2012 primarily relates to the acquisition of
C&M Vetlink.
For the years ended December 27, 2014, December 28, 2013 and December 29, 2012, we had $(2.5) million,
$0.1 million and $3.5 million of non-cash net unrealized gains (losses) related to foreign currency hedging
activities, respectively.
100
ITEM 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
None.
ITEM 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of management, including our principal executive officer and
principal financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and
procedures as of the end of the period covered by this annual report as such term is defined in Rules 13a-15(e) and
15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on
this evaluation, our management, including our principal executive officer and principal financial officer,
concluded that our disclosure controls and procedures were effective as of December 27, 2014 to ensure that all
material information required to be disclosed by us in reports that we file or submit under the Exchange Act is
accumulated and communicated to them as appropriate to allow timely decisions regarding required disclosure and
that all such information is recorded, processed, summarized and reported within the time periods specified in the
SEC’s rules and forms.
Changes in Internal Control over Financial Reporting
The combination of ongoing acquisition integrations and systems implementations undertaken during the
quarter ended December 27, 2014 and carried over from prior quarters, when considered in the aggregate,
represents a material change in our internal control over financial reporting.
During the quarter ended December 27, 2014, we completed the acquisition of a medical business in North
America with approximate aggregate annual revenues of $324.0 million. In addition, post-acquisition integration
related activities continued for our global dental and animal health businesses acquired during prior quarters,
representing aggregate annual revenues of approximately $389.0 million. These acquisitions, the majority of which
utilize separate information and financial accounting systems, have been included in our consolidated financial
statements.
System implementation activities were completed during the quarter ended December 27, 2014 for our
Australian animal health business with approximate aggregate annual revenues of $292.0 million. In addition, we
completed systems implementation solutions for dental businesses within Europe with approximate aggregate
annual revenues of $40.0 million. Finally, systems implementation activities were also completed for new ERP
systems that support our dental business in Thailand with approximate aggregate annual revenues of $18.0 million.
All acquisition integrations and systems implementations involved necessary and appropriate change-
management controls that are considered in our annual assessment of the design and operating effectiveness of our
internal control over financial reporting.
101
Management’s Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial
reporting, as such term is defined in Exchange Act Rule 13a-15(f). Our internal control system is designed to
provide reasonable assurance to our management and Board of Directors regarding the preparation and fair
presentation of published financial statements. Under the supervision and with the participation of our
management, including our principal executive officer and principal financial officer, we conducted an evaluation
of the effectiveness of our internal control over financial reporting based on the framework in Internal Control-
Integrated Framework (2013), updated and reissued by the Committee of Sponsoring Organizations, or the COSO
Framework. Based on our evaluation under the COSO Framework, our management concluded that our internal
control over financial reporting was effective at a reasonable assurance level as of December 27, 2014.
The effectiveness of our internal control over financial reporting as of December 27, 2014 has been
independently audited by BDO USA, LLP, an independent registered public accounting firm, and their attestation is
included herein.
Limitations of the Effectiveness of Internal Control
A control system, no matter how well conceived and operated, can provide only reasonable, not absolute,
assurance that the objectives of the internal control system are met. Because of the inherent limitations of any
internal control system, no evaluation of controls can provide absolute assurance that all control issues, if any,
within a company have been detected.
102
Report of Independent Registered Public Accounting Firm
Board of Directors and Stockholders
Henry Schein, Inc.
Melville, New York
We have audited Henry Schein, Inc.’s internal control over financial reporting as of December 27, 2014, based
on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of the Treadway Commission (the COSO criteria). Henry Schein, Inc.’s management is responsible
for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of
internal control over financial reporting, included in the accompanying “Item 9A, Management’s Report on Internal
Control Over Financial Reporting”. Our responsibility is to express an opinion on the company’s internal control
over financial reporting based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board
(United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about
whether effective internal control over financial reporting was maintained in all material respects. Our audit
included obtaining an understanding of internal control over financial reporting, assessing the risk that a material
weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the
assessed risk. Our audit also included performing such other procedures as we considered necessary in the
circumstances. We believe that our audit provides a reasonable basis for our opinion.
A company’s internal control over financial reporting is a process designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles. A company’s internal control over financial reporting
includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail,
accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable
assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
with generally accepted accounting principles, and that receipts and expenditures of the company are being made
only in accordance with authorizations of management and directors of the company; and (3) provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the
company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect
misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that
controls may become inadequate because of changes in conditions, or that the degree of compliance with the
policies or procedures may deteriorate.
In our opinion, Henry Schein, Inc. maintained, in all material respects, effective internal control over financial
reporting as of December 27, 2014, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board
(United States), the consolidated balance sheets of Henry Schein, Inc. as of December 27, 2014 and December 28,
2013, and the related consolidated statements of income, comprehensive income, changes in stockholders’ equity,
and cash flows for each of the three years in the period ended December 27, 2014 and our report dated February 11,
2015 expressed an unqualified opinion thereon.
/s/ BDO USA, LLP
New York, NY
February 11, 2015
103
ITEM 9B. Other Information.
None.
ITEM 10. Directors, Executive Officers and Corporate Governance
PART III
Information required by this item regarding our directors and executive officers and our corporate governance
is hereby incorporated by reference to the Section entitled “Election of Directors,” with respect to directors, and the
first paragraph of the Section entitled “Corporate Governance - Board of Directors Meetings and Committees -
Audit Committee,” with respect to corporate governance, in each case in our definitive 2015 Proxy Statement to be
filed pursuant to Regulation 14A and to the Section entitled “Executive Officers of the Registrant” in Part I of this
report, with respect to executive officers.
There have been no changes to the procedures by which stockholders may recommend nominees to our Board
of Directors since our last disclosure of such procedures, which appeared in our definitive 2014 Proxy Statement
filed pursuant to Regulation 14A on April 14, 2014.
Information required by this item concerning compliance with Section 16(a) of the Securities Exchange Act of
1934 is hereby incorporated by reference to the Section entitled “Section 16(a) Beneficial Ownership Reporting
Compliance” in our definitive 2015 Proxy Statement.
We have adopted a Code of Ethics that applies to our Chief Executive Officer, Chief Financial Officer, Vice
President of Corporate Finance and Controller. We make available free of charge through our Internet website,
www.henryschein.com, under the “About Henry Schein--Corporate Governance” caption, our Code of Ethics. We
intend to disclose on our Web site any amendment to, or waiver of, a provision of the Code of Ethics.
ITEM 11. Executive Compensation
The information required by this item is hereby incorporated by reference to the Sections entitled
“Compensation Discussion and Analysis,” “Compensation Committee Report” (which information shall be deemed
furnished in this Annual Report on Form 10-K), “Executive and Director Compensation” and “Compensation
Committee Interlocks and Insider Participation” in our definitive 2015 Proxy Statement to be filed pursuant to
Regulation 14A.
104
ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder
Matters
We maintain several stock incentive plans for the benefit of certain officers, directors and employees. All
active plans have been approved by our stockholders. Descriptions of these plans appear in the notes to our
consolidated financial statements. The following table summarizes information relating to these plans as of
December 27, 2014:
Number of Common
Shares to be Issued Upon Weighted- Average
Exercise of Outstanding
Exercise Price of
Outstanding Options
Options and Rights
Number of Common
Shares Available for
Future Issuances
Plan Category
Plans Approved by Stockholders ....................
Plans Not Approved by Stockholders .............
Total ..........................................................
683,759 $
-
683,759 $
53.41
-
53.41
6,006,298
-
6,006,298
The other information required by this item is hereby incorporated by reference to the Section entitled “Security
Ownership of Certain Beneficial Owners and Management” in our definitive 2015 Proxy Statement to be filed
pursuant to Regulation 14A.
ITEM 13. Certain Relationships and Related Transactions, and Director Independence
The information required by this item is hereby incorporated by reference to the Section entitled “Certain
Relationships and Related Transactions” and “Corporate Governance – Board of Directors Meetings and
Committees – Independent Directors” in our definitive 2015 Proxy Statement to be filed pursuant to Regulation
14A.
ITEM 14. Principal Accountant Fees and Services
The information required by this item is hereby incorporated by reference to the Section entitled “Independent
Registered Public Accounting Firm Fees and Pre-Approval Policies and Procedures” in our definitive 2015 Proxy
Statement to be filed pursuant to Regulation 14A.
105
ITEM 15. Exhibits, Financial Statement Schedules
PART IV
1. Financial Statements:
Our Consolidated Financial Statements filed as a part of this report are listed on the index on
page 60.
2. Financial Statement Schedules:
Schedule II
No other schedules are required.
3. Exhibits:
The exhibits required by Item 601 of Regulation S-K and filed herewith are listed in the Exhibit
List immediately preceding the exhibits.
106
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SIGNATURES
Henry Schein, Inc.
By: /s/ STANLEY M. BERGMAN
Stanley M. Bergman
Chairman and Chief Executive Officer
February 11, 2015
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the
following persons on behalf of the Registrant and in the capacities and on the dates indicated.
Signature
/s/ STANLEY M. BERGMAN
Stanley M. Bergman
/s/ STEVEN PALADINO
Steven Paladino
/s/ JAMES P. BRESLAWSKI
James P. Breslawski
/s/ GERALD A. BENJAMIN
Gerald A. Benjamin
/s/ MARK E. MLOTEK
Mark E. Mlotek
/s/ BARRY J. ALPERIN
Barry J. Alperin
/s/ LAWRENCE S. BACOW, PH. D.
Lawrence S. Bacow, Ph. D.
/s/ PAUL BRONS
Paul Brons
/s/ DONALD J. KABAT
Donald J. Kabat
/s/ PHILIP A. LASKAWY
Philip A. Laskawy
/s/ NORMAN S. MATTHEWS
Norman S. Matthews
/s/ CAROL RAPHAEL
Carol Raphael
/s/ E. DIANNE REKOW
E. Dianne Rekow
/s/ BRADLEY T. SHEARES, PH. D.
Bradley T. Sheares, Ph. D.
/s/ LOUIS W. SULLIVAN, MD
Louis W. Sullivan, MD
Capacity
Chairman, Chief Executive Officer
and Director (principal executive officer)
Executive Vice President, Chief Financial
Officer and Director (principal financial and
accounting officer)
Director
Director
Director
Director
Director
Director
Director
Director
Director
Director
Director
Director
Director
107
Date
February 11, 2015
February 11, 2015
February 11, 2015
February 11, 2015
February 11, 2015
February 11, 2015
February 11, 2015
February 11, 2015
February 11, 2015
February 11, 2015
February 11, 2015
February 11, 2015
February 11, 2015
February 11, 2015
February 11, 2015
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Board of Directors and Stockholders
Henry Schein, Inc.
Melville, New York
The audits referred to in our report dated February 11, 2015 relating to the consolidated financial statements of
Henry Schein, Inc., which is contained in Item 8 of this Form 10-K also included the audit of the financial
statement schedule listed in the accompanying index. This financial statement schedule is the responsibility of the
company’s management. Our responsibility is to express an opinion on this financial statement schedule based on
our audits.
In our opinion such financial statement schedule, when considered in relation to the basic consolidated financial
statements taken as a whole, presents fairly, in all material respects, the information set forth therein.
/s/ BDO USA, LLP
New York, NY
February 11, 2015
108
Schedule II
Valuation and Qualifying Accounts
(in thousands)
Additions
Description
Balance at
beginning of
period
Charged to
statement of
income (1)
Charged to
other
accounts (2)
Balance at
Deductions (3)
end of
period
Year ended December 27, 2014:
Allowance for doubtful accounts,
sales returns and other ...................... $
Year ended December 28, 2013:
Allowance for doubtful accounts,
sales returns and other ...................... $
Year ended December 29, 2012:
Allowance for doubtful accounts,
sales returns and other ...................... $
(1) Represents amounts charged to bad debt expense.
78,298 $
4,619 $
5,828 $
(8,074) $
80,671
75,240 $
5,189 $
6,195 $
(8,326) $
78,298
65,853 $
4,407 $
13,305 $
(8,325) $
75,240
(2) Amounts charged to net sales primarily relate to increases in allowances for sales returns.
(3) Deductions primarily consist of fully reserved accounts receivable that have been written off.
109
Exhibits
3.1 Amended and Restated Certificate of Incorporation of Henry Schein, Inc. dated November 2, 1995.
(Incorporated by reference to Exhibit 3.1 to our Annual Report on Form 10-K for the fiscal year ended
December 30, 2006 filed on February 28, 2007.)
3.2 Certificate of Amendment of Amended and Restated Certificate of Incorporation of Henry Schein, Inc.
dated November 12, 1997. (Incorporated by reference to Exhibit 3.2 to our Annual Report on Form 10-K
for the fiscal year ended December 30, 2006 filed on February 28, 2007.)
3.3 Certificate of Amendment of Amended and Restated Certificate of Incorporation of Henry Schein, Inc.
dated June 16, 1998. (Incorporated by reference to Exhibit 3.3 to our Registration Statement on Form S-
3, Reg. No. 333-59793 filed on July 24, 1998.)
3.4 Certificate of Amendment of Amended and Restated Certificate of Incorporation of Henry Schein, Inc.
dated May 25, 2005. (Incorporated by reference to Exhibit 3.1 to our Quarterly Report on Form 10-Q for
the fiscal quarter ended June 25, 2005 filed on August 4, 2005.)
3.5 Certificate of Amendment of Amended and Restated Certificate of Incorporation of Henry Schein, Inc.
dated May 15, 2012. (Incorporated by reference to Exhibit 3.1 of our Current Report on Form 8-K filed
on May 16, 2012.)
3.6 Amended and Restated By-Laws. (Incorporated by reference to Exhibit 3.2 to our Registration Statement
on Form S-1, Reg. No. 33-96528 filed on October 10, 1995.)
3.7 Amendments to the Amended and Restated By-Laws adopted July 15, 1997. (Incorporated by reference
to Exhibit 3.3 to our Registration Statement on Form S-4, Reg. No. 33-36081 filed on September 22,
1997.)
3.8 Amendment to the Amended and Restated By-Laws adopted on May 15, 2012. (Incorporated by
reference to Exhibit 3.2 of our Current Report on Form 8-K filed on May 16, 2012.)
4.1 Master Note Facility, dated as of April 27, 2012, by and among us, Metropolitan Life Insurance
Company, Metlife Investment Advisors Company, LLC and each MetLife affiliate which becomes party
thereto. (Incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on April 30,
2012.)
4.2 Letter Agreement dated as of September 22, 2014 amending the Master Note Purchase Agreement, dated
as of April 27, 2012, by and among us, Metropolitan Life Insurance Company, MetLife Investment
Management, LLC (f/k/a MetLife Investment Advisors Company, LLC) and each MetLife affiliate which
becomes party thereto. (Incorporated by reference to Exhibit 4.3 to our Current Report on Form 8-K filed
on September 26, 2014.)
4.3 Master Note Facility, dated as of August 9, 2010, by and among us, New York Life Investment
Management LLC and each New York Life affiliate which becomes party thereto. (Incorporated by
reference to Exhibit 4.1 to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 26,
2011 filed on May 3, 2011.)*
4.4 Amendment No. 1 to Master Note Facility, dated as of February 14, 2012, by and among us, New York
Life Investment Management LLC and each New York Life affiliate which becomes party thereto.
(Incorporated by reference to Exhibit 4.2 to our Annual Report on Form 10-K for the fiscal year ended
December 31, 2011 filed on February 15, 2012.)
110
Exhibits
4.5 Second Amendment to Master Note Facility, dated as of August 27, 2012, by and among us, New York
Life Investment Management LLC and each NY Life affiliate which becomes party thereto, as amended.
(Incorporated by reference to Exhibit 4.3 to our Current Report on Form 8-K filed on April 30, 2012.)
4.6 Letter Agreement dated as of September 22, 2014 amending the Master Note Facility, dated as of August
9, 2010, by and among us, NYL Investors LLC (as successor in interest to New York Life Investment
Management LLC) and each NY Life affiliate which becomes party thereto, as amended. (Incorporated
by reference to Exhibit 4.2 to our Current Report on Form 8-K filed on September 26, 2014.)
4.7 Private Shelf Agreement, dated as of August 9, 2010, by and among us, Prudential Investment
Management, Inc. and each Prudential affiliate which becomes party thereto. (Incorporated by reference
to Exhibit 4.2 to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 26, 2011 filed on
May 3, 2011.)*
4.8 Amendment to the Private Shelf Agreement, dated as of August 27, 2012, by and among us, Prudential
Investment Management, Inc. and each Prudential affiliate which becomes party thereto. (Incorporated
by reference to Exhibit 4.2 to our Current Report on Form 8-K filed on April 30, 2012.)
4.9 Letter Agreement dated as of September 22, 2014 amending the Private Shelf Agreement, dated as of
August 9, 2010, by and among us, Prudential Investment Management, Inc. and each Prudential affiliate
which becomes party thereto, as amended. (Incorporated by reference to Exhibit 4.1 to our Current
Report on Form 8-K filed on September 26, 2014.)
10.1 Henry Schein, Inc. 1994 Stock Incentive Plan, as amended and restated effective as of March 27, 2007.
(Incorporated by reference to Appendix A to our definitive 2007 Proxy Statement on Schedule 14A filed
on April 10, 2007.)**
10.2 Amendment Number One to the Henry Schein, Inc. 1994 Stock Incentive Plan, effective as of January 1,
2005. (Incorporated by reference to Exhibit 10.2 to our Annual Report on Form 10-K for the fiscal year
ended December 27, 2008 filed on February 24, 2009.)**
10.3 Amendment Number Two to the Henry Schein, Inc. 1994 Stock Incentive Plan, effective as of May 28,
2009. (Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the fiscal
quarter ended June 27, 2009 filed on August 4, 2009.)**
10.4 Amendment Number Three to the Henry Schein, Inc. 1994 Stock Incentive Plan, effective as of February
23, 2010. (Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the fiscal
quarter ended March 27, 2010 filed on May 4, 2010.)**
10.5 Amendment Number Four to the Henry Schein, Inc. 1994 Stock Incentive Plan, effective as of May 18,
2011. (Incorporated by reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q for the fiscal
quarter ended June 25, 2011 filed on August 2, 2011.)**
10.6 Amendment Number Five to the Henry Schein, Inc. 1994 Stock Incentive Plan, effective as of May 18,
2011. (Incorporated by reference to Exhibit 10.3 to our Quarterly Report on Form 10-Q for the fiscal
quarter ended June 25, 2011 filed on August 2, 2011.)**
10.7 Form of Restricted Stock Agreement for time-based restricted stock awards pursuant to the Henry Schein,
Inc. 1994 Stock Incentive Plan (as amended and restated effective as of March 27, 2007). (Incorporated
by reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 27,
2010 filed on May 4, 2010.)**
111
Exhibits
10.8 Form of Restricted Stock Agreement for performance-based restricted stock awards pursuant to the Henry
Schein, Inc. 1994 Stock Incentive Plan (as amended and restated effective as of March 27, 2007).
(Incorporated by reference to Exhibit 10.3 to our Quarterly Report on Form 10-Q for the fiscal quarter
ended March 27, 2010 filed on May 4, 2010.)**
10.9 Form of Restricted Stock Unit Agreement for time-based restricted stock awards pursuant to the Henry
Schein, Inc. 1994 Stock Incentive Plan (as amended and restated effective as of March 27, 2007).
(Incorporated by reference to Exhibit 10.4 to our Quarterly Report on Form 10-Q for the fiscal quarter
ended March 27, 2010 filed on May 4, 2010.)**
10.10 Form of Restricted Stock Unit Agreement for performance-based restricted stock awards pursuant to the
Henry Schein, Inc. 1994 Stock Incentive Plan (as amended and restated effective as of March 27, 2007).
(Incorporated by reference to Exhibit 10.5 to our Quarterly Report on Form 10-Q for the fiscal quarter
ended March 27, 2010 filed on May 4, 2010.)**
10.11 Form of Restricted Stock Agreement for time-based restricted stock awards pursuant to the Henry Schein,
Inc. 1994 Stock Incentive Plan (as amended and restated effective as of March 27, 2007). (Incorporated
by reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 30,
2013 filed on May 7, 2013.)**
10.12 Form of Restricted Stock Agreement for performance-based restricted stock awards pursuant to the Henry
Schein, Inc. 1994 Stock Incentive Plan (as amended and restated effective as of March 27, 2007).
(Incorporated by reference to Exhibit 10.3 to our Quarterly Report on Form 10-Q for the fiscal quarter
ended March 30, 2013 filed on May 7, 2013.)**
10.13 Form of Restricted Stock Unit Agreement for time-based restricted stock awards pursuant to the Henry
Schein, Inc. 1994 Stock Incentive Plan (as amended and restated effective as of March 27, 2007).
(Incorporated by reference to Exhibit 10.4 to our Quarterly Report on Form 10-Q for the fiscal quarter
ended March 30, 2013 filed on May 7, 2013.)**
10.14 Form of Restricted Stock Unit Agreement for performance-based restricted stock awards pursuant to the
Henry Schein, Inc. 1994 Stock Incentive Plan (as amended and restated effective as of March 27, 2007).
(Incorporated by reference to Exhibit 10.5 to our Quarterly Report on Form 10-Q for the fiscal quarter
ended March 30, 2013 filed on May 7, 2013.)**
10.15 Henry Schein, Inc. 2013 Stock Incentive Plan, as amended and restated effective as of May 14, 2013.
(Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on May 16, 2013.)**
10.16 Form of Restricted Stock Agreement for time-based restricted stock awards pursuant to the Henry Schein,
Inc. 2013 Stock Incentive Plan (as amended and restated effective as of May 14, 2013). (Incorporated by
reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 29,
2014 filed on May 6, 2014.)**
10.17 Form of Restricted Stock Agreement for performance-based restricted stock awards pursuant to the Henry
Schein, Inc. 2013 Stock Incentive Plan (as amended and restated effective as of May 14, 2013).
(Incorporated by reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q for the fiscal quarter
ended March 29, 2014 filed on May 6, 2014.)**
112
Exhibits
10.18 Form of Restricted Stock Unit Agreement for time-based restricted stock awards pursuant to the Henry
Schein, Inc. 2013 Stock Incentive Plan (as amended and restated effective as of May 14, 2013).
(Incorporated by reference to Exhibit 10.3 to our Quarterly Report on Form 10-Q for the fiscal quarter
ended March 29, 2014 filed on May 6, 2014.)**
10.19 Form of Restricted Stock Unit Agreement for performance-based restricted stock awards pursuant to the
Henry Schein, Inc. 2013 Stock Incentive Plan (as amended and restated effective as of May 14, 2013).
(Incorporated by reference to Exhibit 10.4 to our Quarterly Report on Form 10-Q for the fiscal quarter
ended March 29, 2014 filed on May 6, 2014.)**
10.20 Henry Schein, Inc. 1996 Non-Employee Director Stock Incentive Plan, as amended by Amendment
Number One, effective as of May 25, 2004. (Incorporated by reference to Exhibit C to our definitive
2004 Proxy Statement on Schedule 14A filed on April 27, 2004.)**
10.21 Amendment Number Two to the Henry Schein, Inc. 1996 Non-Employee Director Stock Incentive Plan,
effective as of January 1, 2005. (Incorporated by reference to Exhibit 10.5 to our Annual Report on
Form 10-K for the fiscal year ended December 27, 2008 filed on February 24, 2009.)**
10.22 Amendment Number Three to the Henry Schein, Inc. 1996 Non-Employee Director Stock Incentive Plan,
effective as of May 10, 2010. (Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form
10-Q for the fiscal quarter ended June 26, 2010 filed on August 2, 2010.)**
10.23 Amendment Number Four to the Henry Schein, Inc. 1996 Non-Employee Director Stock Incentive Plan,
effective as of February 27, 2014. (Incorporated by reference to Exhibit 10.6 to our Quarterly Report on
Form 10-Q for the fiscal quarter ended March 29, 2014 filed on May 6, 2014.)**
10.24 Form of Restricted Stock Unit Agreement for time-based restricted stock awards pursuant to the Henry
Schein, Inc. 1996 Non-Employee Director Stock Incentive Plan (as amended and restated effective as of
April 1, 2003, and as further amended effective as of April 1, 2004 and January 1, 2005). (Incorporated
by reference to Exhibit 10.6 to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 27,
2010 filed on May 4, 2010.)**
10.25 Form of Restricted Stock Unit Agreement for time-based restricted stock awards pursuant to the Henry
Schein, Inc. 1996 Non-Employee Director Stock Incentive Plan (as amended and restated effective as of
April 1, 2003, and as further amended effective as of May 25, 2004, January 1, 2005, May 10, 2010 and
February 27, 2014). (Incorporated by reference to Exhibit 10.5 to our Quarterly Report on Form 10-Q for
the fiscal quarter ended March 29, 2014 filed on May 6, 2014.)**
10.26 Henry Schein, Inc. Supplemental Executive Retirement Plan, amended and restated effective as of
January 1, 2014. (Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the
fiscal quarter ended September 28, 2013 filed on November 5, 2013.)**
10.27 2001 Henry Schein, Inc. Section 162(m) Cash Bonus Plan effective as of June 6, 2001. (Incorporated by
reference to Appendix B to our definitive 2001 Proxy Statement on Schedule 14A filed on April 30,
2001.)**
10.28 Amendment Number One to the 2001 Henry Schein, Inc. Section 162(m) Cash Bonus Plan, effective as
of May 24, 2005. (Incorporated by reference to Exhibit B to our definitive 2005 Proxy Statement on
Schedule 14A, filed on April 22, 2005.)**
113
Exhibits
10.29 Amendment Number Two to the Henry Schein, Inc. Section 162(m) Cash Bonus Plan, effective as of
January 1, 2007. (Incorporated by reference to Exhibit 10.8 to our Annual Report on Form 10-K for the
fiscal year ended December 27, 2008 filed on February 24, 2009.)**
10.30 Amendment Number Three to the Henry Schein, Inc. Section 162(m) Cash Bonus Plan effective as of
December 31, 2009. (Incorporated by reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q for
the fiscal quarter ended June 27, 2009 filed on August 4, 2009.)**
10.31 Amendment Number Four to the Henry Schein, Inc. Section 162(m) Cash Bonus Plan, effective as of
May 14, 2013. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on
May 16, 2013.)**
10.32 Henry Schein, Inc. 2004 Employee Stock Purchase Plan, effective as of May 25, 2004. (Incorporated by
reference to Exhibit D to our definitive 2004 Proxy Statement on Schedule 14A, filed on April 27,
2004.)**
10.33 Henry Schein, Inc. Non-Employee Director Deferred Compensation Plan, amended and restated effective
as of January 1, 2005. (Incorporated by reference to Exhibit 10.11 to our Annual Report on Form 10-K
for the fiscal year ended December 27, 2008 filed on February 24, 2009.)**
10.34 Henry Schein, Inc. Deferred Compensation Plan effective as of January 1, 2011. (Incorporated by
reference to Exhibit 10.23 to our Annual Report on Form 10-K for the fiscal year ended December 25,
2010 filed on February 22, 2011.)**
10.35 Amendment to the Henry Schein, Inc. Deferred Compensation Plan effective as of January 1, 2011.
(Incorporated by reference to Exhibit 10.26 to our Annual Report on Form 10-K for the fiscal year ended
December 31, 2011 filed on February 15, 2012.)**
10.36 Amendment Number Two to the Henry Schein, Inc. Deferred Compensation Plan, effective as of January
1, 2011. (Incorporated by reference to Exhibit 10.20 to our Annual Report on Form 10-K for the fiscal
year ended December 28, 2013 filed on February 11, 2014.)**
10.37 Amendment Number Three to the Henry Schein, Inc. Deferred Compensation Plan, effective as of
January 1, 2014. (Incorporated by reference to Exhibit 10.21 to our Annual Report on Form 10-K for the
fiscal year ended December 28, 2013 filed on February 11, 2014.)**
10.38 Henry Schein Management Team Performance Incentive Plan and Plan Summary, effective as of January
1, 2014. (Incorporated by reference to Exhibit 10.7 to our Quarterly Report on Form 10-Q for the fiscal
quarter ended March 29, 2014 filed on May 6, 2014.)**
10.39 Amended and Restated Employment Agreement dated as of December 31, 2011 between us and Stanley
M. Bergman. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on
October 11, 2011.)**
10.40 Restricted Stock Unit Agreement between us and Stanley M. Bergman pursuant to the Henry Schein, Inc.
1994 Stock Incentive Plan (as amended and restated effective as of March 27, 2007) (Incorporated by
reference to Exhibit 10.2 to our Current Report on Form 8-K filed on October 11, 2011.)**
10.41 Amended and Restated Letter Agreement effective as of December 11, 2008 between us and Stanley
Komaroff. (Incorporated by reference to Exhibit 10.14 to our Annual Report on Form 10-K for the fiscal
year ended December 27, 2008 filed on February 24, 2009.)**
114
Exhibits
10.42 Form of Amended and Restated Change in Control Agreements dated December 12, 2008 between us and
certain executive officers who are a party thereto (Gerald Benjamin, James Breslawski, Leonard David,
Michael S. Ettinger, Stanley Komaroff, Robert Minowitz, Mark Mlotek, Steven Paladino and Michael
Racioppi, respectively). (Incorporated by reference to Exhibit 10.15 to our Annual Report on Form 10-K
for the fiscal year ended December 27, 2008 filed on February 24, 2009.)**
10.43 Form of Amendment to Amended and Restated Change in Control Agreements effective January 1, 2012
between us and certain executive officers who are a party thereto (Gerald Benjamin, James Breslawski,
Leonard David, Michael S. Ettinger, Stanley Komaroff, Robert Minowitz, Mark Mlotek, Steven Paladino
and Michael Racioppi, respectively). (Incorporated by reference to Exhibit 10.1 to our Current Report on
Form 8-K filed on January 20, 2012.)**
10.44 Credit Agreement, dated as of September 12, 2012, among us, the several lenders parties thereto,
JPMorgan Chase Bank, N.A., as administrative agent, HSBC Bank USA, National Association, as
syndication agent, and U.S. Bank National Association, The Bank of Tokyo-Mitsubishi UFJ, Ltd.,
UniCredit Bank AG and The Bank of New York Mellon, as co-documentation agents. (Incorporated by
reference to Exhibit 10.1 to our Current Report on Form 8-K filed on September 13, 2012.)
10.45 First Amendment dated as of September 22, 2014 to the Credit Agreement, dated as of September 12,
2012, by and among us, the several lenders party thereto, JPMorgan Chase Bank, N.A., as administrative
agent and the other agents party thereto. (Incorporated by reference to Exhibit 10.1 to our Current Report
on Form 8-K filed on September 26, 2014.)
10.46 Omnibus Agreement, dated November 29, 2009, by and among us, National Logistics Services, LLC,
Winslow Acquisition Company, Butler Animal Health Holding Company LLC, Butler Animal Health
Supply, LLC, Oak Hill Capital Partners II, L.P., Oak Hill Capital Management Partners II, L.P., W.A.
Butler Company, Burns Veterinary Supply, Inc. and certain other persons party thereto. (Incorporated by
reference to Exhibit 10.1 to our Current Report on Form 8-K filed on November 30, 2009.)
10.47 Amendment No. 1 to the Omnibus Agreement, dated December 31, 2009, by and between us and Butler
Animal Health Holding Company LLC. (Incorporated by reference to Exhibit 10.1 to our Current Report
on Form 8-K filed on January 4, 2010.)
10.48 Put Rights Agreement, dated December 31, 2009, by and among us, Burns Veterinary Supply, Inc. and
Butler Animal Health Holding Company, LLC. (Incorporated by reference to Exhibit 10.3 to our Current
Report on Form 8-K filed on January 4, 2010.)
10.49 First Amendment dated December 1, 2010 to Put Rights Agreement among us, Burns Veterinary Supply,
Inc. and Butler Animal Health Holding Company, LLC. (Incorporated by reference to Exhibit 10.45 to
our Annual Report on Form 10-K for the fiscal year ended December 25, 2010 filed on February 22,
2011.)
10.50 Receivables Purchase Agreement, dated as of April 17, 2013, by and among us, as servicer, HSFR, Inc.,
as seller, The Bank of Tokyo-Mitsubishi UFJ, Ltd., as agent and the various purchaser groups from time
to time party thereto. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed
on April 19, 2013.)
10.51 Amendment No. 1 dated as of September 22, 2014 to the Receivables Purchase Agreement, dated as of
April 17, 2013, by and among us, as servicer, HSFR, Inc., as seller, The Bank of Tokyo-Mitsubishi UFJ,
LTD., New York Branch, as agent and the various purchaser groups from time to time party thereto, as
amended. (Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on
September 26, 2014.)
115
Exhibits
10.52 Receivables Sale Agreement, dated as of April 17, 2013, by and among us, certain of our wholly-owned
subsidiaries and HSFR, Inc., as buyer. (Incorporated by reference to Exhibit 10.2 to our Current Report
on Form 8-K filed on April 19, 2013.)
10.53 Omnibus Amendment No. 1, dated July 22, 2013, to Receivables Purchase Agreement dated as of April
17, 2013, by and among us, as servicer, HSFR, Inc., as seller, The Bank of Tokyo-Mitsubishi UFJ, Ltd.,
as agent, and the various purchaser groups from time to time party thereto and Receivables Sales
Agreement, dated as of April 17, 2013, by and among us, certain of our wholly-owned subsidiaries and
HSFR, Inc., as buyer. (Incorporated by reference to Exhibit 10.5 to our Quarterly Report on Form 10-Q
for the fiscal quarter ended June 29, 2013 filed on August 6, 2013.)
10.54 Omnibus Amendment No. 2, dated April 21, 2014, to Receivables Purchase Agreement dated as of April
17, 2013, as amended, by and among us, as servicer, HSFR, Inc., as seller, The Bank of Tokyo-
Mitsubishi UFJ, Ltd., as agent, and the various purchaser groups from time to time party thereto and
Receivables Sales Agreement, dated as of April 17, 2013, by and among us, certain of our wholly-owned
subsidiaries and HSFR, Inc., as buyer. (Incorporated by reference to Exhibit 10.8 to our Quarterly Report
on Form 10-Q for the fiscal quarter ended March 29, 2014 filed on May 6, 2014.)
10.55 Form of Indemnification Agreement between us and certain directors and executive officers who are a
party thereto (Barry J. Alperin, Gerald A. Benjamin, Stanley M. Bergman, James P. Breslawski, Paul
Brons, Leonard A. David, Michael S, Ettinger, Donald J. Kabat, Stanley Komaroff, Philip A. Laskawy,
Norman S. Matthews, Mark E. Mlotek, Steven Paladino, Michael Racioppi and Louis W. Sullivan, M.D.,
respectively).**+
21.1 List of our Subsidiaries.+
23.1 Consent of BDO USA, LLP.+
31.1 Certification of our Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.+
31.2 Certification of our Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.+
32.1 Certification of our Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.+
101.INS XBRL Instance Document+
101.SCH XBRL Taxonomy Extension Schema Document+
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document+
101.DEF XBRL Taxonomy Extension Definition Linkbase Document+
101.LAB XBRL Taxonomy Extension Label Linkbase Document+
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document+
_________
+ Filed herewith.
* Pursuant to a request for confidential treatment, portions of this Exhibit have been redacted from the publicly
filed document and have been furnished separately to the Securities and Exchange Commission as required by
Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
** Indicates management contract or compensatory plan or agreement.
116
FOLLOW HENRY SCHEIN ON:
Facebook: http://www.facebook.com/henryschein
Twitter: http://twitter.com/henryschein
LinkedIn: http://www.linkedin.com/company/henry-schein
You Tube: http://www.youtube.com/user/henryscheininc
Google+: http://plus.google.com/+henryschein
Instagram: http://instagram.com/henryschein
Pinterest: https://www.pinterest.com/henryschein
Henry Schein, Inc.
135 Duryea Road
Melville, New York 11747
U.S.A.
(631) 843-5500
www.henryschein.com